
<html lang="en"     class="pb-page"  data-request-id="034e09c7-5a60-4fa7-9f05-5302e5532be6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00031"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure–Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists" /></meta><meta name="dc.Creator" content="Xiaodi  Zhao" /></meta><meta name="dc.Creator" content="Dong-Oh  Yoon" /></meta><meta name="dc.Creator" content="Jaeho  Yoo" /></meta><meta name="dc.Creator" content="Hyun-Ju  Park" /></meta><meta name="dc.Description" content="G-protein-coupled receptor 40 (GPR40) is considered as an attractive drug target for treating type 2 diabetes, owing to its role in the free fatty acid-mediated increase in glucose-stimulated insul..." /></meta><meta name="Description" content="G-protein-coupled receptor 40 (GPR40) is considered as an attractive drug target for treating type 2 diabetes, owing to its role in the free fatty acid-mediated increase in glucose-stimulated insul..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 26, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00031" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00031" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00031" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00031" /></link>
        
    
    

<title>Structure–Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00031" /></meta><meta property="og:title" content="Structure–Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0015.jpeg" /></meta><meta property="og:description" content="G-protein-coupled receptor 40 (GPR40) is considered as an attractive drug target for treating type 2 diabetes, owing to its role in the free fatty acid-mediated increase in glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To identify a new chemotype of GPR40 agonist, a series of 2-aryl-substituted indole-5-propanoic acid derivatives were designed and synthesized. We identified two GPR40 agonist lead compounds—4k (3-[2-(4-fluoro-2-methylphenyl)-1H-indol-5-yl]propanoic acid) and 4o (3-[2-(2,5-dimethylphenyl)-1H-indol-5-yl]propanoic acid), having GSIS and glucagon-like peptide 1 secretory effects. Unlike previously reported GPR40 partial agonists that only activate the Gq pathway, 4k and 4o activated both the Gq and Gs signaling pathways and were characterized as GPR40 full agonists. In in vivo efficacy studies, 4o significantly improved glycemic control in both C57BL/6J and db/db mice and increased plasma-active GLP-1 in C57BL/6J mice. Thus, 4o represents a promising lead for further development as a novel GPR40 full agonist against type 2 diabetes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00031"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00031">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00031&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00031&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00031&amp;href=/doi/10.1021/acs.jmedchem.1c00031" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4130-4149</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00003" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00044" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure–Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaodi Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaodi Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaodi++Zhao">Xiaodi Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong-Oh Yoon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong-Oh Yoon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong-Oh++Yoon">Dong-Oh Yoon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jaeho Yoo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaeho Yoo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaeho++Yoo">Jaeho Yoo</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hyun-Ju Park</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hyun-Ju Park</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#660e1f13080c135e5326150d0d1348030213"><span class="__cf_email__" data-cfemail="016978746f6b74393441726a6a742f646574">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hyun-Ju++Park">Hyun-Ju Park</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6802-1412" title="Orcid link">http://orcid.org/0000-0001-6802-1412</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00031&amp;href=/doi/10.1021%2Facs.jmedchem.1c00031" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4130–4149</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 26, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 January 2021</li><li><span class="item_label"><b>Published</b> online</span>26 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00031" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00031</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4130%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaodi%2BZhao%252C%2BDong-Oh%2BYoon%252C%2BJaeho%2BYoo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.1c00031%26title%3DStructure%25E2%2580%2593Activity%2BRelationship%2BStudy%2Band%2BBiological%2BEvaluation%2Bof%2B2-%2528Disubstituted%2Bphenyl%2529-indole-5-propanoic%2BAcid%2BDerivatives%2Bas%2BGPR40%2BFull%2BAgonists%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4149%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00031"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">661</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00031" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure–Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaodi&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Dong-Oh&quot;,&quot;last_name&quot;:&quot;Yoon&quot;},{&quot;first_name&quot;:&quot;Jaeho&quot;,&quot;last_name&quot;:&quot;Yoo&quot;},{&quot;first_name&quot;:&quot;Hyun-Ju&quot;,&quot;last_name&quot;:&quot;Park&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4130-4149&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00031&quot;},&quot;abstract&quot;:&quot;G-protein-coupled receptor 40 (GPR40) is considered as an attractive drug target for treating type 2 diabetes, owing to its role in the free fatty acid-mediated increase in glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To identify a new chemotype of GPR40 agonist, a series of 2-aryl-substituted indole-5-propanoic acid derivatives were designed and synthesized. We identified two GPR40 agonist lead compounds—4k (3-[2-(4-fluoro-2-methylphenyl)-1H-indol-5-yl]propanoic acid) and 4o (3-[2-(2,5-dimethylphenyl)-1H-indol-5-yl]propanoic acid), having GSIS and glucagon-like peptide 1 secretory effects. Unlike previously reported GPR40 partial agonists that only activate the Gq pathway, 4k and 4o activated both the Gq and Gs signaling pathways and were characterized as GPR40 full agonists. In in vivo efficacy studies, 4o significantly improved glycemic control in both C57BL/6J and db/db mice and increased plasma-active GLP-1 in C57BL/6J mice. Thus, 4o represents a promising lead for further develop&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00031&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00031" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00031&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00031" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00031&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00031" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00031&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00031&amp;href=/doi/10.1021/acs.jmedchem.1c00031" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00031" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00031" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00031%26sid%3Dliteratum%253Aachs%26pmid%3D33769827%26genre%3Darticle%26aulast%3DZhao%26date%3D2021%26atitle%3DStructure%25E2%2580%2593Activity%2BRelationship%2BStudy%2Band%2BBiological%2BEvaluation%2Bof%2B2-%2528Disubstituted%2Bphenyl%2529-indole-5-propanoic%2BAcid%2BDerivatives%2Bas%2BGPR40%2BFull%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4130%26epage%3D4149%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">G-protein-coupled receptor 40 (GPR40) is considered as an attractive drug target for treating type 2 diabetes, owing to its role in the free fatty acid-mediated increase in glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To identify a new chemotype of GPR40 agonist, a series of 2-aryl-substituted indole-5-propanoic acid derivatives were designed and synthesized. We identified two GPR40 agonist lead compounds—<b>4k</b> (3-[2-(4-fluoro-2-methylphenyl)-1<i>H</i>-indol-5-yl]propanoic acid) and <b>4o</b> (3-[2-(2,5-dimethylphenyl)-1<i>H</i>-indol-5-yl]propanoic acid), having GSIS and glucagon-like peptide 1 secretory effects. Unlike previously reported GPR40 partial agonists that only activate the G<sub>q</sub> pathway, <b>4k</b> and <b>4o</b> activated both the G<sub>q</sub> and G<sub>s</sub> signaling pathways and were characterized as GPR40 full agonists. In <i>in vivo</i> efficacy studies, <b>4o</b> significantly improved glycemic control in both C57BL/6J and db/db mice and increased plasma-active GLP-1 in C57BL/6J mice. Thus, <b>4o</b> represents a promising lead for further development as a novel GPR40 full agonist against type 2 diabetes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by elevated circulating glucose levels owing to glucose intolerance, which is attributed to deficient insulin production in the pancreas, or resistance to insulin actions.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> According to the “Global Report on Diabetes” published by the World Health Organization (WHO) in 2016, the number of adult patients with diabetes has increased by over 4 times since 1980 to 422 million worldwide, of which 90% of patients have type 2 diabetes (T2DM), constituting a serious global health burden.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">G-protein-coupled receptor 40 (GPR40) [also called free fatty acid (FFA) receptor 1, FFAR1], known as a G<sub>q</sub>- and G<sub>s</sub>-coupled G-protein-coupled receptor (GPCR), is predominantly expressed in pancreatic β-cells and enteroendocrine cells and regulates insulin secretion after activation by endogenous ligands such as medium- and long-chain FFAs or its agonists.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Fatty acids including eicosatrienoic acid, docosahexaenoic acid (DHA),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and linoleic acid (LA) are known as endogenous GPR40 agonists.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> In contrast to the most common therapeutic agents such as insulin or sulfonylureas, GPR40 agonists modulate insulin secretion in a glucose-dependent manner, posing little risk of hypoglycemia and other side effects.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Therefore, drugs targeting GPR40 may improve glycemic control more efficiently than glucose-independent insulin secretagogues such as sulfonylureas.</div><div class="NLM_p">Owing to the critical role of GPR40 in the treatment of T2DM, GPR40 is considered an important target for the development of antidiabetic agents. Several synthetic GPR40 agonists have been reported in the literature, among which partial agonists TAK875, AMG-837, and MK8666 have entered clinical evaluation (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14">(10−14)</a> Unfortunately, in 2013, the GPR40 partial agonist TAK875 was withdrawn from phase III clinical trials owing to liver safety concerns.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Reportedly, TAK875 affected bile acid and bilirubin homeostasis and induced hyperbilirubinemia and cholesteric hepatotoxicity; these effects possibly associated with the chemical structure.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative GPR40 Agonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, AM-1638 and AP8 have been reported as GPR40 allosteric full agonists (AgoPAMs), activating both the G<sub>q</sub> and G<sub>s</sub> pathways, showing a significant effect on glucagon-like peptide 1 (GLP-1) secretion. Compared with partial agonists, AM1638 demonstrates greater glycemic control in mice presenting diet-induced obesity, revealing a significant increase in plasma insulin as well as AUC<sub>insulin</sub> at all time points assessed.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> AgoPAMs were confirmed to have both GLP-1-dependent and GLP-1-independent effects, such that their effect on GLP-1 secretion could enhance glucose-stimulated insulin secretion (GSIS) in a manner superior to that demonstrated by partial agonists.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Furthermore, it has been suggested that signal transduction through GPR40 is tissue dependent—in enteroendocrine cells, the coactivation of G<sub>q</sub> and G<sub>s</sub> is the main pathway stimulating the release of incretins,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> while in pancreatic β-cells, the GSIS effects are mainly mediated through G<sub>q</sub>.<a onclick="showRef(event, 'ref9 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref9 ref20 ref21">(9,20,21)</a> In the G<sub>s</sub> pathway, the dissociated G<sub>s</sub> subunit activates adenylyl cyclase, thus increasing the cyclic adenosine monophosphate (cAMP) levels. Subsequently, cAMP activates cAMP-dependent protein kinase A to further stimulate the secretion of incretins such as glucose-dependent insulinotropic polypeptide or GLP-1, which are known to enhance insulin secretion upon binding to their receptors.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, the GPR40 full agonist, which concomitantly activates G<sub>q</sub>- and G<sub>s</sub>-coupled GPR40, appears to be a more efficient strategy to achieve a combined increase in intracellular Ca<sup>2+</sup> and cAMP for insulin secretion.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Furthermore, Ueno et al.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> have suggested that GPR40 full agonists play an important role in feeding suppression and weight loss through their incretin secretory activity.</div><div class="NLM_p last">Recently, we identified a series of indole-5-propanoic acid derivatives, possessing a mono-substituted phenyl at the C2 position of indole, as potential antidiabetic candidates.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Herein, we evaluated the structure–activity relationship (SAR) of the second series of indole-5-propanoic acids with disubstituted phenyl at the C2 position of indole as GPR40 agonists. After performing further functional and mechanistic studies <i>in vitro</i> and <i>in vivo</i>, we identified <b>4k</b> and <b>4o</b> as GPR40 full agonists activating both the G<sub>q</sub> and G<sub>s</sub> pathways, revealing excellent GSIS and GLP-1 secretory effects as well as <i>in vivo</i> antidiabetic activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives</h3><div class="NLM_p">Previously, we reported the synthesis of indole derivatives,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and this synthetic route has generated additional indole derivatives possessing the disubstituted phenyl group. For the synthesis of <b>4a–4r</b>, compound <b>1</b> was used as a key intermediate, and various disubstituted phenyl halides were generated as target derivatives. In the first step, the Sonogashira reaction afforded <b>2a–2r</b> from various disubstituted halides, and then indole cyclization using AuCl<sub>3</sub> generated 2-aryl substituted indole compounds, <b>3a–3r</b>. For the target compounds, <b>4a–4r</b>, the ethyl ester group of <b>3a–3r</b> was hydrolyzed using NaOH (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ar-Br or I, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, DMF, 90 °C, and 30–69%; (b) AuCl<sub>3</sub>, EtOH, 60 °C, and 50–82%; and (c) 1 N NaOH, MeOH, 60 °C, and 52–75%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> SAR Study and Identification of <b>4k</b> and <b>4o</b> as GPR40 Full Agonists</h3><div class="NLM_p">Recently, we reported potent GPR40 agonists categorized as indole propanoic acid derivatives linked with a substituted aryl group. To determine the GPR40 agonistic activities of compounds, we performed the serum response element (SRE) luciferase reporter assay<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> using stable GPR40-expressing Chinese hamster ovary (CHO) cells in comparison with TAK875. We measured the activities of compounds in CHO cells transfected only with the SRE plasmid, and the observed effects were similar to those recorded with dimethyl sulfoxide (DMSO), confirming the reliability of GPR40 activity assays (non-specific % activity in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Another antidiabetic target, peroxisome proliferator-activated receptor-gamma (PPARγ), is also activated by fatty acids; hence, GPR40 agonists may possess PPARγ agonistic activity. Additionally, several indole-5-acetic acid derivatives and α-alkoxy-indole-5-propionic acid derivatives, which are structurally similar to our compounds, have been reported as PPAR agonists.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Thus, we determined PPARγ transactivation activities of synthesized compounds at a concentration of 10 μM to check the selectivity for GPR40 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activity of 2-(Di-halogen-substituted phenyl)-indole Propanoic Acid</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0011.gif" alt="" id="GRAPHIC-d7e423-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">GPR40</th><th class="rowsep1 colsep0" colspan="2" align="center">PPARγ</th><th class="rowsep1 colsep0" align="center" char="±">non-specific</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">SRE (DMSO 100%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">2,3-di-Cl</td><td class="colsep0 rowsep0" align="left">4.78 ± 2.52</td><td class="colsep0 rowsep0" align="char" char="±">81.23 ± 17.56</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">12.75 ± 0.063</td><td class="colsep0 rowsep0" align="char" char="±">81.25 ± 0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="left">2,4-di-Cl</td><td class="colsep0 rowsep0" align="left">20.59 ± 2.44</td><td class="colsep0 rowsep0" align="char" char="±">48.04 ± 3.17</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">5.39 ± 0.37</td><td class="colsep0 rowsep0" align="char" char="±">101.04 ± 2.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b></td><td class="colsep0 rowsep0" align="left">2,5-di-Cl</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">22.8 ± 0.12</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">2.69 ± 0.82</td><td class="colsep0 rowsep0" align="char" char="±">94.79 ± 7.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b></td><td class="colsep0 rowsep0" align="left">2,6-di-Cl</td><td class="colsep0 rowsep0" align="left">2.41 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">78.28 ± 2.83</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">11.52 ± 0.92</td><td class="colsep0 rowsep0" align="char" char="±">97.92 ± 1.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4e</b></td><td class="colsep0 rowsep0" align="left">2-F-3-Cl</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">6.81 ± 0.010</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">18.2 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">93.75 ± 11.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4f</b></td><td class="colsep0 rowsep0" align="left">2-F-4-Cl</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">2.18 ± 0.080</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">3.64 ± 0.013</td><td class="colsep0 rowsep0" align="char" char="±">96.88 ± 1.47</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Luciferase reporter assay.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Percent activity compared to 10 μM TAK875 (EC<sub>50</sub> = 20.2 nM in this reporter assay).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Percent activity compared to 1 μM rosiglitazone. NA, no activity (EC<sub>50</sub> > 25 μM); NT, not tested; GPR40, G-protein-coupled receptor 40; SRE, serum response element; PPARγ, peroxisome proliferator-activated receptor-gamma; and DMSO, dimethyl sulfoxide.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activity of 2-(Disubstituted phenyl)-indole Propanoic Acid</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0012.gif" alt="" id="GRAPHIC-d7e684-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">GPR40</th><th class="rowsep1 colsep0" colspan="2" align="center">PPARγ</th><th class="rowsep1 colsep0" align="center" char="±">non-specific</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">SRE (DMSO 100%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4g</b></td><td class="colsep0 rowsep0" align="left">2-Me-3-Cl</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">108.63 ± 4.00</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">59.93 ± 1.41</td><td class="colsep0 rowsep0" align="char" char="±">104.17 ± 8.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4h</b></td><td class="colsep0 rowsep0" align="left">2-Me-4-Cl</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">108.82 ± 8.77</td><td class="colsep0 rowsep0" align="left">27.77 ± 1.32</td><td class="colsep0 rowsep0" align="char" char="±">104.3 ± 1.39</td><td class="colsep0 rowsep0" align="char" char="±">103.12 ± 10.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left">2-Me-5-Cl</td><td class="colsep0 rowsep0" align="left">16.26 ± 1.41</td><td class="colsep0 rowsep0" align="char" char="±">35.04 ± 0.12</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">18.28 ± 1.53</td><td class="colsep0 rowsep0" align="char" char="±">104.17 ± 5.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4j</b></td><td class="colsep0 rowsep0" align="left">2-Me-4-Br</td><td class="colsep0 rowsep0" align="left">0.73 ± 0.089</td><td class="colsep0 rowsep0" align="char" char="±">95.34 ± 12.00</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">30.56 ± 1.28</td><td class="colsep0 rowsep0" align="char" char="±">191.67 ± 13.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="left">2-Me-4-F</td><td class="colsep0 rowsep0" align="left">0.040 ± 0.010</td><td class="colsep0 rowsep0" align="char" char="±">111.39 ± 16.10</td><td class="colsep0 rowsep0" align="left">56.94 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">32.52 ± 2.51</td><td class="colsep0 rowsep0" align="char" char="±">104.17 ± 7.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4l</b></td><td class="colsep0 rowsep0" align="left">2-Cl-4-amino</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">24.71 ± 0.17</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">67.71 ± 1.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4m</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub>-4-Cl</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">7.67 ± 0.07</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">15.87 ± 2.18</td><td class="colsep0 rowsep0" align="char" char="±">66.55 ± 4.21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Luciferase reporter assay.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Percent activity compared to 10 μM TAK875 (EC<sub>50</sub> = 20.2 nM in this reporter assay).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Percent activity compared to 1 μM rosiglitazone. NA, no activity (EC<sub>50</sub> > 25 μM); NT, not tested; GPR40, G-protein-coupled receptor 40; SRE, serum response element; PPARγ, peroxisome proliferator-activated receptor-gamma; and DMSO, dimethyl sulfoxide.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activity of 2-(Dimethyl-substituted phenyl)-indole Propanoic Acid</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0013.gif" alt="" id="GRAPHIC-d7e979-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">GPR40</th><th class="rowsep1 colsep0" colspan="2" align="center">PPARγ</th><th class="rowsep1 colsep0" align="center" char="±">non-specific</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">SRE (DMSO 100%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4n</b></td><td class="colsep0 rowsep0" align="left">2,4-di-Me</td><td class="colsep0 rowsep0" align="char" char="±">0.410 ± 0.062</td><td class="colsep0 rowsep0" align="char" char="±">61.82 ± 18.61</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">2.51 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">106.29 ± 9.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="left">2,5-di-Me</td><td class="colsep0 rowsep0" align="char" char="±">0.417 ± 0.056</td><td class="colsep0 rowsep0" align="char" char="±">102.52 ± 4.38</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">15.18 ± 2.05</td><td class="colsep0 rowsep0" align="char" char="±">109.27 ± 2.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left">2,6-di-Me</td><td class="colsep0 rowsep0" align="char" char="±">0.729 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">69.48 ± 3.00</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">0.52 ± 0.053</td><td class="colsep0 rowsep0" align="char" char="±">86.42 ± 1.40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Luciferase reporter assay.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Percent activity compared to 10 μM TAK875 (EC<sub>50</sub> = 20.2 nM in this reporter assay).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Percent activity compared to 1 μM rosiglitazone. NA, no activity (EC<sub>50</sub> > 25 μM); NT, not tested; GPR40, G-protein-coupled receptor 40; SRE, serum response element; PPARγ, peroxisome proliferator-activated receptor-gamma; and DMSO, dimethyl sulfoxide.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Metabolic Stability of Compound <b>4k</b> and <b>4o</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">mouse CL<sub>h.int</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">human CL<sub>h.int</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="left">≤4</td><td class="colsep0 rowsep0" align="left">≤4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">≤4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Microsomal stability: clearance intrinsic (μL/min/mg).</p></div></div></div><div class="NLM_p">First, we prepared di-halogen derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and observed that except for 2,3-di-Cl and 2,6-di-Cl derivatives demonstrating some activity at micromolar levels, other derivatives presented poor agonistic activity. In contrast, as expected, methyl-halogen or dimethyl derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) achieved dramatically improved activity. As listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the derivatives with 2-Me-3-Cl, 2-Me-4-Cl, and 2-Me-5-Cl substituents were prepared to explore the effect of substitution at different positions on the phenyl ring. Among these compounds, <b>4h</b> (2-Me-4-Cl) showed the highest activity with an EC<sub>50</sub> value of 0.25 μM, suggesting that the 2-Me-4-halogen substitution might be beneficial for desired activities. Therefore, <b>4j</b> (2-Me-4-Br) and <b>4k</b> (2-Me-4-F) were synthesized to examine the effect of different halogens. For halogen substituents at the C-4 position, the order of activity was F > Cl > Br. In addition to methyl-halogen, dimethyl substitutions also demonstrated good activity in the order of <b>4n</b> (2, 4) ≈ <b>4o</b> (2, 5) > <b>4p</b> (2, 6) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Considering both EC<sub>50</sub> and <i>E</i><sub>max</sub> values, we selected <b>4k</b> and <b>4o</b> as lead compounds with EC<sub>50</sub> values of 40 and 417 nM, respectively, while demonstrating negligible activities for PPARγ.</div><div class="NLM_p">Reportedly, GPR40 full agonists have revealed a greater ability to improve insulin secretion and glycemic control.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Hence, we evaluated whether <b>4k</b> and <b>4o</b> are full or partial agonists. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A, <b>4k</b>, <b>4o</b>, and DHA showed 110–120% of the response demonstrated by TAK875 at 30 ng/well of GPR40. When the plasmid expression level was reduced to 0.5 ng/well (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), <b>4k</b> and <b>4o</b> displayed an <i>E</i><sub>max</sub> of approximately 120% when compared with DHA, which is about 3-fold higher than that of partial agonist TAK875. Similar experimental results were reported with GPR40 full agonists in other studies.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Thus, we characterized <b>4k</b> and <b>4o</b> as full agonists of GPR40.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GPR40 transcription activity of <b>4k</b> and <b>4o</b>. Effect of <b>4k</b> and <b>4o</b>, in comparison with DHA and TAK875, in CHO cells transfected with 30 ng/well of GPR40 expression plasmid (A) and 0.5 ng/well of GPR40 expression plasmid (B). (C) GPR40 transactivation by <b>4k</b>, <b>4o</b>, and TAK875. Transcriptional activity was determined in CHO cells transiently co-transfected with GPR40 plasmid and luciferase reporter SRE-Luc (G<sub>q</sub>), CRE-Luc (G<sub>s</sub>), or SRF-Luc (G<sub>12/13</sub>). After 3 h of transfection, cells were treated with compounds (10 μM) for an additional 24 h. <sup>###</sup><i>p</i> ≤ 0.01; ***<i>p</i> ≤ 0.005 vs DMSO alone. (D) Concentration-dependent CRE-Luc reporter assay and (E) detection of cAMP accumulation in the presence of <b>4k</b>, <b>4o</b>, and TAK875.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recent evidence indicates that GPR40 has the propensity to couple with G<sub>q</sub>, G<sub>s</sub>, or G<sub>12/13</sub> proteins depending on the type of agonist.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Partial agonists signaling through G<sub>q</sub> alone demonstrate low incretin responses, whereas full agonists signaling through both G<sub>q</sub> and G<sub>s</sub> result in robust incretin responses.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Several allosteric full agonists activate the G<sub>12/13</sub>-mediated signaling pathway, associated with protein kinase D activation and actin remodeling, further contributing to the release of insulin vesicles.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> Therefore, we determined the signaling pathway mediating the effects of <b>4k</b> and <b>4o</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, TAK875, <b>4k</b>, and <b>4o</b> demonstrated high luciferase activity in the SRE-Luc (G<sub>q</sub>) reporter assay, which is used to determine EC<sub>50</sub> values. TAK875 demonstrated a luciferase activity value similar to DMSO in CRE-Luc (G<sub>s</sub>) and SRF-Luc (G<sub>12/13</sub>) reporter assays. In contrast, <b>4k</b> and <b>4o</b> showed 5.27- and 3.32-fold higher values than DMSO, with EC<sub>50</sub> values of 0.521 and 12.88 μM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D), respectively, in the CRE-Luc (G<sub>s</sub>) assay. Additionally, an assay to monitor the intracellular cAMP levels (cAMP-Glo assay, Promega) was performed to confirm the G<sub>s</sub>-mediated agonistic activity of <b>4k</b> and <b>4o</b>, as the activation of adenylyl cyclase by G<sub>s</sub> enhances cAMP production (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>E). In this assay system, luminescence is inversely proportional to cAMP levels, and the results revealed that <b>4k</b> and <b>4o</b> increased cAMP in a concentration-dependent manner, demonstrating EC<sub>50</sub> values of 0.681 and 7.53 μM, respectively. Mechanistic studies substantiated that <b>4k</b> and <b>4o</b> activated signaling through both G<sub>q</sub> and G<sub>s</sub> pathways but not through G<sub>12/13</sub>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <b>4k</b> and <b>4o</b> Showed Potent <i>In Vitro</i> GSIS and GLP-1 Secretory Effects</h3><div class="NLM_p">To evaluate insulin secretion induced by <b>4k</b> and <b>4o</b>, we performed GSIS assays in MIN6 cells. The effect on insulin secretion was verified at a glucose concentration of 17 mM by comparing to that at 3 mM, as GPR40 activation stimulates insulin secretion in a glucose-dependent manner. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, increasing concentrations (1 to 10 μM) of <b>4k</b> and <b>4o</b> enhanced GSIS by approximately 1.16-fold and 1.12-fold, respectively, in the presence of 17 mM glucose comparable to that induced by 1 μM TAK875. Co-treatment of the test compounds with GW1100, a known GPR40 antagonist,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> attenuated the effects of TAK875, <b>4k</b>, and <b>4o</b> on insulin secretion in MIN6 cells. This confirmed that the effects of <b>4k</b> and <b>4o</b> on GSIS were mediated <i>via</i> GPR40 activation. However, these effects were minimal in the presence of 3 mM glucose. At high concentrations (10 μM), <b>4k</b> and <b>4o</b> stimulated MIN6 cells to release small amounts of insulin when compared with the blank controls (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). However, TAK875, even at 10 μM, failed to stimulate insulin release with 3 mM glucose. Despite the effects observed at high glucose conditions, the effects of <b>4k</b> and <b>4o</b> on insulin release at low glucose concentrations were minimal.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A,B) Evaluation of GSIS by <b>4k</b> and <b>4o</b> in MIN6 cells, in comparison with TAK875. The data are presented as mean ± standard error (<i>n</i> = 3). <sup>###</sup><i>p</i> ≤ 0.01; *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs 17 mM glucose alone by Student’s <i>t</i>-test. (C) <b>4k</b> and <b>4o</b> promote GLP-1 secretion in STC-1 cells. The data are presented as mean ± standard error (<i>n</i> = 3). *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs DMSO. GLP-1, glucagon-like peptide 1; DMSO, dimethyl sulfoxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We further investigated the effects of <b>4k</b> and <b>4o</b> on GLP-1 secretion in STC-1 cells, a known phenotype of intestinal endocrine L-cells secreting GLP-1. The observed GLP-1 secretory effect was dose dependent, demonstrating a significant (<i>P</i> ≤ 0.005) increase with <b>4k</b> and <b>4o</b> (30 μM) or LA (100 μM), whereas TAK875 induced little increase in GLP-1 secretion (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). These results are consistent with the observation that GPR40 AgoPAMs enhance therapeutic effects through increased levels of insulinotropic incretins secreted from the stomach,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> indicating that these full agonists show a dual mechanism of action when compared with partial agonists, increasing both GSIS and GLP-1 secretion.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Evaluation of Lipotoxicity, Pharmacokinetic Properties, and Selectivity of <b>4k</b> and <b>4o</b></h3><div class="NLM_p">Next, we examined whether <b>4k</b> and <b>4o</b> could induce lipotoxicity or enhance FFA-induced lipotoxicity in pancreatic β-cells, as previously published literature has indicated that long-term treatment with FFAs could lead to impaired beta-cell functions and cellular apoptosis.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> MIN6 cells were exposed to a bovine serum albumin–palmitic acid (BSA–PA) conjugate for 72 h, resulting in increased caspase 3/7 activity in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), substantiating the effects of FFA on lipotoxicity in pancreatic β-cells. However, long-term exposure of pancreatic β-cells to <b>4k</b> or <b>4o</b> did not enhance caspase 3/7 activity even at a concentration of 100 μM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Although the lipotoxic effects induced by 500 μM BSA–PA conjugates were not prevented by <b>4k</b> and <b>4o</b>, the addition of 50 μM <b>4k</b> and <b>4o</b> did not increase the caspase 3/7 activity induced by BSA–PA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). This observation suggests that GPR40 activation by <b>4k</b> and <b>4o</b> does not exacerbate FFA-induced lipotoxicity in pancreatic β-cells.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>4k</b> and <b>4o</b> do not exacerbate FFA-induced apoptotic signaling in MIN6 cells. (A) Caspase 3/7 activity in MIN6 cells after 72 h of exposure to 62.5 to 1000 μM BSA–PA conjugate or 0.5 to 100 μM of drugs. (B) Co-treatment of <b>4k</b> or <b>4o</b> with BSA–PA conjugate. The data are presented as mean ± standard error (<i>n</i> = 3). *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs DMSO. BSA–PA, bovine serum albumin–palmitic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Typically, compounds consisting of propionic acid and benzyl moiety are known to present issues concerning metabolic stability and are vulnerable to phase I metabolism. In some reported GPR40 agonists possessing a propanoic acid functional group, the beta position is substituted to improve their metabolic stability by avoiding β-oxidation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Therefore, we inspected the liver microsomal stability of <b>4k</b> and <b>4o</b>, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, and observed that both compounds exhibited good metabolic stability in mouse and human models, despite their unprotected beta position.</div><div class="NLM_p">As <b>4k</b> and <b>4o</b> exhibited good metabolic stability and no lipotoxicity in pancreatic β-cells, we evaluated their <i>in vivo</i> pharmacokinetic properties following their administration at doses of 10, 30, and 90 mg/kg. As outlined in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, although <b>4k</b> showed higher agonistic activity toward GPR40, <b>4o</b> showed excellent PK properties at the maximal plasma concentrations (<i>C</i><sub>max</sub>), and plasma exposure (AUC) improved by 2–3-fold compared to <b>4k</b> at 10 mg/kg. Unfortunately, the <i>T</i><sub>1/2</sub>, <i>T</i><sub>max</sub>, and mean residence time were rapid. In FASSIF solubility tests, both compounds demonstrated good solubility (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf" class="ext-link">Supporting Information</a> Table S1).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of <b>4k</b> and <b>4o</b> in CD-1 Mice after Oral Administration<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg, PO)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> ± SE (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>last</sub> ± SE (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>last</sub> ± SE (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–<i>t</i></sub> ± SE (h × ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">MRT<sub>last</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char="±">3740 ± 261</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">4857 ± 787</td><td class="colsep0 rowsep0" align="char" char="±">1.23 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">1.16</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char="±">24,000 ± 3940</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">33,609 ± 1467</td><td class="colsep0 rowsep0" align="char" char="±">1.24 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char="±">52,933 ± 15,107</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">1246 ± 587</td><td class="colsep0 rowsep0" align="char" char="±">114,427 ± 15,531</td><td class="colsep0 rowsep0" align="char" char="±">2.06 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char="±">10,257 ± 794</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">63 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">9625 ± 912</td><td class="colsep0 rowsep0" align="char" char="±">1.14 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char="±">28,733 ± 3283</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">189 ± 28</td><td class="colsep0 rowsep0" align="char" char="±">38,718 ± 4063</td><td class="colsep0 rowsep0" align="char" char="±">1.34 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">1.36</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char="±">65,000 ± 3027</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char="±">2680 ± 473</td><td class="colsep0 rowsep0" align="char" char="±">18,6071 ± 15,885</td><td class="colsep0 rowsep0" align="char" char="±">2.31 ± 0.18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Abbreviations: <i>T</i><sub>1/2</sub>, elimination half-life; <i>T</i><sub>max</sub>, time to reach <i>C</i><sub>max</sub>; <i>C</i><sub>max</sub>, peak plasma concentration of a drug after administration; <i>T</i><sub>last</sub>, time of the last measurable (positive) concentration; <i>C</i><sub>last</sub>, concentration corresponding to <i>T</i><sub>last</sub>; AUC, area under the concentration–time curve; and MRT<sub>last</sub>, mean residence time (MRT) from the time of dosing to the time of the last measurable concentration. <i>In vivo</i> PK assays were performed by NECMD (National Efficacy Evaluation Center for Metabolic Disease Therapeutics, <a href="http://necmd.co.kr" class="extLink">http://necmd.co.kr</a>), South Korea.</p></div></div></div><div class="NLM_p">Owing to the high potency of our compounds toward GPR40, the selectivity of compounds <b>4k</b> and <b>4o</b> was evaluated in comparison with other related FFARs including FFAR2 (GPR43), FFAR3 (GPR41), and FFAR4 (GPR120). FFAR4 (GPR120) is activated by medium- and/or long-chain fatty acids similar to FFAR1 (GPR40), while FFAR3 (GPR41) and FFAR4 (GPR120) are activated by short-chain fatty acids. Favorably, both compounds showed minimal effects on GPR43 and GPR41 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Although the EC<sub>50</sub> value of <b>4o</b> for GPR120 was determined as 14.81 μM, <b>4o</b> was 35 times more selective for GPR40, thus indicating robust selectivity.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Selectivity of Compounds <b>4k</b> and <b>4o</b> for FFAR1 (GPR40) over FFAR2 (GPR43), FFAR3 (GPR41), and FFAR4 (GPR120)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">EC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">FFAR1</th><th class="colsep0 rowsep0" align="center">FFAR2</th><th class="colsep0 rowsep0" align="center">FFAR3</th><th class="colsep0 rowsep0" align="center">FFAR4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0398 ± 0.0097</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="char" char="±">0.417 ± 0.056</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">14.81 ± 0.57</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">NA, no activity (EC<sub>50</sub> > 25 μM); FFAR, FFA receptor; and GPR, G-protein-coupled receptor.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Investigation of Binding Modes of <b>4k</b> and <b>4o</b> by Kinetic Analysis and Molecular Docking</h3><div class="NLM_p">Radioligand-binding studies have demonstrated the positive cooperation between partial agonists such as TAK875, AMG-837, and AgoPAM AM-1638,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> suggesting the presence of multiple ligand binding sites. As TAK875 reportedly occupies a specific binding pocket<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and FFAs present in circulation act as endogenous ligands, we performed the SRE reporter assay to investigate the cooperative effect between our compounds and TAK875 or DHA.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, both <b>4k</b> and <b>4o</b> enhanced the agonistic activity of TAK875 and DHA, indicating that <b>4k</b> and <b>4o</b> might be positive allosteric modulators of DHA and TAK875 on GPR40. Notably, <b>4k</b> demonstrated significantly greater effects than <b>4o</b>, significantly shifting the concentration–response curve toward the left (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,C). These data suggest that <b>4k</b> and <b>4o</b> are full allosteric agonists of GPR40 and positive allosteric modulators of TAK875. Hence, we explored the binding sites of these compounds on GPR40.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>4k</b> and <b>4o</b> show positive cooperativity with the partial agonist TAK875 and endogenous ligand DHA<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> in functional assays. The effects of increasing concentrations of TAK875 (A,B) or DHA (C,D) on the dose–response curves of <b>4k</b> (A,C) and <b>4o</b> (B,D) are illustrated in the reporter assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the results from kinetic and mutation studies (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf" class="ext-link">Supporting Information</a> Figures S1–S3), which suggest that <b>4k</b> and <b>4o</b> bind into the pocket for allosteric full-agonist binding (inner-leaflet pocket) in GPR40, we performed docking modeling for <b>4k</b> and <b>4o</b> to understand their binding modes using the Glide XP module of Schrödinger Program.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The ligands were docked into the binding site of AgoPAM AP8 in the X-ray structure of the MK8666-AP8-GPR40 ternary complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY">5TZY</a>). As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, the binding pose of <b>4k</b> and <b>4o</b> was almost identical and similar to the X-ray pose of AP8, overlapping in the middle and bottom regions of the AP8 binding site (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The ligand was well fitted in the lipid-facing inner-leaflet pocket, consisting of TM3 and TM4, and interacted with the residues in TM2, TM3, TM4, and intracellular loop 2 (ICL2). The disubstituted phenyl ring of the ligand bound to the hydrophobic pocket, consisting of A129<sup>4.48</sup>, I130<sup>4.49</sup>, L193<sup>5.49</sup>, P194<sup>5.50</sup>, I197<sup>5.53</sup>, and V126<sup>4.45</sup> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B,C). The carboxylate moiety of the ligand was anchored at the bottom of the pocket <i>via</i> hydrogen bonds with a side-chain OH group of S123<sup>4.42</sup>, Y44<sup>2.42</sup>, and Y114 in ICL2. The interaction between the ligand and ICL2 was retained, contributing to the stabilization of the α-helical conformation of ICL2 and the high efficacy of the GPR40 full agonist AP8.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> An additional hydrogen bond with S123<sup>4.42</sup> was formed, resulting in tight binding in the inner-leaflet pocket. Notably, indole N–H of <b>4k</b> and <b>4o</b> formed a hydrogen bond with the backbone amide carbonyl oxygen of A98<sup>3.44</sup>, indicating that the indole-NH group is crucial for receptor binding (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>4k</b>, <b>4o</b>, and <b>6k</b> at the AP8-binding site of GPR40 (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY">5TZY</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>). (A) Superimposition of <b>4k</b> and <b>4o</b> over the X-ray pose of AP8 (depicted as a blue stick) in the inner-leaflet pocket of GPR40. <b>4k</b> and <b>4o</b> are rendered as yellow and magenta sticks, respectively. The binding site is represented as a gray molecular surface. (B) A close-up view of key interactions involved in stabilizing <b>4k</b> in the binding pocket. Hydrogen bonds are depicted as yellow dotted lines. (C) 2D view of interactions between <b>4k</b> and GPR40. (D) Binding mode of <b>4k</b> and <b>6k</b>. <b>6k</b> is depicted as a green stick. Surrounding key amino acid residues are shown as gray sticks and are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To verify the significance of indole-NH as an H-bond donor for GPR40 binding, we synthesized derivatives of <b>4k</b> and <b>4o</b> by incorporating a methyl group into the indole-NH (<b>6k</b> and <b>6o</b>) by following the synthetic route in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The <i>N</i>-methyl indole derivatives were prepared from the intermediates, <b>3k</b> and <b>3o</b>, obtained from <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Methylation of the indole-NH was performed under potassium <i>tert</i>-butoxide for the deprotonation of indole-NH, with iodomethane used as the methyl source to give <b>5k</b> and <b>5o</b>, respectively. Post methylation, the final products, <b>6k</b> and <b>6o</b>, were easily obtained by hydrolysis using NaOH. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, the reporter assays assessing the GPR40 agonistic effects of these derivatives showed a loss of activity at an EC<sub>50</sub> > 25 μM and revealed that the indole-NH group is important for receptor binding.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) potassium <i>tert</i>-butoxide (1.5 equiv), iodomethane (2.0 equiv), THF, and r.t. and (b) NaOH, MeOH, and 40 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Activity of <i>N</i>-Methylated Indole Derivative of <b>4k</b> and <b>4o</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0014.gif" alt="" id="GRAPHIC-d7e2531-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">GPR40</th><th class="rowsep1 colsep0" colspan="2" align="center">PPARγ</th><th class="rowsep1 colsep0" align="center" char="±">non-specific</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)</th><th class="colsep0 rowsep0" align="center" char="±">SRE (DMSO 100%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6k</b></td><td class="colsep0 rowsep0" align="left">2-Me-4-F</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="±">16.88 ± 0.85</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">6.32 ± 2.09</td><td class="colsep0 rowsep0" align="char" char="±">95.89 ± 1.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6o</b></td><td class="colsep0 rowsep0" align="left">2,5-di-Me</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="±">20.31 ± 0.61</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="±">0.01 ± 0.054</td><td class="colsep0 rowsep0" align="char" char="±">91.14 ± 2.14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">NT, not tested; GPR40, G-protein-coupled receptor 40; SRE, serum response element; PPARγ, peroxisome proliferator-activated receptor-gamma; and DMSO, dimethyl sulfoxide.</p></div></div></div><div class="NLM_p last">As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D, we evaluated the docking pose of the <i>N</i>-methylated indole derivative <b>6k</b> in the AP8-binding pocket. In addition to the loss of a hydrogen bond with A98<sup>3.44</sup>, owing to the steric hindrance generated by the <i>N</i>-methyl group, the indole ring was rotated to favor the 2-aryl indole ring close to an orthogonal conformation, keeping the ligand <b>6k</b> away from the hydrophobic pocket. The docked pose of <b>6k</b> clarified the loss of agonistic activity.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <b>4o</b> Exhibits the Glucose-Lowering Effect and Increases the Plasma GLP-1 Level in Rodent Models</h3><div class="NLM_p">To assess the effects on the intrinsic activity <i>in vivo</i>, the ability of <b>4k</b> and <b>4o</b> to improve glycemic control was investigated in mice. For both compounds, oral glucose tolerance tests were performed in C57BL/6J and db/db mice at a dose of 30 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A–D). In these assays, compounds were orally administered 1 h prior to glucose, and plasma glucose levels were measured at −60, 0, 15, 30, 60, and 120 min. Although <b>4k</b> exhibited excellent activity <i>in vitro</i>, significant glucose lowering effects were not observed at 30 mg/kg (mpk). Relative to the vehicle controls, <b>4o</b> (30 mpk) exerted stronger hypoglycemic effects than those of TAK875 (10 mpk). Marked improvements in glucose tolerance were observed with 22.9 and 14.4% in C57BL/6J and db/db mouse models, respectively, which decreased the glucose AUC<sub>0–120 min</sub>. These data suggested that 30 mpk doses of compound <b>4o</b> were highly effective in reducing the glucose levels in both db/db (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B) and C57BL/6J mice (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D). Therefore, the ability of <b>4o</b> to stimulate the secretion of incretin GLP-1 in C57BL/6J mice was also evaluated. A single dose of 30 mpk of <b>4o</b> or TAK875 was administered concomitantly with 10 mpk dipeptidyl peptidase-4 (DPP4) inhibitor (KR-62436) to inhibit the degradation of active GLP-1, and plasma level of active GLP-1 was measured at 30 min following dosing. To determine the direct non-glucose-dependent GLP-1 secretion induced by drug alone, <b>4o</b> or TAK875 was administered orally to the fasted-state C57BL/6 mice. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E, <b>4o</b> significantly improved the level of active GLP-1 that is 162% increase relative to the control mice treated with only DPP4 inhibitor. The effect of partial agonist TAK875 on GLP-1 secretion, which was nominal in the published animal studies,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> was also evaluated upon treating the same dose of 30 mpk, although GPR40 agonistic activity of TAK875 (EC<sub>50</sub> = 20.2 nM) is about 20 times more potent than <b>4o</b> (EC<sub>50</sub> = 417 nM) according to the current reporter assay. In addition, TAK875 has advanced to phase III clinical trial with the ideal pharmacokinetic/pharmacodynamic properties optimized in animals and human. TAK875 showed 173% increase of active GLP-1 level, which is similar to the effect of <b>4o</b>. In the cell-based GLP-1 secretion data shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, <b>4o</b> exhibited higher activity in stimulating GLP-1 secretion in STC-1 cells than TAK875 as a result of its full agonistic activity. However, due to poor PK property of <b>4o</b>, <i>in vivo</i> GLP-1 elevation effect should be underestimated compared with TAK875. We believe that these <i>in vivo</i> results are quite promising since <b>4o</b> and TAK875 produced the same level of endogenous active GLP-1 secretion in spite of inferior potency and PK property of <b>4o</b> compared with TAK875. If we further improve the PK properties of <b>4o</b><i>via</i> bioisosteric replacement or drug latentiation (prodrug design) to increase the <i>in vivo</i> efficacy, <b>4o</b> can be optimized to a drug candidate. In summary, <b>4o</b> showed good agonistic effects on GPR40 <i>in vitro</i>, promoted the release of insulin and GLP-1 from pancreatic cells and endocrine cells, and exerted satisfactory activity in the glucose level control and GLP-1 stimulation <i>in vivo</i>.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Anti-diabetic efficacy of <b>4k</b> and <b>4o</b> in rodent Models. <i>In vivo</i> glucose-lowering effect of <b>4k</b> and <b>4o</b> in C57BL/6J (A,B) or db/db mice (C,D), and GLP-1 secretion effect of <b>4o</b> in C57BL/6J mice (E). Time-dependent changes in plasma glucose levels (A,C) after oral administration of full agonists <b>4k</b> and <b>4o</b> or partial agonist TAK875. (B,D) Incremental AUC<sub>0–120</sub> min of plasma glucose levels. Compounds were administered orally 1 h before oral administtation of glucose, and plasma glucose levels were measured at −60, 0, 15, 30, 60, and 120 min. Values are presented as mean ± SD (<i>n</i> = 8). (E) The <i>in vivo</i> effect of <b>4o</b> on the level of plasma-active GLP-1 in C57BL/6J mice. Following the administration of 30 mpk TAK875 or <b>4o</b>, together with the 10 mpk DPP4 inhibitor (KR-62436) at <i>t</i> = 0 min, the levels of serum-active GLP-1 were measured at 30 min. Only the 10 mpk DPP4 inhibitor was treated with the control group. Values are presented as mean ± SD (<i>n</i> = 5). **<i>p</i> ≤ 0.01 compared with the control by Students’ <i>t</i>-test. Assays were performed by NECMD (National Efficacy Evaluation Center for Metabolic Disease Therapeutics, <a href="http://necmd.co.kr" class="extLink">http://necmd.co.kr</a>), South Korea.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">GPR40 is considered as a promising new drug target for the treatment of T2DM owing to its role in FFA-mediated enhancement of GSIS in pancreatic β-cells. As targeting GRP40 presents a minimal risk for developing hypoglycemia, numerous synthetic GPR40 agonists have been developed. Recently, it has been reported that full GPR40 agonists enhance GLP-1 secretion and GSIS better than partial agonists, and therefore, we focused on the development of novel full agonists in this study.</div><div class="NLM_p last">Previously, we reported the synthesis and characterization of novel GPR40 agonists by employing an indole-5-propanoic acid moiety as a simplified rigid scaffold. Various derivatives, with a disubstituted aryl group linked to the C2 position of the indole ring, were synthesized, and the SAR was assessed based on their GPR40 agonistic activities, as determined by the SRE luciferase assay. Among the derivatives, <b>4k</b> and <b>4o</b> were identified as potent GPR40 full agonists, which activated both G<sub>q</sub> and G<sub>s</sub> pathways and revealed positive cooperation with the partial agonist TAK875 and the FFA, DHA. Excellent effects on insulin and GLP-1 secretion were observed in MIN6 cells and STC-1 cells, respectively, suggesting a powerful and dual mechanism of action stimulating insulin secretion. Importantly, <b>4k</b> and <b>4o</b> did not induce lipotoxicity or exacerbate FA-induced lipotoxicity in pancreatic β-cells, thereby avoiding undesirable effects. Additionally, both compounds were highly selective for GPR40 over other FFARs and PPARγ, substantially reducing the risk of unexpected side effects. Furthermore, both compounds showed good microsomal stability and acceptable ADME (absorption, distribution, metabolism, and excretion) profiles. In <i>in vivo</i> efficacy studies, 30 mg/kg of <b>4o</b> effectively reduced glucose excursion and improved glycemic control in both C57BL/6J and db/db mice and increased the level of plasma-active GLP-1 significantly in C57BL/6J mice. This study encouraged us to undertake in-depth mechanistic investigations on GPR40 full agonists as well as to further optimize the PK properties by utilizing a bioisosteric replacement approach, whose results will be published in a timely manner.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General</h4><div class="NLM_p last">All chemical reagents and solvents were obtained from commercial sources and used without further purification. The reactions were performed under an inert atmosphere of nitrogen or argon and reaction yields obtained were not optimized. The reactions were assessed using thin-layer chromatography (TLC) using Merck TLC silica gel 60 F254 glass plates detected with a UV lamp and <i>p</i>-anisaldehyde or KMnO<sub>4</sub> stain. The intermediates were purified using silica column chromatography in the Yamazen purification system (W-Prep 2XY) with a pre-packed cartridge (WACHERS flash cartridge, 40–63 μm silica gel). The final purification of compounds was performed by reverse column chromatography using the BIOTAGE system (ISOLERA) with a pre-packed cartridge (WakosilSiC18, 15–30 μm C18 silica gel). <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz using the Bruker instrument. Chemical shifts were measured in parts per million (ppm, δ) using the residual solvent and tetramethylsilane as internal standards. The multiplicities of resonance patterns are presented as brs = broad singlet, s = singlet, d = doublet, dd = doublet of doublets, ddd = double of double of doublets, t = triplet, td = triplet of doublets, q = quartet, and m = multiplet with coupling constants (<i>J</i>) reported in hertz (Hz). Low-resolution mass spectrometry (LRMs) was performed using a Waters SQ Detector 2 in the electron spray ionization (ESI) mode. High-resolution mass analyses were identified using JEOL JMS-700 with EI (electron ionization) or ultra-high-performance liquid chromatography (ultra-HPLC) coupled to quadrupole-time-of-flight mass spectrometry with ESI. This instrument was equipped with an Acquity UPLC system (Waters Co., Milford, MA, USA) coupled to a Waters Acquity Xevo G2 Q-TOF system (Waters Corp., Manchester, UK) and an Acquity UPLC BEH C18 column (50 mm × 2.1 mm, 1.7 μm) from Waters. Mass spectrometry was performed with an ESI source operated in both negative (NEG) and positive (POS) ionization modes. The chemical purity of the final compounds was evaluated at 225 nm using HPLC (ACE or an XBridge C18 5 μm 150 × 4.6 mm I.D. column, gradient condition 10–100% A in B over 20 min, solvent A = ACN with 0.1% trifluoroacetic acid (TFA) and B = H<sub>2</sub>O with 0.1% TFA, flow rate = 1 mL/min, and temperature = 25 °C). All the final compounds tested had an HPLC purity of >95% (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_001.csv" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedures for the Synthesis of Compounds</h4><div class="NLM_p">Procedure I: After dissolving ethyl 3-(4-amino-3-ethynylphenyl)propanoate (1.0 equiv) in dimethylformamide (DMF; 0.1 M), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.05 equiv), CuI (0.05 equiv), aryl halide (1.2 equiv), and trimethylamine (5.0 equiv) were added at room temperature. Then, the mixture was stirred at 80 °C for 6 h and was then cooled to room temperature. The reaction was quenched with water, and the final mixture was extracted using ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified using silica gel column chromatography.</div><div class="NLM_p">Procedure II: AuCl<sub>3</sub> (0.2 equiv) was added to an ethanolic solution (0.1 M) of product <b>3</b> (1.0 equiv). The reaction mixture was stirred at 60 °C for 2–4 h and cooled to room temperature. The reaction mixture was concentrated without workup under reduced pressure, and the residue was purified using silica gel column chromatography.</div><div class="NLM_p">Procedure III: NaOH (1<i>N</i> in H<sub>2</sub>O, 1.5 equiv) was added to a methanolic solution (0.1 M) of product <b>4</b> (1.0 equiv). The reaction mixture was stirred at 40 °C for 2 h and cooled to room temperature. After acidification with HCl (1 N in H<sub>2</sub>O, 1.6 equiv), the resulting mixture was concentrated under reduced pressure, and the residue was purified using reverse column chromatography.</div><div class="NLM_p">Procedure IV: Product <b>4</b> (1.0 equiv) was dissolved in tetrahydrofuran (THF; 0.1 M), followed by the addition of potassium <i>tert</i>-butoxide (1 M in THF, 1.5 equiv) and methyl iodide (2.0 equiv) to this solution. The reaction mixture was stirred at room temperature for 2 h. After dilution of the reaction mixture with water, the final mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The resulting mixture was concentrated under reduced pressure, and the residue was purified using reverse column chromatography.</div><div class="NLM_p">Procedure V: To a DMF solution (0.1 M) dissolved in acid (1.0 equiv), HATU (1.2 equiv), ammonium chloride (1.5 equiv), and N,N-diisopropylethylamine (3.0 equiv) were added at 25 °C. The reaction mixture was stirred at room temperature for 1 h. After completing the reaction, the reaction mixture was diluted with water, and the final mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The resulting mixture was concentrated under reduced pressure, and the residue was purified using reverse column chromatography.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 3-(2-(2,3-Dichlorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4a</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list1" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2a</b> was prepared from <b>1</b> (50 mg, 0.26 mmol) and 1-bromo-2,3-dichlorobenzene (40.1 μL, 0.31 mmol) in accordance with procedure I to generate 47.3 mg (50%) of a pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45 (d, <i>J</i> = 7.7 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (d, <i>J</i> = 1.7 Hz, 1H), 7.17 (t, <i>J</i> = 7.9 Hz, 1H), 7.01 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.34.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last">(br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 7.9, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 146.9, 133.5, 133.2, 131.6, 130.9, 130.7, 129.9, 129.8, 127.2, 125.4, 114.6, 106.9, 92.5, 91.2, 60.4, 36.2, 30.0, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 362.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3a</b> was prepared from <b>2a</b> (47.3 mg, 0.13 mmol) in accordance with procedure II to generate 32.2 mg (68%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.64 (br s, 1H), 7.51 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.47 (s, 1H), 7.45 (dd, <i>J</i> = 8.0, 1.6, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.25 (t, <i>J</i> = 7.9 Hz, 1H), 7.08 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.78 (dd, <i>J</i> = 2.1, 0.7 Hz, 1H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 3.05 (dd, <i>J</i> = 8.1, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.2, 135.2, 134.8, 134.3, 133.7, 132.6, 130.0, 129.6, 129.0, 128.2, 127.6, 123.8, 120.0, 111.1, 104.0, 60.4, 36.8, 31.2, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 362.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(4)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4a</b> was prepared from <b>3a</b> (32.2 mg, 89.0 μmol) in accordance with procedure III to generate 22.3 mg (75%) of a pale yellow amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 52:48, isocratic condition). HPLC purity = 99.1%, <i>t</i><sub>R</sub> = 15.15. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.51 (br s, 1H), 7.49 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.45 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.35 (s, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (t, <i>J</i> = 7.9 Hz, 1H), 6.99 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.70 (dd, <i>J</i> = 2.1, 0.6 Hz, 1H), 2.88 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.54 (dd, <i>J</i> = 7.8, 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.3, 136.0, 135.1, 134.6, 134.1, 133.0, 130.4, 130.2, 130.0, 128.9, 128.5, 124.1, 120.2, 111.8, 104.2, 36.3, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 334.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>NO<sub>2</sub>, 334.0402; found, 334.0405.</p></td></tr></table></div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 3-(2-(2,4-Dichlorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4b</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list2" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2b</b> was prepared from <b>1</b> (50 mg, 0.26 mmol) and 1-bromo-2,4-dichlorobenzene (40.1 μL, 0.31 mmol) in accordance with procedure I to generate 50.9 mg (59%) of pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.44 (m, 2H), 7.25–7.19 (m, 2H), 7.01 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.34 (br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 146.7, 135.9, 134.2, 133.3, 131.5, 130.6, 129.9, 129.2, 127.1, 122.0, 114.7, 107.0, 92.7, 90.6, 60.4, 36.2, 30.0, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 362.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3b</b> was prepared from <b>2b</b> (50.9 mg, 0.14 mmol) in accordance with procedure II to generate 34.4 mg (68%) of a yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.69 (br s, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.49 (d, <i>J</i> = 2.1 Hz, 1H), 7.46 (s, 1H), 7.34–7.28 (m, 2H), 7.08 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.78 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 3.05 (dd, <i>J</i> = 8.1, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.2, 135.2, 134.2, 133.9, 132.6, 131.8, 131.3, 130.5, 129.8, 128.3, 127.6, 123.8, 119.9, 111.1, 103.7, 60.4, 36.8, 31.2, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 362.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4b</b> was prepared from <b>3b</b> (34.4 mg, 95.0 μmol) in accordance with procedure III to generate 21.4 mg (68%) of a pale yellow amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 55:45, isocratic condition). HPLC purity = 98.1%, <i>t</i><sub>R</sub> = 14.60. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.53 (br s, 1H), 7.54 (d, <i>J</i> = 8.6 Hz, 1H), 7.51 (d, <i>J</i> = 1.3 Hz, 1H), 7.36–7.26 (m, 3H), 6.98 (dd, <i>J</i> = 8.2 Hz, 1H), 6.72 (s, 1H), 2.88 (t, <i>J</i> = 7.5 Hz, 2H), 2.54 (t, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.4, 136.1, 134.5, 133.9, 133.0, 132.8, 132.2, 130.9, 130.7, 129.0, 128.1, 124.0, 120.2, 111.8, 104.0, 36.3, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 334.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>NO<sub>2</sub>, 334.0402; found, 334.0394.</p></td></tr></table></div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 3-(2-(2,5-Dichlorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4c</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list3" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2c</b> was prepared from <b>1</b> (50 mg, 0.26 mmol) and 2-bromo-1,4-dichlorobenzene (70 mg, 0.31 mmol) in accordance with procedure I to generate 48.8 mg (52%) of a pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.52 (d, <i>J</i> = 2.5 Hz, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 1H), 7.23–7.19 (m, 2H), 7.02 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.35 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 7.9, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 146.9, 133.5, 132.4, 132.2, 131.6, 130.8, 130.2, 130.0, 129.0, 124.8, 114.7, 106.8, 93.0, 90.4, 60.4, 36.2, 30.0, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 362.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3c</b> was prepared from <b>2c</b> (48.8 mg, 0.13 mmol) in accordance with procedure II to generate 24.5 mg (50%) of an off white solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.73 (br s, 1H), 7.63 (d, <i>J</i> = 2.5 Hz, 1H), 7.47 (s, 1H), 7.39 (d, <i>J</i> = 8.6 Hz, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.21 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 7.09 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.82 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.05 (dd, <i>J</i> = 8.1, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 135.3, 133.9, 133.1, 132.6 (2C), 131.9, 130.1, 129.4, 128.5, 128.2, 124.0, 120.1, 111.1, 104.1, 60.4, 36.8, 31.2, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 362.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4c</b> was prepared from <b>3c</b> (24.8 mg, 68.0 μmol) in accordance with procedure III to generate 16.7 mg (74%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 50:50, isocratic condition). HPLC purity = 93.0%, <i>t</i><sub>R</sub> = 14.97. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.10 (br s, 1H), 11.44 (br s, 1H), 7.81 (d, <i>J</i> = 2.5 Hz, 1H), 7.61 (d, <i>J</i> = 8.6 Hz, 1H), 7.45–7.41 (m, 2H), 7.34 (d, <i>J</i> = 8.3 Hz, 1H), 7.04 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 6.94 (d, <i>J</i> = 1.5 Hz, 1H), 2.90 (t, <i>J</i> = 7.6 Hz, 2H), 2.66 (t, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.9, 135.2, 132.7 (2C), 132.2, 131.9, 131.8, 129.4 (2C), 128.3, 127.9, 123.3, 119.4, 111.3, 103.7, 36.2, 30.6. LRMs-ESI (<i>m</i>/<i>z</i>): 334.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>NO<sub>2</sub>, 334.0402; found, 334.0395.</p></td></tr></table></div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 3-(2-(2,6-Dichlorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4d</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list4" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2d</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 2-bromo-1,3-dichlorobenzene (125 μL, 0.55 mmol) in accordance with procedure I to generate 73.1 mg (44%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.27 (d, <i>J</i> = 1.6 Hz, 1H), 7.17 (t, <i>J</i> = 8.5 Hz, 1H), 7.03 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 6.67 (d, <i>J</i> = 8.2 Hz, 1H), 4.41 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.85 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.58 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 147.0, 136.4, 131.7, 130.9, 129.9, 128.6, 127.5, 123.5, 114.6, 107.0, 97.2, 88.8, 60.4, 36.2, 30.0, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 362.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3d</b> was prepared from <b>2d</b> (64.4 mg, 0.18 mmol) in accordance with procedure II to generate 34.4 mg (53%) of a yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.16 (br s, 1H), 7.51 (s, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 2H), 7.34 (d, <i>J</i> = 8.3 Hz, 1H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 7.09 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.61 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.06 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.68 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 136.2, 134.8, 132.3, 131.6, 131.5, 130.1, 128.4, 128.2, 123.4, 120.2, 111.0, 104.9, 60.4, 36.9, 31.2, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 362.2 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4d</b> was prepared from <b>3d</b> (28.8 mg, 79.5 μmol) in accordance with procedure III to generate 17.2 mg (65%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 46:54, isocratic condition). HPLC purity = 98.8%, <i>t</i><sub>R</sub> = 13.60. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.26 (br s, 1H), 7.45–7.41 (m, 2H), 7.36 (s, 1H), 7.33–7.26 (m, 2H), 7.34 (s, 1H), 6.98 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.37 (dd, <i>J</i> = 2.1, 0.8 Hz, 1H), 2.89 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.55 (dd, <i>J</i> = 7.8, 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.1, 136.6, 135.6, 132.8, 132.6, 132.4, 131.4, 128.9, 128.8, 123.6, 120.1, 111.7, 103.9, 36.4, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 334.1 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>NO<sub>2</sub>, 334.0402; found, 334.0411.</p></td></tr></table></div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 3-(2-(3-Chloro-2-fluorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4e</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list5" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2e</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 1-bromo-3-chloro-2-fluorobenzene (115 mg, 0.55 mmol) in accordance with procedure I to generate 108 mg (68%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42–7.34 (m, 2H), 7.21 (d, <i>J</i> = 1.8 Hz, 1H), 7.06 (t, <i>J</i> = 7.9 Hz, 1H), 7.01 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.26 (br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.56 (dd, <i>J</i> = 8.0, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 157.9 (d, <i>J</i> = 252.3 Hz), 146.6, 131.5, 131.0, 130.7, 130.3, 130.0, 124.4 (d, <i>J</i> = 5.0 Hz), 121.4 (d, <i>J</i> = 17.5 Hz), 114.7, 113.8 (d, <i>J</i> = 15.6 Hz), 107.0, 92.7 (d, <i>J</i> = 3.9 Hz), 86.9, 60.4, 36.2, 30.0, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 346.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3e</b> was prepared from <b>2e</b> (98.0 mg, 0.28 mmol) in accordance with procedure II to generate 41.0 mg (42%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:dichloromethane = 1:2, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (br s, 1H), 7.65 (dd, <i>J</i> = 1.3, 8.5 Hz, 1H), 7.46–7.10 (m, 3H), 7.34–7.30 (m, 2H), 7.04 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.76 (d, <i>J</i> = 1.4 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.04 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.2, 154.6 (d, <i>J</i> = 248.7 Hz), 135.5, 132.6, 131.7, 129.1, 128.2, 126.1 (d, <i>J</i> = 3.6 Hz), 125.0 (d, <i>J</i> = 4.3 Hz), 124.0, 122.3 (d, <i>J</i> = 18.6 Hz), 121.6 (d, <i>J</i> = 11.4 Hz), 119.9, 111.1, 102.4 (d, <i>J</i> = 3.4 Hz), 60.3, 36.7, 31.2, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 346.2 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4e</b> was prepared from <b>3e</b> (31.9 mg, 92.0 μmol) in accordance with procedure III to generate 28.9 mg (99%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 55:45, isocratic condition). HPLC purity = 99.0%, <i>t</i><sub>R</sub> = 14.30. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.63 (br s, 1H), 7.63 (td, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.36–7.31 (m, 3H), 7.16 (td, <i>J</i> = 8.0, 1.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.83 (td, <i>J</i> = 2.0, 0.6 Hz, 1H), 2.88 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.54 (dd, <i>J</i> = 7.8, 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.1, 155.1 (d, <i>J</i> = 249.6 Hz), 136.4, 133.2, 131.8 (d, <i>J</i> = 2.4 Hz), 129.7, 129.2, 127.0 (d, <i>J</i> = 3.3 Hz), 126.0 (d, <i>J</i> = 4.4 Hz), 124.4, 122.6 (d, <i>J</i> = 12.0 Hz), 122.2 (d, <i>J</i> = 18.2 Hz), 120.3, 111.9, 103.5 (d, <i>J</i> = 11.8 Hz), 36.2, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 318.2 [M + H]<sup>+</sup>. HRMS-EI (<i>m</i>/<i>z</i>): [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>ClFNO<sub>2</sub>, 317.0614; found, 317.0611.</p></td></tr></table></div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 3-(2-(4-Chloro-2-fluorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4f</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list6" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2f</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 1-bromo-4-chloro-2-fluorobenzene (68.8 μL, 0.55 mmol) in accordance with procedure I to generate 90.4 mg (57%) of a pale brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45–7.40 (m, 1H), 7.21 (d, <i>J</i> = 2.2 Hz, 1H), 7.17–7.12 (m, 2H), 7.01 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.15 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 162.1 (d, <i>J</i> = 254.2 Hz), 146.5, 134.7 (d, <i>J</i> = 9.7 Hz), 133.3, 131.5, 130.5, 130.0, 124.6 (d, <i>J</i> = 3.7 Hz), 116.5 (d, <i>J</i> = 24.7 Hz), 114.7, 110.9 (d, <i>J</i> = 15.9 Hz), 107.2, 92.4 (d, <i>J</i> = 3.6 Hz), 86.9, 60.4, 36.2, 30.0, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 346.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3f</b> was prepared from <b>2f</b> (60.0 mg, 0.17 mmol) in accordance with procedure II to generate 31.6 mg (53%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/dichloromethane = 1:2, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (br s, 1H), 7.65 (dd, <i>J</i> = 1.3, 8.5 Hz, 1H), 7.46–7.10 (m, 3H), 7.34–7.30 (m, 2H), 7.04 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.76 (d, <i>J</i> = 1.4 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.04 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.2, 158.8 (d, <i>J</i> = 249.6 Hz), 135.5, 133.5 (d, <i>J</i> = 11.2 Hz), 132.7, 131.8, 128.6 (d, <i>J</i> = 5.1), 128.3, 125.3 (d, <i>J</i> = 3.3 Hz), 123.9, 119.9, 118.8 (d, <i>J</i> = 11.5 Hz), 117.2 (d, <i>J</i> = 26.7 Hz), 111.0, 101.8 (d, <i>J</i> = 3.0 Hz), 60.4, 36.8, 31.2, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 346.2 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4f</b> was prepared from <b>3f</b> (13.3 mg, 63.0 μmol) in accordance with procedure III to generate 23.3mg (67%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 57:43, isocratic condition). HPLC purity = 98.4%, <i>t</i><sub>R</sub> = 14.58. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.68 (br s, 1H), 7.76 (t, <i>J</i> = 8.4 Hz, 1H), 7.43 (s, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H), 7.36–7.30 (m, 2H), 7.07 (dd, <i>J</i> = 8.4, 1.4 Hz, 1H), 6.88 (s, 1H), 2.96 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.62 (dd, <i>J</i> = 7.8, 7.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.1, 159.6 (d, <i>J</i> = 251.2 Hz), 136.4, 133.6 (d, <i>J</i> = 10.7 Hz), 133.2, 131.8 (d, <i>J</i> = 2.6 Hz), 129.4 (d, <i>J</i> = 4.9 Hz), 129.3, 125.7 (d, <i>J</i> = 3.5 Hz), 124.2, 120.2, 119.9 (d, <i>J</i> = 11.9 Hz), 117.4, 111.8, 103.0 (d, <i>J</i> = 6.9 Hz), 36.2, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 318.2 [M + H]<sup>+</sup>. HRMS-EI (<i>m</i>/<i>z</i>): [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>ClFNO<sub>2</sub>, 317.0614; found, 317.0612.</p></td></tr></table></div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 3-(2-(3-Chloro-2-methylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4g</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list7" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2g</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 1-bromo-3-chloro-2-methylbenzene (71.7 μL, 0.55 mmol) in accordance with procedure I to generate 74.6 mg (47%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41 (d, <i>J</i> = 7.7 Hz, 1H), 7.33 (d, <i>J</i> = 7.9 Hz, 1H), 7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 (t, <i>J</i> = 7.9 Hz, 1H), 7.01 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.19 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.84 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.59 (s, 3H), 2.58 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 146.1, 137.5, 134.8, 131.7, 130.4, 130.2 (2C), 129.2, 126.6, 125.1, 114.7, 107.8, 92.9, 90.5, 60.4, 36.2, 30.0, 18.5, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 342.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3g</b> was prepared from <b>2g</b> (66.3 mg, 0.19 mmol) in accordance with procedure II to generate 43.8 mg (66%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.08 (br s, 1H), 7.47 (s, 1H), 7.40 (d, <i>J</i> = 7.9 Hz, 1H), 7.36–7.31 (m, 2H), 7.19 (t, <i>J</i> = 7.6 Hz, 1H), 7.07 (d, <i>J</i> = 8.3 Hz, 1H), 6.51 (s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.06 (t, <i>J</i> = 7.8 Hz, 2H), 2.68 (t, <i>J</i> = 7.8 Hz, 2H), 2.49 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 137.1, 135.8, 135.0, 134.9, 134.6, 132.5, 129.0, 128.9, 128.1, 126.7, 123.1, 119.8, 110.8, 103.3, 60.4, 36.9, 31.2, 18.0, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 342.2 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4g</b> was prepared from <b>3g</b> (35.5 mg, 103 μmol) in accordance with procedure III to generate 27.1 mg (84%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 53:47, isocratic condition). HPLC purity = 99.1%, <i>t</i><sub>R</sub> = 14.84. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.31 (br s, 1H), 7.36–7.32 (m, 3H), 7.27 (d, <i>J</i> = 8.3 Hz, 1H), 7.17 (t, <i>J</i> = 7.8 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.40 (d, <i>J</i> = 1.1 Hz, 1H), 2.88 (t, <i>J</i> = 7.6 Hz, 2H), 2.54 (t, <i>J</i> = 7.6 Hz, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.2, 137.7, 135.9, 135.8, 135.7, 134.8, 132.8, 129.3, 129.2, 129.0, 127.5, 123.4, 120.0, 111.6, 103.0, 36.3, 31.3, 17.9. LRMs-ESI (<i>m</i>/<i>z</i>): 314.1 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>ClNO<sub>2</sub>, 314.0948; found, 314.0952.</p></td></tr></table></div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 3-(2-(4-Chloro-2-methylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4h</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list8" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2h</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 1-bromo-4-chloro-2-methylbenzene (72.7 μL, 0.55 mmol) in accordance with procedure I to generate 51.4 mg (33%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (s, 1H), 7.20 (d, <i>J</i> = 1.7 Hz, 1H), 7.16 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.00 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 6.67 (d, <i>J</i> = 8.2 Hz, 1H), 4.17 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.84 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 146.0, 141.4, 133.9, 132.8, 131.7, 130.2, 130.1, 129.6, 126.0, 121.7, 114.7, 108.0, 92.5, 90.8, 60.4, 36.2, 30.0, 20.9, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 342.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3h</b> was prepared from <b>2h</b> (36.4 mg, 0.11 mmol) in accordance with procedure II to generate 24.0 mg (66%) of a brown solid, purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (br s, 1H), 7.47 (s, 1H), 7.38 (d, <i>J</i> = 8.2 Hz, 1H), 7.34–7.29 (m, 2H), 7.24 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.07 (d, <i>J</i> = 8.3 Hz, 1H), 6.54 (s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.06 (dd, <i>J</i> = 8.1, 7.7 Hz, 2H), 2.68 (dd, <i>J</i> = 8.0, 7.7 Hz, 2H), 2.47 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 137.9, 136.6, 134.9, 133.6, 132.5, 131.2, 130.9, 130.1, 129.0, 126.2, 123.1, 119.8, 110.8, 103.1, 60.4, 36.9, 31.2, 21.0, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 342.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4h</b> was prepared from <b>3h</b> (39.9 mg, 0.12 mmol) in accordance with procedure III to generate 30.0 mg (80%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 53:47, isocratic condition). HPLC purity = 98.9%, <i>t</i><sub>R</sub> = 14.89. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.43 (br s, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.44 (s, 1H), 7.40–7.36 (m, 2H), 7.31 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.07 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.55 (dd, <i>J</i> = 2.2, 0.7 Hz, 1H), 3.00 (t, <i>J</i> = 7.7 Hz, 2H), 2.66 (t, <i>J</i> = 7.8 Hz, 2H), 2.48 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.5, 138.8, 137.1, 135.9, 133.3, 132.7, 132.1, 131.2, 131.0, 129.5, 126.5, 123.3, 119.9, 111.5, 102.9, 36.4, 31.3, 20.8. LRMs-ESI (<i>m</i>/<i>z</i>): 314.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>ClNO<sub>2</sub>, 314.0948; found, 314.0951.</p></td></tr></table></div></div><div id="sec4_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 3-(2-(5-Chloro-2-methylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4i</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list9" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2i</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 2-bromo-4-chloro-1-methylbenzene (72.7 μL, 0.55 mmol) in accordance with procedure I to generate 44.3 mg (28%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46 (d, <i>J</i> = 2.1 Hz, 1H), 7.21–7.11 (m, 3H), 7.00 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.67 (d, <i>J</i> = 8.3 Hz, 1H), 4.19 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.84 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.1, 7.4 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 146.2, 138.0, 131.7, 131.21, 131.15, 130.7, 130.3, 130.2, 128.3, 124.8, 114.7, 107.7, 92.3, 91.1, 60.4, 36.2, 30.0, 20.5, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 342.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3i</b> was prepared from <b>2i</b> (40.0 mg, 0.12 mmol) in accordance with procedure II to generate 26.6 mg (66%) of a pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.15 (br s, 1H), 7.47 (s, 1H), 7.44 (s, 1H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (d, <i>J</i> = 1.1 Hz, 2H), 7.07 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 6.56 (d, <i>J</i> = 1.5 Hz, 1H), 4.14 (q, <i>J</i> = 7.2 Hz, 2H), 3.05 (dd, <i>J</i> = 8.1, 7.6 Hz, 2H), 2.68 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.45 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 136.3, 135.0, 134.4, 134.2, 132.5, 132.4, 131.6, 128.9, 128.6, 127.7, 123.3, 119.9, 110.9, 103.4, 60.4, 36.9, 31.2, 20.7, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 342.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4i</b> was prepared from <b>3i</b> (22.1 mg, 64.0 μmol) in accordance with procedure III to generate 16.2 mg (81%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 53:47, isocratic condition). HPLC purity = 98.8%, <i>t</i><sub>R</sub> = 14.90. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.34 (br s, 1H), 7.45 (d, <i>J</i> = 1.6 Hz, 1H), 7.34 (s, 1H), 7.26 (d, <i>J</i> = 8.3 Hz, 1H), 7.24–7.16 (m, 2H), 6.96 (d, <i>J</i> = 8.3 Hz, 1H), 6.48 (d, <i>J</i> = 1.1 Hz, 1H), 2.88 (t, <i>J</i> = 7.6 Hz, 2H), 2.54 (t, <i>J</i> = 7.6 Hz, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.4, 136.9, 135.9, 135.4, 135.0, 133.1, 132.9, 131.6, 129.4, 129.0, 127.9, 123.6, 120.0, 111.6, 103.2, 36.4, 31.3, 20.5. LRMs-ESI (<i>m</i>/<i>z</i>): 314.1 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>ClNO<sub>2</sub>, 314.0948; found, 314.0950.</p></td></tr></table></div></div><div id="sec4_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-(2-(4-Bromo-2-methylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4j</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list10" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2j</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 4-bromo-1-iodo-2-methylbenzene (79.4 μL, 0.55 mmol) in accordance with procedure I to generate 147 mg (83%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 4:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.40 (s, 1H), 7.36–7.29 (m, 2H), 7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.00 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.17 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.84 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.48 (s, 3H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 146.0, 141.6, 133.0, 132.5, 131.7, 130.2, 130.1, 128.9, 122.19, 122.15, 114.7, 108.0, 92.6, 91.0, 60.4, 36.2, 30.0, 20.8, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 386.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3j</b> was prepared from <b>2j</b> (100 mg, 0.26 mmol) in accordance with procedure II to generate 80.4 mg (80%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (br s, 1H), 7.65 (dd, <i>J</i> = 1.3, 8.5 Hz, 1H), 7.46–7.10 (m, 3H), 7.34–7.30 (m, 2H), 7.04 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.76 (d, <i>J</i> = 1.4 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.04 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 138.2, 136.5, 134.9, 133.8, 132.4, 131.6, 130.3, 129.1, 128.9, 123.1, 121.8, 119.7, 110.8, 103.1, 60.4, 36.8, 31.2, 20.9, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 386.2 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4j</b> was prepared from <b>3j</b> (26.1 mg, 67.0 μmol) in accordance with procedure III to generate 17.2 mg (72%) of a yellow amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 60:40, isocratic condition). HPLC purity = 99.5%, <i>t</i><sub>R</sub> = 15.20. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.06 (br s, 1H), 7.47 (s, 1H), 7.46 (d, <i>J</i> = 1.8 Hz, 1H), 7.39 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.33 (d, <i>J</i> = 7.37 Hz, 1H), 7.31 (d, <i>J</i> = 8.1 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 7.54 (dd, <i>J</i> = 2.0, 0.7 Hz, 1H), 3.07 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.74 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 2.46 (s, 3H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 177.7, 138.2, 136.6, 134.9, 133.8, 132.0, 131.5, 130.3, 129.1, 129.0, 123.0, 121.8, 119.7, 110.8, 103.1, 36.2, 30.8, 20.9. LRMs-ESI (<i>m</i>/<i>z</i>): 358.1 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>BrNO<sub>2</sub>, 358.0443; found, 358.0438.</p></td></tr></table></div></div><div id="sec4_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-(2-(4-Fluoro-2-methylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4k</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list11" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2k</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 4-fluoro-1-iodo-2-methylbenzene (72.8 μL, 0.55 mmol) in accordance with procedure I to generate 103 mg (69%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.54–7.49 (m, 2H), 7.36–7.32 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.67 (d, <i>J</i> = 8.2 Hz, 1H), 4.18 (br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 8.0, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 163.5, 161.0, 145.9, 142.3 (d, <i>J</i> = 8.2 Hz), 133.4 (d, <i>J</i> = 8.7 Hz), 131.6, 130.0 (d, <i>J</i> = 26.4 Hz), 119.2 (d, <i>J</i> = 3.0 Hz), 116.5 (d, <i>J</i> = 21.9 Hz), 114.6, 112.9 (d, <i>J</i> = 21.9 Hz), 108.1, 92.4, 89.5, 60.4, 36.2, 30.0, 21.1, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 326.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3k</b> was prepared from <b>2k</b> (64.3 mg, 0.20 mmol) in accordance with procedure II to generate 34.3 mg (53%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 10:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.30 (br s, 1H), 7.65 (dd, <i>J</i> = 1.3, 8.5 Hz, 1H), 7.46–7.10 (m, 3H), 7.34–7.30 (m, 2H), 7.04 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.76 (d, <i>J</i> = 1.4 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.04 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 162.3 (d, <i>J</i> = 247.34 Hz), 138.8 (d, <i>J</i> = 7.8 Hz), 136.9, 134.8, 132.4, 130.7 (d, <i>J</i> = 8.6 Hz), 129.0, 128.9 (d, <i>J</i> = 3.3 Hz), 122.9, 119.7, 117.6 (d, <i>J</i> = 21.2 Hz), 113.0 (d, <i>J</i> = 21.2 Hz), 110.7, 102.7, 60.4, 36.9, 31.2, 21.1, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 326.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4k</b> was prepared from <b>3k</b> (24.3 mg, 75.0 μmol) in accordance with procedure III to generate 22.1 mg (99%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 53:57, isocratic condition). HPLC purity = 99.9%, <i>t</i><sub>R</sub> = 13.81. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.27 (br s, 1H), 7.40 (m, 1H), 7.31 (s, 1H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 7.01 (dd, <i>J</i> = 10.1, 2.5 Hz, 1H), 6.97–6.91 (m, 2H), 6.39 (d, <i>J</i> = 1.9 Hz, 1H), 2.87 (t, <i>J</i> = 7.6 Hz, 2H), 2.54 (t, <i>J</i> = 7.6 Hz, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.3, 162.6 (d, <i>J</i> = 244.7 Hz), 139.5 (d, <i>J</i> = 8.1 Hz), 137.4, 135.8, 132.7, 131.5 (d, <i>J</i> = 8.7 Hz), 128.9 (d, <i>J</i> = 2.9 Hz), 129.5, 123.1, 119.8, 113.2 (d, <i>J</i> = 21.4 Hz), 111.5, 102.4, 36.4, 31.2, 20.9. LRMs-ESI (<i>m</i>/<i>z</i>): 298.2 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>FNO<sub>2</sub>, 298.1243; found, 298.1242.</p></td></tr></table></div></div><div id="sec4_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 3-(2-(4-Amino-2-chlorophenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4l</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list12" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2l</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 4-bromo-3-chloroaniline (114 mg, 0.55 mmol) in accordance with procedure I to generate 45.6 mg (29%) of a pale brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 3:1 and then dichloromethane only, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.19 (d, <i>J</i> = 2.0 Hz, 1H), 6.96 (dd, <i>J</i> = 8.2, 2.1, 1H), 6.74 (d, <i>J</i> = 2.3 Hz, 1H), 6.65 (d, <i>J</i> = 8.2 Hz, 1H), 6.54 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 4.31 (br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 3.89 (br s, 2H), 2.83 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 2.56 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.1, 147.3, 146.3, 136.3, 133.7, 131.1, 129.8, 129.6, 115.0, 114.4, 113.3, 112.6, 108.3, 92.1, 88.9, 60.4, 36.3, 30.0, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 343.3 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3l</b> was prepared from <b>2l</b> (39.3 mg, 0.11 mmol) in accordance with procedure II to generate 8.00 mg (20%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 1:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.60 (br s, 1H), 7.43 (s, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 1H), 7.02 (dd, <i>J</i> = 8.3, 1.3 Hz, 1H), 6.76 (d, <i>J</i> = 2.3 Hz, 1H), 6.40 (d, <i>J</i> = 1.9 Hz, 1H), 6.61 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 3.83 (br s, 2H), 3.04 (dd, <i>J</i> = 8.1, 7.7 Hz, 2H), 2.66 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 147.0, 136.1, 134.9, 132.2, 132.1, 131.6, 128.6, 122.8, 121.3, 119.5, 116.2, 114.0, 110.8, 101.6, 60.3, 36.9, 31.3, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 343.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4l</b> was prepared from <b>3l</b> (8.00 mg, 23 μmol) in accordance with procedure III to generate 6.30 mg (87%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 40:60, isocratic condition). HPLC purity = 88.2%, <i>t</i><sub>R</sub> = 9.64. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.39 (br s, 1H), 7.39–7.35 (m, 2H), 7.33 (d, <i>J</i> = 8.3 Hz, 1H), 7.00 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.78 (d, <i>J</i> = 2.3 Hz, 1H), 6.67 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.88 (dd, <i>J</i> = 1.4, 0.6 Hz, 1H), 4.51 (br s, 2H), 2.95 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.62 (dd, <i>J</i> = 7.8, 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.2, 149.6, 136.7, 135.6, 132.62, 132.56, 132.0, 129.4, 122.9, 120.4, 119.6, 115.7, 114.0, 111.4, 101.7, 36.4, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 315.1 [M + H]<sup>+</sup>. HRMS-EI (<i>m</i>/<i>z</i>): [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub>, 314.0817; found, 314.0819.</p></td></tr></table></div></div><div id="sec4_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 3-(2-(4-Chloro-2-(trifluoromethyl)phenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4m</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list13" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2m</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 1-bromo-4-chloro-2-(trifluoromethyl)benzene (80.9 μL, 0.55 mmol) in accordance with procedure I to generate 110 mg (60%) of a brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 1.3 Hz, 1H), 7.59 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (dd, <i>J</i> = 8.3, 1.3 Hz, 1H), 7.20 (d, <i>J</i> = 1.4 Hz, 1H), 7.02 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 6.65 (d, <i>J</i> = 8.3 Hz, 1H) 4.25 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.57 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.9, 146.9, 134.8, 133.8, 132.0 (d, <i>J</i> = 30.8 Hz), 131.82, 131.78, 130.9, 130.0, 126.4 (q, <i>J</i> = 5.3 Hz), 123.0 (d, <i>J</i> = 274.0 Hz), 120.3, 114.8, 106.8, 93.2, 89.5, 60.4, 36.2, 29.9, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 396.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3m</b> was prepared from <b>2m</b> (101 mg, 0.25 mmol) in accordance with procedure II to generate 43.7 mg (44%) of a brown solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.26 (br s, 1H), 7.78 (s, 1H), 7.58 (s, 2H), 7.48 (s, 1H), 7.33 (d, <i>J</i> = 8.3, 1H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 6.63 (s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.06 (dd, <i>J</i> = 8.0, 7.7 Hz, 2H), 2.68 (dd, <i>J</i> = 8.0, 7.7 Hz, 2H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.2, 135.5, 134.3, 134.0, 133.7, 132.7, 132.0, 130.7, 129.3 (d, <i>J</i> = 31.17 Hz), 128.5, 126.9 (q, <i>J</i> = 5.81 Hz), 123.8, 123.4 (d, <i>J</i> = 273.9 Hz), 120.0, 111.0, 104.3, 60.4, 37.0, 31.2, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 396.6 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4m</b> was prepared from <b>3m</b> (33.8 mg, 80.0 μmol) in accordance with procedure III to generate 17.2 mg (58%) of a white amorphous solid, purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 62:38, isocratic condition). HPLC purity = 98.3%, <i>t</i><sub>R</sub> = 15.11. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.34 (br s, 1H), 7.78 (d, <i>J</i> = 1.8 Hz, 1H), 7.62 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.35 (s, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 6.99 (d, <i>J</i> = 8.4 Hz, 1H), 6.47 (s, 1H), 2.88 (t, <i>J</i> = 7.6 Hz, 2H), 2.54 (t, <i>J</i> = 7.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.2, 136.2, 134.6, 134.5, 134.4, 133.2, 132.6, 131.8, 130.0 (q, <i>J</i> = 30.9 Hz), 129.1, 127.2 (q, <i>J</i> = 5.8 Hz), 124.0 (d, <i>J</i> = 273.0 Hz), 123.9, 120.1, 111.7, 104.0, 36.4, 31.3. LRMs-ESI (<i>m</i>/<i>z</i>): 368.3 [M + H]<sup>+</sup>. HRMS-EI (<i>m</i>/<i>z</i>): [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>13</sub>ClF<sub>3</sub>NO<sub>2</sub>, 367.0587; found, 367.0582.</p></td></tr></table></div></div><div id="sec4_1_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 3-(2-(2,4-Dimethylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4n</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list14" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2n</b> was prepared from <b>1</b> (50 mg, 0.26 mmol) and 2-bromo-2,4-dimethylbenzene (42.2 μL, 0.31 mmol) in accordance with procedure I to generate 31.4 mg (38%) of a pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.05 (s, 1H), 7.00–6.95 (m, 2H), 6.65 (d, <i>J</i> = 8.2 Hz, 1H), 4.19 (br s, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 2.57 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 2.47 (s, 3H), 2.33 (s, 3H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 145.9, 139.5, 138.4, 131.7, 131.6, 130.4, 130.1, 129.6, 126.5, 120.1, 114.6, 108.6, 93.7, 89.1, 60.4, 36.3, 30.0, 21.4, 20.9, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 322.7 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3n</b> was prepared from <b>2n</b> (31.4 mg, 97.7 μmol) in accordance with procedure II to generate 22.5 mg (72%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.11 (br s, 1H), 7.44 (s, 1H), 7.34 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.12 (s, 1H), 7.07 (d, <i>J</i> = 7.8 Hz, 1H), 7.03 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 6.51 (d, <i>J</i> = 1.5 Hz, 1H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 3.05 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.67 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.45 (s, 3H), 2.36 (s, 3H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.4, 138.0, 137.8, 135.9, 134.8, 132.2, 131.8, 129.8, 129.2, 128.9, 126.8, 122.6, 119.6, 110.7, 102.4, 60.4, 37.0, 31.3, 21.1, 21.0, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 322.6 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4n</b> was prepared from <b>3n</b> (22.5 mg, 70.0 μmol) in accordance with procedure III to generate 16.1 mg (78%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 57:43, isocratic condition). HPLC purity = 97.8%, <i>t</i><sub>R</sub> = 15.14. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.24 (br s, 1H), 7.31–7.27 (m, 2H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 7.06 (s, 1H), 7.01 (d, <i>J</i> = 7.8 Hz, 1H), 6.92 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.38 (dd, <i>J</i> = 2.2, 0.7 Hz, 1H), 2.87 (t, <i>J</i> = 7.7 Hz, 2H), 2.54 (t, <i>J</i> = 7.7 Hz, 2H), 2.34 (s, 3H), 2.25 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.4, 138.6, 138.2, 136.3, 135.7, 132.5, 132.2, 130.3, 129.6, 129.4, 127.2, 122.9, 119.7, 111.4, 102.0, 36.4, 31.3, 20.9, 20.7. LRMs-ESI (<i>m</i>/<i>z</i>): 294.5 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>19</sub>NO<sub>2</sub>, 294.1494; found, 294.1491.</p></td></tr></table></div></div><div id="sec4_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 3-(2-(2,5-Dimethylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4o</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list15" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2o</b> was prepared from <b>1</b> (61 mg, 0.28 mmol) and 2-bromo-1,4-dimethylbenzene (46.9 μL, 0.34 mmol) in accordance with procedure I to generate 32.0 mg (52%) of a pale brown oil, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.32 (s, 1H), 7.21 (d, <i>J</i> = 1.9 Hz, 1H), 7.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.05 (d, <i>J</i> = 7.7 Hz, 1H), 6.98 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.67 (d, <i>J</i> = 8.2 Hz, 1H), 4.19 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.84 (dd, <i>J</i> = 8.0, 7.6 Hz, 2H), 2.57 (dd, <i>J</i> = 8.1, 7.5 Hz, 2H), 2.47 (s, 3H), 2.31 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 146.0, 136.5, 135.1, 132.2, 131.6, 130.1, 129.7, 129.4, 129.1, 122.9, 114.6, 108.5, 93.8, 89.5, 60.4, 36.3, 30.0, 20.8, 20.5, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 322.7 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3o</b> was prepared from <b>2o</b> (26.0 mg, 80.9 μmol) in accordance with procedure II to generate 18.3 mg (70%) of a brown amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 68:32, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10 (br s, 1H), 7.46 (s, 1H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (s, 1H), 7.20 (d, <i>J</i> = 7.8 Hz, 1H), 7.09 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.05 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.54 (d, <i>J</i> = 1.4 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.06 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.68 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.45 (s, 3H), 2.37 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 138.0, 135.6, 134.8, 132.9, 132.4, 132.2, 131.0, 129.5, 129.1, 128.6, 122.7, 119.7, 110.7, 102.6, 60.3, 36.9, 31.2, 21.0, 20.6, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 322.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4o</b> was prepared from <b>3o</b> (11.4 mg, 35.0 μmol) in accordance with procedure III to generate 8.42 mg (82%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 57:43, isocratic condition). HPLC purity = 96.6%, <i>t</i><sub>R</sub> = 14.59. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 9.28 (br s, 1H), 7.31 (s, 1H), 7.27–7.24 (m, 2H), 7.11 (d, <i>J</i> = 7.7 Hz, 1H), 7.01 (dd, <i>J</i> = 7.7, 1.1 Hz, 1H), 6.93 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.42 (dd, <i>J</i> = 2.1, 0.7 Hz, 1H), 3.06 (dd, <i>J</i> = 7.7, 7.6 Hz, 2H), 2.54 (dd, <i>J</i> = 7.8, 7.5 Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.4, 138.6, 136.1, 135.8, 133.3, 133.0, 132.6, 131.5, 130.1, 129.6, 129.0, 123.0, 119.8, 111.4, 102.3, 36.5, 31.3, 20.6, 20.5. LRMs-ESI (<i>m</i>/<i>z</i>): 294.5 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>19</sub>NO<sub>2</sub>, 294.1494; found, 294.1501.</p></td></tr></table></div></div><div id="sec4_1_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-(2-(2,6-Dimethylphenyl)-1<i>H</i>-indol-5-yl)propanoic Acid (<b>4p</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list16" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>2p</b> was prepared from <b>1</b> (100 mg, 0.46 mmol) and 2-bromo-1,3-dimethylbenzene (61.3 μL, 0.46 mmol) in accordance with procedure I to generate 30.0 mg (20%) of a pale yellow oil, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 4:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.22 (s, 1H), 7.16–7.06 (m, 3H), 6.99 (d, <i>J</i> = 8.2 Hz, 1H), 6.68 (d, <i>J</i> = 8.2 Hz, 1H), 4.19 (br s, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.85 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.58 (dd, <i>J</i> = 7.9, 7.6 Hz, 2H), 2.51 (s, 6H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.0, 145.8, 139.8, 131.6, 130.2, 129.7, 127.7, 126.8, 123.2, 114.6, 108.7, 94.5, 92.3, 60.4, 36.3, 30.1, 21.4, 14.2. LRMs-ESI (<i>m</i>/<i>z</i>): 322.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>3p</b> was prepared from <b>2p</b> (19.6 mg, 61.0 μmol) in accordance with procedure II to generate 14.5 mg (74%) of a pale yellow sticky solid, which was purified by silica gel column chromatography (<i>n</i>-hexane:ethyl acetate = 5:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86 (br s, 1H), 7.47 (s, 1H), 7.31 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (t, <i>J</i> = 8.2 Hz, 1H), 7.13 (s, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.33 (dd, <i>J</i> = 2.0, 0.7 Hz, 1H), 4.15 (q, <i>J</i> = 7.1 Hz, 2H), 3.07 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.69 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.17 (s, 6H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 138.3, 136.6, 134.7, 133.1, 132.0, 129.1, 128.5, 127.3, 122.3, 119.6, 110.6, 102.3, 60.3, 36.9, 31.2, 20.5, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 322.5 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>4p</b> was prepared from <b>3p</b> (12.7 mg, 39.0 μmol) in accordance with procedure III to generate 11.4 mg (80%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 57:43, isocratic condition). HPLC purity = 98.4%, <i>t</i><sub>R</sub> = 14.88. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.00 (br s, 1H), 10.90 (s, 1H), 7.29 (s, 1H), 7.19–7.13 (m, 2H), 7.09–7.05 (m, 2H), 6.87 (dd, <i>J</i> = 8.3, 1.0 Hz, 1H), 6.14 (d, <i>J</i> = 1.4 Hz, 1H), 2.83 (t, <i>J</i> = 7.5 Hz, 2H), 2.49 (t, <i>J</i> = 7.5 Hz, 2H), 2.04 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.6, 137.8, 136.8, 135.2, 133.9, 131.6, 128.8, 128.5, 127.7, 121.9, 119.2, 111.3, 101.0, 36.8, 31.2, 20.8. LRMs-ESI (<i>m</i>/<i>z</i>): 294.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>19</sub>NO<sub>2</sub>, 294.1494; found, 294.1495.</p></td></tr></table></div></div><div id="sec4_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-(2-(4-Fluoro-2-methylphenyl)-1-methyl-1<i>H</i>-indol-5-yl)propanoic Acid (<b>6k</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list17" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>5k</b> was prepared from <b>3k</b> (34.1 mg, 105 μmol) in accordance with procedure IV to generate 21.4 mg (60%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 7:1, isocratic condition). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46 (d, <i>J</i> = 0.8 Hz, 1H), 7.29–7.21 (m, 2H), 7.11 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.02 (dd, <i>J</i> = 10.0, 2.6 Hz, 1H), 6.95 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 6.35 (s, 1H), 4.15 (q, <i>J</i> = 7.1 Hz, 2H), 3.47 (s, 3H), 3.07 (dd, <i>J</i> = 8.2, 7.6 Hz, 2H), 2.68 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.17 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 162.9 (d, <i>J</i> = 247.5 Hz), 140.6 (d, <i>J</i> = 8.1 Hz), 139.7, 136.2, 132.6 (d, <i>J</i> = 8.4 Hz), 132.0, 128.5 (d, <i>J</i> = 3.0 Hz), 128.1, 122.2, 119.6, 116.7 (d, <i>J</i> = 21.2 Hz), 112.5 (d, <i>J</i> = 21.2 Hz), 109.4, 101.6, 60.4, 37.0, 31.2, 30.3, 20.2, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 340.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>6k</b> was prepared from <b>5k</b> (21.4 mg, 63.0 μmol) in accordance with procedure III to generate 18.4 mg (94%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 59:41, isocratic condition). HPLC purity = 100%, <i>t</i><sub>R</sub> = 14.32. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 8.81 (br s, 1H), 7.33 (d, <i>J</i> = 0.8 Hz, 1H), 7.27–7.21 (m, 2H), 7.04 (dd, <i>J</i> = 10.1, 2.7 Hz, 1H), 7.02 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.96 (td, <i>J</i> = 8.6, 2.7 Hz, 1H), 6.24 (s, 1H), 3.37 (s, 3H), 2.90 (t, <i>J</i> = 7.6 Hz, 2H), 2.55 (dd, <i>J</i> = 7.7, 7.5 Hz, 2H), 2.08 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.2, 163.4 (d, <i>J</i> = 245.0 Hz), 141.6 (d, <i>J</i> = 8.4 Hz), 140.2, 136.9, 132.4 (d, <i>J</i> = 8.5 Hz), 132.7, 129.4 (d, <i>J</i> = 3.0 Hz), 128.7, 122.7, 119.9, 117.0 (d, <i>J</i> = 21.6 Hz), 112.9 (d, <i>J</i> = 21.4 Hz), 110.3, 101.6, 36.4, 31.3, 30.4, 19.9. LRMs-ESI (<i>m</i>/<i>z</i>): 312.3 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>18</sub>FNO<sub>2</sub>, 312.1400; found, 312.1401.</p></td></tr></table></div></div><div id="sec4_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-(2-(2,5-Dimethylphenyl)-1-methyl-1<i>H</i>-indol-5-yl)propanoic Acid (<b>6q</b>)</h5><div class="NLM_p last"><table class="listgroup" border="0" width="95%" id="list18" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>5q</b> was prepared from <b>3q</b> (31.4 mg, 98.0 μmol) in accordance with procedure IV to generate 19.2 mg (59%) of a pale yellow solid, which was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 7:1, isocratic condition). HPLC purity = 98.3%, <i>t</i><sub>R</sub> = 15.10. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46 (d, <i>J</i> = 0.8 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.21–7.13 (m, 2H), 7.12–7.07 (m, 2H), 7.12 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.35 (s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.48 (s, 3H), 3.07 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.68 (dd, <i>J</i> = 8.3, 7.6 Hz, 2H), 2.35 (s, 3H), 2.14 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 173.3, 141.1, 136.2, 135.0, 134.8, 132.4, 131.9, 131.7, 130.0, 129.4, 128.3, 121.9, 119.6, 109.4, 101.1, 60.3, 37.0, 31.3, 30.4, 20.9, 19.5, 14.3. LRMs-ESI (<i>m</i>/<i>z</i>): 336.4 [M + H]<sup>+</sup>.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>6q</b> was prepared from <b>5q</b> (19.2 mg, 57.2 μmol) in accordance with procedure III to generate 16.2 mg (92%) of a white amorphous solid, which was purified by C18 reverse column chromatography (acetonitrile with 0.1% formic acid/water with 0.1% formic acid = 64:36, isocratic condition). HPLC purity = 98.4% %, <i>t</i><sub>R</sub> = 15.10. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): δ 8.77 (br s, 1H), 7.31 (d, <i>J</i> = 0.8 Hz, 1H), 7.23 (d, <i>J</i> = 8.4 Hz, 1H), 7.15 (d, <i>J</i> = 7.8 Hz, 1H), 7.10 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.05 (s, 1H), 6.99 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.21 (s, 1H), 3.37 (s, 3H), 2.89 (t, <i>J</i> = 7.6 Hz, 2H), 2.55 (dd, <i>J</i> = 7.7, 7.5 Hz, 2H), 2.25 (s, 3H), 2.02 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN): δ 174.1, 141.6, 136.8, 135.7, 135.3, 132.9, 132.6, 132.0, 130.5, 130.0, 128.8, 122.5, 119.8, 110.2, 101.1, 36.4, 31.3, 30.5, 20.5, 19.2. LRMs-ESI (<i>m</i>/<i>z</i>): 308.4 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub>, 308.1651; found, 308.1662.</p></td></tr></table></div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Molecular Modeling</h3><div class="NLM_p last">Before the docking study, ligands were energy-minimized using the OPLS2005 force field charge in the LigPrep motif. Different conformations of the prepared GPR40 structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY">5TZY</a>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> were obtained from the IFD module implemented in the Schrödinger software suite.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The receptor grid box was defined as a 20 Å × 20 Å × 20 Å space region centered at the original ligand AP8 to include GPR40 full agonist binding sites for each conformation of the GPR40 protein. The original ligand was re-docked into the complex structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY">5TZY</a>) with a root-mean-square deviation of 0.6513 (Glide XP mode), suggesting that the docking method was able to reproduce the ligand’s active conformation. The best poses were selected by visual inspection and docking scoring.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> SRE Reporter Luciferase Assay</h3><div class="NLM_p last">Stable GPR40-transfected CHO cells were plated in 96-well white plates (Costar) in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) containing 10% fetal bovine serum (FBS) and 1% penicillin with 1.5 × 10<sup>4</sup> cells/well. After incubation for 24 h, SRE plasmids (pGL4.33[<i>luc2P</i>/SRE/Hygro]), Promega (Madison, WI) were transfected into CHO-GPR40 cells using the MaestroFectin transfection reagent (Omics Bio) according to the manufacturer’s instructions. After incubating for 3 h, the transfected CHO-GPR40 cells were treated with various concentrations of the compounds. Control cells were treated with 100 μL of 1% DMSO. After incubating for 24 h, firefly luciferase activity was measured using the Bright-Glo Assay System (Cat. #E2620; Promega) according to the manufacturer’s instructions. All individual <i>in vitro</i> assays for determining average efficiencies were performed more than twice using triplicate wells for each treatment.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> CRE Reporter Assay</h3><div class="NLM_p last">Briefly, CHO-GPR40 cells were plated in 96-well plates in DMEM (HyClone) containing 10% charcoal-stripped FBS and 1% penicillin at a density of 1.5 × 10<sup>4</sup> cells/well. After incubating for 24 h, the cells were transfected with the Cignal CRE Reporter (QIAGEN, Cignal CRE (Luc) Reporter kit, CCS-002L) using Lipofetamine2000 (Invitrogen) as the transfection reagent, according to the manufacturer’s instructions. After 6 h, the transfected CHO cells were treated with various concentrations of the compounds or GW9508. Control cells were treated with 1% DMSO. After incubating for 24 h, a dual-luciferase assay was performed according to the manufacturer’s instructions. The promoter activity values are expressed as arbitrary units using the Renilla reporter for internal normalization. After incubating for 24 h, the luciferase activity was measured using the dual-luciferase assay system (Promega) according to the manufacturer’s instructions. All individual <i>in vitro</i> assays for determining the average efficiencies were performed twice using triplicate wells for each treatment.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> cAMP-Glo Assay</h3><div class="NLM_p last">Briefly, CHO-GPR40 cells were plated in 96-well plates in DMEM (HyClone) containing 10% charcoal-stripped FBS and 1% penicillin at a density of 1.5 × 10<sup>4</sup> cells/well. After incubating for 24 h, the cells were washed twice using an induction buffer. Next, 40 μL of the induction buffer and desired concentration of the compounds were added into each well and incubated in a humidified 5% CO<sub>2</sub> cell culture incubator. After incubating for 30 min, the cells were lysed using a lysis buffer, and the luciferase activity was measured according to the manufacturer’s instructions (cAMP-Glo Assay, V1501, Promega). All individual <i>in vitro</i> assays for determining the average efficiencies were performed thrice using triplicate wells for each treatment.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> GLP-1 Secretion Assay</h3><div class="NLM_p last">Briefly, STC-1 cells were plated in 96-well poly-<span class="smallcaps smallerCapital">d</span>-lysine coated plates (Corning) at a density of 10,000 cells per well in DMEM (HyClone) containing 15% charcoal-stripped FBS and 1% penicillin. The plate was incubated for 48 h at 37 °C in a humidified 5% CO<sub>2</sub> cell culture incubator. After incubation, cells were carefully washed using 200 μL of pre-warmed Hank’s balanced salt buffer (HBSS) with 0.1% BSA to eliminate background secretions. Then, the cells were starved in HBSS with 0.1% BSA for 3 h. The compounds were diluted in DMEM with 0.1% BSA containing 5 μM of the DPP-4 inhibitor, KR-62436 (761414-79-3, Sigma-Aldrich). Then, the plate was incubated for 1 h at 37 °C. Next, the cell supernatant was collected and stored at −80 °C until analysis. The secreted GLP-1 was evaluated using the mouse/human/rat GLP-1/glucagon-like peptide 1 ELISA kit (LS-F412, LSBIO) according to the manufacturer’s instructions.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Insulin Secretion Assay</h3><div class="NLM_p last">Briefly, MIN6 insulinoma cells were plated in 96-well plates (5 × 10<sup>5</sup> cells/well) to assess insulin release. On day 1 of the experiment, the culture medium was aspirated, and the cells were twice washed with HEPES-balanced Krebs/Ringer bicarbonate buffer (KRBB) containing 0.5% fatty acid-free BSA (KRBB buffer) and then starved at 37 °C for 2 h in KRBB containing 3 mM glucose. After starvation, the cells were incubated with compounds at 37 °C for 2 h in KRBB buffer containing 3 mM or 17 mM glucose. Insulin levels in the supernatant were determined using a mouse high-range insulin ELISA kit (ALPCO, Windham, NH) according to the manufacturers’ instructions.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> PPAR-γ Transactivation Activity</h3><div class="NLM_p last">Briefly, CHO cells were plated in 96-well plates in DMEM (HyClone) containing 10% charcoal-stripped FBS and 1% penicillin at a density of 1.5 × 10<sup>4</sup> cells/well. After incubating for 24 h, the cells were co-transfected using the Cignal PPAR Reporter (QIAGEN, Cignal PPAR (Luc) Reporter kit, CCS-3026L) along with pCMV6-hPPARG-GFP (Origene, RG201538) using Lipofetamine2000 (Invitrogen) according to the manufacturer’s instructions. After 6 h, the transfected CHO cells were treated with various concentrations of compounds or rosiglitazone. Control cells were treated with 1% DMSO. After incubating for 24 h, a dual-luciferase assay was performed following the manufacturer’s instructions. The promoter activity values are expressed as arbitrary units using the Renilla reporter for internal normalization. After incubating for 24 h, the luciferase activity was measured using the dual-luciferase assay system (Promega) according to the manufacturer’s instructions. All individual <i>in vitro</i> assays for determining average efficiencies were performed thrice using triplicate wells for each treatment.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Measurement of Caspase 3/7 Activity</h3><div class="NLM_p last">To prepare 1 mM PA–BSA conjugates, 55.7 mg of sodium palmitic acid was dissolved in 10 mL of hot distilled water and added to 10 mL of RPMI 1640 medium at 37 °C containing 20% (w/v) FFA-free BSA under stirring, followed by filtration (0.22 mm). MIN6 cells were seeded at a density of 2 × 10<sup>4</sup> cells/well in 96-well black clear plates (CORNING) and cultured overnight. After discarding the medium, 1% BSA and PA–BSA conjugates (62.5, 125, 250, 500, and 1000 μM), in combination with 0.1% DMSO or compounds, were added to the plates and cultured for 72 h. After incubation, caspase 3/7 activity was measured using the Apo-ONE homogeneous caspase 3/7 assay (Promega) according to the manufacturers’ instructions. The fluorescence intensity was measured at excitation and emission wavelengths of 485 and 535 nm, respectively.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>In Vivo</i> Pharmacokinetic Study</h3><div class="NLM_p last">Pharmacokinetic study was conducted by National Efficacy Evaluation Center for Metabolic Disease Therapeutics, Korea. Briefly, 5 week old male CD-1 mice were randomly assigned to three groups (<i>n</i> = 3 for each group, group: 10, 30, or 90 mpk) and fasted 12 h with free access to water before dosing. About 10, 30, or 90 mpk of compounds <b>4k</b> and <b>4o</b> were administered to mice by oral gavage.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The formulations were prepared by dissolving compounds in DMSO. Tail bleeds were taken at 1/3, 2/3, 1, 1.5, 2, 3, 4, 6, and 8 h. Plasma samples were obtained after centrifugation at 5000 rpm (1500 g). The samples were measured using the TQ5500 LC/MS/MS (AB/SCIEX) MRM mode. Pharmacokinetic parameters were calculated by the non-compartmental analysis model using WinNonlin software (Pharsight, version 7.0).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>In Vivo</i> Oral Glucose Tolerance Test</h3><div class="NLM_p last">Oral glucose tolerance test was conducted by National Efficacy Evaluation Center for Metabolic Disease Therapeutics, Korea. Briefly, 8 week old male C57BL/6J mice and 6 week old male db/db mice were used. The day before OGTT, animals were allowed to fastt in clean cages. The following day, the animals were weighted, bled <i>via</i> the tail vein, and randomized into four groups for each (<i>n</i> = 8 per group) so that each group had similar mean and standard deviation of body weight and blood glucose. A single dose of vehicle, TAK875 (10 mpk), or selected compounds (30 mpk) were orally administered 60 min prior to an OGTT of glucose. Plasma glucose levels were determined from tail bleeds taken at 0, 15, 30, 60, and 120 min after the glucose challenge. An average of two readings was reported at each time point.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Measurement of Plasma-Active GLP-1 in the Fasted State of C57BL/6J Mice</h3><div class="NLM_p last">Plasma-active GLP-1 measurement was conducted by National Efficacy Evaluation Center for Metabolic Disease Therapeutics, Korea. Briefly, 8 week old male C57BL/6J mice were used. Before experiment, the mice were allowed to fast in clean cages overnight (for 16 h). On the day of experiment, the mice were randomized into three groups for each (<i>n</i> = 5 per group) and were dosed with compounds (30 mg/kg, p.o.) and a DPP4 inhibitor (10 mg/kg, i.p., KR-62436, Sigma Aldrich, USA). The plasma samples were collected from tail vein at 30 min into prechilled EDTA tubes containing a protease inhibitor cocktail (Sigma-Aldrich, USA) and a DPP4 inhibitor. The plasma-active GLP-1 levels were measured using an ELISA kit (catalog no: GP121-K01, Eagle Biosciences, Amherst, NH, USA) according to the manufacturer’s instruction.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00031" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00031?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00031</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula string (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compliance statement (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Atomic coordinates for docking models for the compounds (<b>4k</b><a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_003.pdb" class="ext-link">PDB</a>, <b>4o</b><a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_004.pdb" class="ext-link">PDB</a>, and <b>6k</b><a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_005.pdb" class="ext-link">PDB</a>) in Figure 5, will be released upon article publication</p></li><li><p class="inline">Solubility of <b>4k</b> and <b>4o</b>, site-directed mutation assay data and method, and HPLC and HRMS spectra for the compounds studied in this paper (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_001.csv">jm1c00031_si_001.csv (0.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_002.pdf">jm1c00031_si_002.pdf (322.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_003.pdb">jm1c00031_si_003.pdb (473.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_004.pdb">jm1c00031_si_004.pdb (471.68 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_005.pdb">jm1c00031_si_005.pdb (473.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf">jm1c00031_si_006.pdf (4.25 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00031" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun-Ju Park</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Sungkyunkwan
University, Suwon 16419, South Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6802-1412" title="Orcid link">http://orcid.org/0000-0001-6802-1412</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4bcada1babea1ece194a7bfbfa1fab1b0a1"><span class="__cf_email__" data-cfemail="4b23323e25213e737e0b3820203e652e2f3e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaodi Zhao</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Sungkyunkwan
University, Suwon 16419, South Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong-Oh Yoon</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Sungkyunkwan
University, Suwon 16419, South Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaeho Yoo</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, Sungkyunkwan
University, Suwon 16419, South Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.Z. and D.-O.Y. have equally contributed to this work. H.-J.P. directed this project and designed the experiments; X.Z. also designed the experiments and performed the biological assays and docking simulation; D.-O.Y. synthesized all compounds; J.Y. contributed to the structural charaterization of compounds. H.-J.P. wrote the manuscript, with assistance from X.Z. and D.-O.Y. All authors have approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge the contribution of graduate student Wonyoung Lee for reiterating reporter assays to validate the GPR40 agonistic activities (EC<sub>50</sub> values) for the compounds and Dr. Yan Jin and Professor Jeongmee Lee at our department for identifying the compounds by HRMS. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean Government (NRF-2018R1D1A1B07051124 and NRF-2019R1A5A2027340 to H.-J. Park) and in part by Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry for Health and Welfare, Korea (HI15C0987 to NECMD).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">GPR40</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor 40</p></td></tr><tr><td class="NLM_term">FFAR</td><td class="NLM_def"><p class="first last">free fatty acid receptor</p></td></tr><tr><td class="NLM_term">GSIS</td><td class="NLM_def"><p class="first last">glucose-stimulated insulin secretion</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">SRE</td><td class="NLM_def"><p class="first last">serum response element</p></td></tr><tr><td class="NLM_term">DHA</td><td class="NLM_def"><p class="first last">docosahexaenoic acid</p></td></tr><tr><td class="NLM_term">LA</td><td class="NLM_def"><p class="first last">linoleic acid</p></td></tr><tr><td class="NLM_term">AgoPAM</td><td class="NLM_def"><p class="first last">allosteric agonist and positive allosteric modulator</p></td></tr><tr><td class="NLM_term">ICL</td><td class="NLM_def"><p class="first last">intracellular loop</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">PPARγ</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor-gamma</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83236" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83236" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danaei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finucane, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzadfar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khang, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzati, M.</span></span> <span> </span><span class="NLM_article-title">National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(11)60679-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2FS0140-6736%2811%2960679-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21705069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlyltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=31-40&author=G.+Danaeiauthor=M.+M.+Finucaneauthor=Y.+Luauthor=G.+M.+Singhauthor=M.+J.+Cowanauthor=C.+J.+Paciorekauthor=J.+K.+Linauthor=F.+Farzadfarauthor=Y.-H.+Khangauthor=G.+A.+Stevensauthor=M.+Raoauthor=M.+K.+Aliauthor=L.+M.+Rileyauthor=C.+A.+Robinsonauthor=M.+Ezzati&title=National%2C+regional%2C+and+global+trends+in+fasting+plasma+glucose+and+diabetes+prevalence+since+1980%3A+systematic+analysis+of+health+examination+surveys+and+epidemiological+studies+with+370+country-years+and+2%C2%B77+million+participants&doi=10.1016%2Fs0140-6736%2811%2960679-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants</span></div><div class="casAuthors">Danaei, Goodarz; Finucane, Mariel M.; Lu, Yuan; Singh, Gitanjali M.; Cowan, Melanie J.; Paciorek, Christopher J.; Lin, John K.; Farzadfar, Farshad; Khang, Young-Ho; Stevens, Gretchen A.; Rao, Mayuree; Ali, Mohammed K.; Riley, Leanne M.; Robinson, Carolyn A.; Ezzati, Majid; Danaei, Goodarz; Finucane, Mariel M.; Lu, Yuan; Singh, Gitanjali M.; Cowan, Melanie J.; Paciorek, Christopher J.; Lin, John K.; Farzadfar, Farshad; Khang, Young-Ho; Stevens, Gretchen A.; Rao, Mayuree; Ali, Mohammad K.; Riley, Leanne M.; Robinson, Carolyn A.; Ezzati, Majid; Abdeen, Ziad; Aekplakorn, Wichai; Afifi, Mustafa M.; Agabiti-Rosei, Enrico; Salinas, Carlos A. Aguilar; Alnsour, Mohannad; Ambady, Ramachandran; Barbagallo, Carlo M.; Barcelo, Alberto; Barros, Henrique; Bautista, Leonelo E.; Benetos, Athanase; Bjerregaad, Peter; Bo, Simona; Bovert, Pascal; Burszytn, Michael; Cabrera de Leon, Antonio; Castellano, Maurizio; Castetbon, Katia; Chaouki, Noureddine; Chen, Chien-Jen; Chua, Lily; Cifkova, Renata; Corsi, Anna Maria; Delgado, Elias; Doi, Yasufumi; Esteghamati, Alireza; Fall, Caroline H. D.; Fan, Jian-Gao; Ferreccio, Catterina; Fezeu, Leopold; Fuller, Eva L.; Giampaoli, Simona; Gomez, Luis F.; Carvajal, Ramiro Guerrero; Herman, Willaim H.; Herrera, Victor M.; Ho, Suzanne; Hussain, Akhtar; Ikeda, Nayu; Jafar, Tazeen H.; Jonas, Jost B.; Kadiki, Othman A.; Karalis, Ioannis; Katz, Joanne; Khalilzadeh, Omid; Kiechl, Stefan; Kurjata, Pawel; Lee, Jeannette; Lee, Jeannette; Lim, Stephen; Lim, T. O.; Lin, Cheng-Chieh; Lin, Xu; Lin, Hsien-Ho; Liu, Xiaoqing; Lorbeer, Roberto; Ma, Stefan; Maggi, Stefania; Magliano, Dianna J.; McFarlane-Anderson, Norma; Miettola, Juhani; Miranda, J. Jaime; Mohamed, Mostafa K.; Mohan, V.; Mokdad, Ali; Morales, Dante D.; Nabipour, Iraj; Nakagami, Tomoko; Nangia, Vinay; Neuhauser, Hannelore; Noale, Marianna; Onat, Altan; Orostegui, Myriam; panagiotakos, Demosthenes B.; Passos, Valeria M. A.; Perez, Cynthia; Pichardo, Rafael; Phua, Hwee Pin; Plans, Pedro; Qiao, Qing; Ramos, Luiz R.; Rampal, Sanjay; Rampal, Lekhraj; Redon, Josep; Revilla, Luis; Rosero-Bixby, Luis; Sanisoglu, Selim Y.; Scazufca, Marcia; Schaan, Beatriz D.; Sekuri, Cevad; Shera, Abdul S.; Shi, Zumin; Silva, Egle; Simons, Leon A.; Soederberg, Stefan; Solfrizzi, Vincenzo; Soysal, Ahmet; Stein, Aryeh D.; Stessman, Jochanan; Vanderpump, Mark P.; Viet, Lucie; Vollenweider, Peter; Wang, Ningli; Wang, Ya X.; Waspadji, Sarwono; Willeit, Johann; Woodward, Mark; Xu, Laing; Yang, Xiaoguang; Yoon, Jin-Sang; Yu, Zhijie; Zhang, Jian; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9785</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Data for trends in glycemia and diabetes prevalence are needed to understand the effects of diet and lifestyle within populations, assess the performance of interventions, and plan health services.  No consistent and comparable global anal. of trends has been done.  We estd. trends and their uncertainties in mean fasting plasma glucose (FPG) and diabetes prevalence for adults aged 25 years and older in 199 countries and territories.  We obtained data from health examn. surveys and epidemiol. studies (370 country-years and 2.7 million participants).  We converted systematically between different glycemic metrics.  For each sex, we used a Bayesian hierarchical model to est. mean FPG and its uncertainty by age, country, and year, accounting for whether a study was nationally, subnationally, or community representative.  In 2008, global age-standardized mean FPG was 5.50 mmol/L (95% uncertainty interval 5.37-5.63) for men and 5.42 mmol/L (5.29-5.54) for women, having risen by 0.07 mmol/L and 0.09 mmol/L per decade, resp.  Age-standardized adult diabetes prevalence was 9.8% (8.6-11.2) in men and 9.2% (8.0-10.5) in women in 2008, up from 8.3% (6.5-10.4) and 7.5% (5.8-9.6) in 1980.  The no. of people with diabetes increased from 153 (127-182) million in 1980, to 347 (314-382) million in 2008.  We recorded almost no change in mean FPG in east and southeast Asia and central and eastern Europe.  Oceania had the largest rise, and the highest mean FPG (6.09 mmol/L, 5.73-6.49 for men; 6.08 mmol/L, 5.72-6.46 for women) and diabetes prevalence (15.5%, 11.6-20.1 for men; and 15.9%, 12.1-20.5 for women) in 2008.  Mean FPG and diabetes prevalence in 2008 were also high in south Asia, Latin America and the Caribbean, and central Asia, north Africa, and the Middle East.  Mean FPG in 2008 was lowest in sub-Saharan Africa, east and southeast Asia, and high-income Asia-Pacific.  In high-income subregions, western Europe had the smallest rise, 0.07 mmol/L per decade for men and 0.03 mmol/L per decade for women; North America had the largest rise, 0.18 mmol/L per decade for men and 0.14 mmol/L per decade for women.  Glycemia and diabetes are rising globally, driven both by population growth and ageing and by increasing age-specific prevalences.  Effective preventive interventions are needed, and health systems should prep. to detect and manage diabetes and its sequelae.  Funding: Bill & Melinda Gates Foundation and WHO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Jw1i50e7MbVg90H21EOLACvtfcHk0lgU0mCacHoL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlyltbo%253D&md5=ba23963b4ccdf9d19804194ac9dad09f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960679-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960679-X%26sid%3Dliteratum%253Aachs%26aulast%3DDanaei%26aufirst%3DG.%26aulast%3DFinucane%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DG.%2BM.%26aulast%3DCowan%26aufirst%3DM.%2BJ.%26aulast%3DPaciorek%26aufirst%3DC.%2BJ.%26aulast%3DLin%26aufirst%3DJ.%2BK.%26aulast%3DFarzadfar%26aufirst%3DF.%26aulast%3DKhang%26aufirst%3DY.-H.%26aulast%3DStevens%26aufirst%3DG.%2BA.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DM.%2BK.%26aulast%3DRiley%26aufirst%3DL.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BA.%26aulast%3DEzzati%26aufirst%3DM.%26atitle%3DNational%252C%2520regional%252C%2520and%2520global%2520trends%2520in%2520fasting%2520plasma%2520glucose%2520and%2520diabetes%2520prevalence%2520since%25201980%253A%2520systematic%2520analysis%2520of%2520health%2520examination%2520surveys%2520and%2520epidemiological%2520studies%2520with%2520370%2520country-years%2520and%25202%25C2%25B77%2520million%2520participants%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D31%26epage%3D40%26doi%3D10.1016%2Fs0140-6736%2811%2960679-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span> <span> </span><span class="NLM_article-title">Free Fatty Acid Receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1002/med.21441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1002%2Fmed.21441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28328012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=381-425&author=Z.+Liauthor=X.+Xuauthor=W.+Huangauthor=H.+Qian&title=Free+Fatty+Acid+Receptor+1+%28FFAR1%29+as+an+emerging+therapeutic+target+for+type+2+diabetes+mellitus%3A+recent+progress+and+prevailing+challenges&doi=10.1002%2Fmed.21441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges</span></div><div class="casAuthors">Li, Zheng; Xu, Xue; Huang, Wenlong; Qian, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">381-425</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFAR1/GPR40) amplifies glucose-dependent insulin secretion; therefore, it has attracted widespread attention as a promising antidiabetic target.  Current clin. proof of concept also indicates that FFAR1 agonists achieve the initially therapeutic endpoint for the treatment of type 2 diabetes mellitus (T2DM) without the hypoglycemic risk.  Thus, many pharmaceutical companies and academic institutes are competing to develop FFAR1 agonists.  However, several candidates have been discontinued in clin. trials, often without reporting the underlying reasons.  Herein, we review the challenges and corresponding strategies chosen by different medicinal chem. teams to improve the physicochem. properties, potency, pharmacokinetics, and safety profiles of FFAR1 agonists, with a brief introduction to the biol. and pharmacol. of related targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0HQt6yW9YZbVg90H21EOLACvtfcHk0lgU0mCacHoL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrY%253D&md5=5cf3e724e97cb0ae2e6741ee5d85663a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fmed.21441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21441%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DH.%26atitle%3DFree%2520Fatty%2520Acid%2520Receptor%25201%2520%2528FFAR1%2529%2520as%2520an%2520emerging%2520therapeutic%2520target%2520for%2520type%25202%2520diabetes%2520mellitus%253A%2520recent%2520progress%2520and%2520prevailing%2520challenges%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D381%26epage%3D425%26doi%3D10.1002%2Fmed.21441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olokoba, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obateru, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olokoba, L. B.</span></span> <span> </span><span class="NLM_article-title">Type 2 diabetes mellitus: a review of current trends</span>. <i>Oman Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.5001/omj.2012.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.5001%2Fomj.2012.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23071876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=269-273&author=A.+B.+Olokobaauthor=O.+A.+Obateruauthor=L.+B.+Olokoba&title=Type+2+diabetes+mellitus%3A+a+review+of+current+trends&doi=10.5001%2Fomj.2012.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 diabetes mellitus: a review of current trends</span></div><div class="casAuthors">Olokoba, Abdulfatai B.; Obateru, Olusegun A.; Olokoba, Lateefat B.</div><div class="citationInfo"><span class="NLM_cas:title">Oman Medical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">OMJMAF</span>;
        ISSN:<span class="NLM_cas:issn">1999-768X</span>.
    
            (<span class="NLM_cas:orgname">Oman Medical Specialty Board</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (DM) is a chronic metabolic disorder in which prevalence has been increasing steadily all over the world.  As a result of this trend, it is fast becoming an epidemic in some countries of the world with the no. of people affected expected to double in the next decade due to increase in ageing population, thereby adding to the already existing burden for healthcare providers, esp. in poorly developed countries.  This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications.  Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment.  Only articles in English were included.  Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Assocn. (ADA) criteria which include both clin. and lab. parameters.  No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers like metformin, a biguanide that reduces insulin resistance, is still the recommended first line medication esp. for obese patients.  Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin.  Recent research into the pathophysiol. of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11β-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine.  Inhaled insulin was licensed for use in 2006 but has been withdrawn from the market because of low patronage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FqowDHbsTLVg90H21EOLACvtfcHk0lj8tXjolcEmlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsLzE&md5=3696f50d1424f787219201349414c833</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.5001%2Fomj.2012.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5001%252Fomj.2012.68%26sid%3Dliteratum%253Aachs%26aulast%3DOlokoba%26aufirst%3DA.%2BB.%26aulast%3DObateru%26aufirst%3DO.%2BA.%26aulast%3DOlokoba%26aufirst%3DL.%2BB.%26atitle%3DType%25202%2520diabetes%2520mellitus%253A%2520a%2520review%2520of%2520current%2520trends%26jtitle%3DOman%2520Med.%2520J.%26date%3D2012%26volume%3D27%26spage%3D269%26epage%3D273%26doi%3D10.5001%2Fomj.2012.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burant, C. F.</span></span> <span> </span><span class="NLM_article-title">Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">S175</span>– <span class="NLM_lpage">S179</span>, <span class="refDoi"> DOI: 10.2337/dcs13-2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.2337%2FdcS13-2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23882043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ksrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=S175-S179&author=C.+F.+Burant&title=Activation+of+GPR40+as+a+therapeutic+target+for+the+treatment+of+type+2+diabetes&doi=10.2337%2Fdcs13-2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes</span></div><div class="casAuthors">Burant, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S175-S179</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review.  The stimulation of insulin secretion by glucose can be modulated by multiple nutritive, hormonal, and pharmacol. inputs.  Fatty acids potentiate insulin secretion through the generation of intracellular signaling mols. and through the activation of cell surface receptors.  The G-protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (we will use GPR40 in this review), has emerged as an important component in the fatty acid augmentation of insulin secretion.  By signaling predominantly through Gαq/11, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion.  Synthetic small-mol. agonists of GPR40 enhance insulin secretion in a glucose-dependent manner in vitro and in vivo with a mechanism similar to that found with fatty acids.  GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.  Recent phase I and phase II clin. trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis.  These data suggest that targeting the GPR40 receptor can be a viable therapeutic option for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Q7a81IRLMLVg90H21EOLACvtfcHk0lj8tXjolcEmlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ksrrJ&md5=c93db4fe37969f285dcde2896b8facef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2337%2FdcS13-2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252FdcS13-2037%26sid%3Dliteratum%253Aachs%26aulast%3DBurant%26aufirst%3DC.%2BF.%26atitle%3DActivation%2520of%2520GPR40%2520as%2520a%2520therapeutic%2520target%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3DS175%26epage%3DS179%26doi%3D10.2337%2Fdcs13-2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Defossa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2991</span>– <span class="NLM_lpage">3000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bmcl.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=24881568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslKnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2991-3000&author=E.+Defossaauthor=M.+Wagner&title=Recent+developments+in+the+discovery+of+FFA1+receptor+agonists+as+novel+oral+treatment+for+type+2+diabetes+mellitus&doi=10.1016%2Fj.bmcl.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus</span></div><div class="casAuthors">Defossa, Elisabeth; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2991-3000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Despite the availability of established medication for treatment of type 2 diabetes mellitus (T2DM) there still remains a significant unmet need for new effective, oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile.  In this regard the FFA1 receptor has emerged as an attractive target in recent years.  Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells.  The current review highlights on the latest developments and clin. data from evolving research on the potential of FFA1 agonists as effective treatment for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozko1kPZFdu7Vg90H21EOLACvtfcHk0lj8tXjolcEmlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslKnsL8%253D&md5=d7b5d1e01b15d3434bcd8efa3173c4c2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DDefossa%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DM.%26atitle%3DRecent%2520developments%2520in%2520the%2520discovery%2520of%2520FFA1%2520receptor%2520agonists%2520as%2520novel%2520oral%2520treatment%2520for%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2991%26epage%3D3000%26doi%3D10.1016%2Fj.bmcl.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukusumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+fatty+acids+regulate+insulin+secretion+from+pancreatic+%CE%B2+cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic β cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0liK2VoxV9JX7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520fatty%2520acids%2520regulate%2520insulin%2520secretion%2520from%2520pancreatic%2520%25CE%25B2%2520cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briscoe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilert, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshourbagy, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinage, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekeres, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignar, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, A. I.</span></span> <span> </span><span class="NLM_article-title">The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">11303</span>– <span class="NLM_lpage">11311</span>, <span class="refDoi"> DOI: 10.1074/jbc.m211495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1074%2Fjbc.M211495200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=12496284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1KgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=11303-11311&author=C.+P.+Briscoeauthor=M.+Tadayyonauthor=J.+L.+Andrewsauthor=W.+G.+Bensonauthor=J.+K.+Chambersauthor=M.+M.+Eilertauthor=C.+Ellisauthor=N.+A.+Elshourbagyauthor=A.+S.+Goetzauthor=D.+T.+Minnickauthor=P.+R.+Murdockauthor=H.+R.+Saulsauthor=U.+Shabonauthor=L.+D.+Spinageauthor=J.+C.+Strumauthor=P.+G.+Szekeresauthor=K.+B.+Tanauthor=J.+M.+Wayauthor=D.+M.+Ignarauthor=S.+Wilsonauthor=A.+I.+Muir&title=The+orphan+G+protein-coupled+receptor+GPR40+is+activated+by+medium+and+long+chain+fatty+acids&doi=10.1074%2Fjbc.m211495200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids</span></div><div class="casAuthors">Briscoe, Celia P.; Tadayyon, Mohammad; Andrews, John L.; Benson, William G.; Chambers, Jon K.; Eilert, Michelle M.; Ellis, Catherine; Elshourbagy, Nabil A.; Goetz, Aaron S.; Minnick, Dana T.; Murdock, Paul R.; Sauls, Howard R., Jr.; Shabon, Usman; Spinage, Lisa D.; Strum, Jay C.; Szekeres, Philip G.; Tan, Kong B.; Way, James M.; Ignar, Diane M.; Wilson, Shelagh; Muir, Alison I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">11303-11311</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GPR40 is a member of a subfamily of homologous G protein-coupled receptors that include GPR41 and GPR43 and that have no current function or ligand ascribed.  Ligand fishing expts. in HEK293 cells expressing human GPR40 revealed that a range of satd. and unsatd. carboxylic acids with carbon chain lengths greater than six were able to induce an elevation of [Ca2+]i, measured using a fluorometric imaging plate reader. 5,8,11-Eicosatriynoic acid was the most potent fatty acid tested, with a pEC50 of 5.7.  G protein coupling of GPR40 was examd. in Chinese hamster ovary cells expressing the Gαq/i-responsive Gal4-Elk1 reporter system.  Expression of human GPR40 led to a constitutive induction of luciferase activity, which was further increased by exposure of the cells to eicosatriynoic acid.  Neither the constitutive nor ligand-mediated luciferase induction was inhibited by pertussis toxin treatment, suggesting that GPR40 was coupled to Gαq/11.  Expression anal. by quant. reverse transcription-PCR showed that GPR40 was specifically expressed in brain and pancreas, with expression in rodent pancreas being localized to insulin-producing β-cells.  These data suggest that some of the physiol. effects of fatty acids in pancreatic islets and brain may be mediated through a cell-surface receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXzfE9PNW7-LVg90H21EOLACvtfcHk0liK2VoxV9JX7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1KgsbY%253D&md5=a8c2105e13f07a7487315d7515fdcf56</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211495200%26sid%3Dliteratum%253Aachs%26aulast%3DBriscoe%26aufirst%3DC.%2BP.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%2BL.%26aulast%3DBenson%26aufirst%3DW.%2BG.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DEilert%26aufirst%3DM.%2BM.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMinnick%26aufirst%3DD.%2BT.%26aulast%3DMurdock%26aufirst%3DP.%2BR.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DShabon%26aufirst%3DU.%26aulast%3DSpinage%26aufirst%3DL.%2BD.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DSzekeres%26aufirst%3DP.%2BG.%26aulast%3DTan%26aufirst%3DK.%2BB.%26aulast%3DWay%26aufirst%3DJ.%2BM.%26aulast%3DIgnar%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26atitle%3DThe%2520orphan%2520G%2520protein-coupled%2520receptor%2520GPR40%2520is%2520activated%2520by%2520medium%2520and%2520long%2520chain%2520fatty%2520acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D11303%26epage%3D11311%26doi%3D10.1074%2Fjbc.m211495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendoloski, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3762</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1021/jp980230o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp980230o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=3762-3772&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=Prediction+of+hydrophobic+%28lipophilic%29+properties+of+small+organic+molecules+using+fragmental+methods%3A+an+analysis+of+ALOGP+and+CLOGP+methods&doi=10.1021%2Fjp980230o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3762-3772</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. hydrophobicity (lipophilicity), usually quantified as log P (the logarithm of 1-octanol/water partition coeff.), is an important mol. characteristic in drug discovery.  ALOGP and CLOGP are two of the most widely used methods for the estn. of log P.  This work describes an extensive reparametrization of the at. log P values and a detailed comparison of the performance of ALOGP and CLOGP methods on the Pomona Medchem database.  Only the "star list" compds. having precisely measured log P values were used in this anal.  While the overall results with both methods are similar, anal. shows that the CLOGP method is better for very small mols. in the range of 1-20 atoms.  The two methods are almost comparable in the range of 21-45 atoms, while the ALOGP method has better accuracy for mols. with more than 45 atoms.  Although the rms deviation and the correlation coeff. for CLOGP predictions were marginally better than those for corresponding ALOGP predictions, the latter showed a very stable performance for all classes of org. compds. analyzed.  Importantly, the ALOGP method can be used to compute ests. for all mols. in the database, whereas the CLOGP method fails to offer ests. for a substantial part of the database.  Finally, unlike CLOGP and other methods of predicting lipophilicity, the ALOGP method has multiple uses, such as the estn. of local hydrophobicity, the visualization of mol. hydrophobicity maps, and the evaluation of hydrophobic interactions in protein-ligand complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXdn8wsqV3frVg90H21EOLACvtfcHk0livahjJ2XOMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D&md5=ef58841437913e164dc2d6e73eb5c87d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjp980230o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp980230o%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520hydrophobic%2520%2528lipophilic%2529%2520properties%2520of%2520small%2520organic%2520molecules%2520using%2520fragmental%2520methods%253A%2520an%2520analysis%2520of%2520ALOGP%2520and%2520CLOGP%2520methods%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1998%26volume%3D102%26spage%3D3762%26epage%3D3772%26doi%3D10.1021%2Fjp980230o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yada, T.</span></span> <span> </span><span class="NLM_article-title">Oleic acid interacts with GPR40 to induce Ca<sup>2+</sup> signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release</span>. <i>Am. J. Physiol.: Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">E670</span>– <span class="NLM_lpage">E677</span>, <span class="refDoi"> DOI: 10.1152/ajpendo.00035.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1152%2Fajpendo.00035.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=15914509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFens7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2005&pages=E670-E677&author=K.+Fujiwaraauthor=F.+Maekawaauthor=T.+Yada&title=Oleic+acid+interacts+with+GPR40+to+induce+Ca2%2B+signaling+in+rat+islet+beta-cells%3A+mediation+by+PLC+and+L-type+Ca2%2B+channel+and+link+to+insulin+release&doi=10.1152%2Fajpendo.00035.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet β-cells: Mediation by PLC and L-type Ca2+ channel and link to insulin release</span></div><div class="casAuthors">Fujiwara, Ken; Maekawa, Fumihiko; Yada, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">4, Pt. 1</span>),
    <span class="NLM_cas:pages">E670-E677</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">It has long been thought that long-chain free fatty acids (FFAs) stimulate insulin secretion via mechanisms involving their metab. in pancreatic β-cells.  Recently, it was reported that FFAs function as endogenous ligands for GPR40, a G protein-coupled receptor, to amplify glucose-stimulated insulin secretion in an insulinoma cell line and rat islets.  However, signal transduction mechanisms for GPR40 in β-cells are little known.  The present study was aimed at elucidating GPR40-linked Ca2+ signaling mechanisms in rat pancreatic β-cells.  The authors employed oleic acid (OA), an FFA that has a high affinity for the rat GPR40, and examd. its effect on cytosolic Ca2+ concn. ([Ca2+]i) in single β-cells by fura 2 fluorescence imaging.  OA at 1-10 μM concn.-dependently increased [Ca2+]i in the presence of 5.6, 8.3, and 11.2 mM, but not 2.8 mM, glucose.  OA-induced [Ca2+]i increases at 11.2 mM glucose were inhibited in β-cells transfected with small interfering RNA targeted to rat GPR40 mRNA.  OA-induced [Ca2+]i increases were also inhibited by phospholipase C (PLC) inhibitors, U73122 and neomycin, Ca2+-free conditions, and an L-type Ca2+ channel blocker, nitrendipine.  Furthermore, OA increased insulin release from isolated islets at 8.3 mM glucose, and it was markedly attenuated by PLC and L-type Ca2+ channel inhibitors.  These results demonstrate that OA interacts with GPR40 to increase [Ca2+]i via PLC- and L-type Ca2+ channel-mediated pathway in rat islet β-cells, which may be link to insulin release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp05YzJpu8oXrVg90H21EOLACvtfcHk0livahjJ2XOMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFens7fF&md5=735907743264c8a62a74a35ab7a9d9af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1152%2Fajpendo.00035.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpendo.00035.2005%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DF.%26aulast%3DYada%26aufirst%3DT.%26atitle%3DOleic%2520acid%2520interacts%2520with%2520GPR40%2520to%2520induce%2520Ca2%252B%2520signaling%2520in%2520rat%2520islet%2520beta-cells%253A%2520mediation%2520by%2520PLC%2520and%2520L-type%2520Ca2%252B%2520channel%2520and%2520link%2520to%2520insulin%2520release%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Endocrinol.%2520Metab.%26date%3D2005%26volume%3D289%26spage%3DE670%26epage%3DE677%26doi%3D10.1152%2Fajpendo.00035.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span> <span> </span><span class="NLM_article-title">TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.183772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fjpet.111.183772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21752941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=228-237&author=Y.+Tsujihataauthor=R.+Itoauthor=M.+Suzukiauthor=A.+Haradaauthor=N.+Negoroauthor=T.+Yasumaauthor=Y.+Momoseauthor=K.+Takeuchi&title=TAK-875%2C+an+orally+available+G+protein-coupled+receptor+40%2Ffree+fatty+acid+receptor+1+agonist%2C+enhances+glucose-dependent+insulin+secretion+and+improves+both+postprandial+and+fasting+hyperglycemia+in+type+2+diabetic+rats&doi=10.1124%2Fjpet.111.183772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats</span></div><div class="casAuthors">Tsujihata, Yoshiyuki; Ito, Ryo; Suzuki, Masami; Harada, Ayako; Negoro, Nobuyuki; Yasuma, Tsuneo; Momose, Yu; Takeuchi, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-237</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA1) is highly expressed in pancreatic β cells and mediates free fatty acid-induced insulin secretion.  This study examd. the pharmacol. effects and potential for avoidance of lipotoxicity of [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate) (TAK-875), a novel, orally available, selective GPR40 agonist.  Insulinoma cell lines and primary rat islets were used to assess the effects of TAK-875 in vitro.  The in vivo effects of TAK-875 on postprandial hyperglycemia, fasting hyperglycemia, and normoglycemia were examd. in type 2 diabetic and normal rats.  In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concn., consistent with activation of the Gqα signaling pathway.  The insulinotropic action of TAK-875 (10 μM) in INS-1 833/15 and primary rat islets was glucose-dependent.  Prolonged exposure of cytokine-sensitive INS-1 832/13 to TAK-875 for 72 h at pharmacol. active concns. did not alter glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas prolonged exposure to palmitic or oleic acid impaired β cell function and survival.  In an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats, TAK-875 (1-10 mg/kg p.o.) showed a clear improvement in glucose tolerance and augmented insulin secretion.  In addn., TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg.  TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlHyHXk_pVjbVg90H21EOLACvtfcHk0livahjJ2XOMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbbL&md5=2c7f2d472a9608d41b60f05c3fffd509</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.183772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.183772%26sid%3Dliteratum%253Aachs%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26atitle%3DTAK-875%252C%2520an%2520orally%2520available%2520G%2520protein-coupled%2520receptor%252040%252Ffree%2520fatty%2520acid%2520receptor%25201%2520agonist%252C%2520enhances%2520glucose-dependent%2520insulin%2520secretion%2520and%2520improves%2520both%2520postprandial%2520and%2520fasting%2520hyperglycemia%2520in%2520type%25202%2520diabetic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D228%26epage%3D237%26doi%3D10.1124%2Fjpet.111.183772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfleiderer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristiansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1021/ml100106c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100106c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=345-349&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=N.+Mertenauthor=M.+Pfleidererauthor=K.+K.+Karlsenauthor=S.+S.+Rasmussenauthor=M.+Steensgaardauthor=A.+Hamacherauthor=J.+Schmidtauthor=C.+Drewkeauthor=R.+K.+Petersenauthor=K.+Kristiansenauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Structure%E2%80%93Activity+Study+of+Dihydrocinnamic+Acids+and+Discovery+of+the+Potent+FFA1+%28GPR40%29+Agonist+TUG-469&doi=10.1021%2Fml100106c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span></div><div class="casAuthors">Christiansen, Elisabeth; Due-Hansen, Maria E.; Urban, Christian; Merten, Nicole; Pfleiderer, Michael; Karlsen, Kasper K.; Rasmussen, Sanne S.; Steensgaard, Mette; Hamacher, Alexandra; Schmidt, Johannes; Drewke, Christel; Petersen, Rasmus Koefoed; Kristiansen, Karsten; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic β-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes.  Several FFA1 agonists contg. the para-substituted dihydrocinnamic acid moiety are known.  We here present a structure-activity relationship study of this compd. family suggesting that the central methyleneoxy linker is preferable for the smaller compds., whereas the central methyleneamine linker gives higher potency to the larger compds.  The study resulted in the discovery of the potent and selective full FFA1 agonist TUG-469 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Ue5bdjcoY7Vg90H21EOLACvtfcHk0lj2vquI0BGt-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D&md5=e3a7642f2fd42b1bc932fa9470cfb75c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml100106c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100106c%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DPfleiderer%26aufirst%3DM.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DRasmussen%26aufirst%3DS.%2BS.%26aulast%3DSteensgaard%26aufirst%3DM.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DR.%2BK.%26aulast%3DKristiansen%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DStructure%25E2%2580%2593Activity%2520Study%2520of%2520Dihydrocinnamic%2520Acids%2520and%2520Discovery%2520of%2520the%2520Potent%2520FFA1%2520%2528GPR40%2529%2520Agonist%2520TUG-469%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D345%26epage%3D349%26doi%3D10.1021%2Fml100106c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span> <span> </span><span class="NLM_article-title">AMG 837: a potent, orally bioavailable GPR40 agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1267</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bmcl.2011.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22217876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1267-1270&author=J.+B.+Houzeauthor=L.+Zhuauthor=Y.+Sunauthor=M.+Akermanauthor=W.+Qiuauthor=A.+J.+Zhangauthor=R.+Sharmaauthor=M.+Schmittauthor=Y.+Wangauthor=J.+Liuauthor=J.+Liuauthor=J.+C.+Medinaauthor=J.+D.+Reaganauthor=J.+Luoauthor=G.+Tonnauthor=J.+Zhangauthor=J.+Y.-L.+Luauthor=M.+Chenauthor=E.+Lopezauthor=K.+Nguyenauthor=L.+Yangauthor=L.+Tangauthor=H.+Tianauthor=S.+J.+Shuttleworthauthor=D.+C.-H.+Lin&title=AMG+837%3A+a+potent%2C+orally+bioavailable+GPR40+agonist&doi=10.1016%2Fj.bmcl.2011.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 837: A potent, orally bioavailable GPR40 agonist</span></div><div class="casAuthors">Houze, Jonathan B.; Zhu, Liusheng; Sun, Ying; Akerman, Michelle; Qiu, Wei; Zhang, Alex J.; Sharma, Rajiv; Schmitt, Michael; Wang, Yingcai; Liu, Jiwen; Liu, Jinqian; Medina, Julio C.; Reagan, Jeff D.; Luo, Jian; Tonn, George; Zhang, Jane; Lu, Jenny Ying-Lin; Chen, Michael; Lopez, Edwin; Nguyen, Kathy; Yang, Li; Tang, Liang; Tian, Hui; Shuttleworth, Steven J.; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1267-1270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents.  Optimization of a series of β-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJp4-u_YDyLVg90H21EOLACvtfcHk0lj2vquI0BGt-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D&md5=7e7d38679794abb7244d5a64d6f5ecd7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAkerman%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.-L.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26atitle%3DAMG%2520837%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520GPR40%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1267%26epage%3D1270%26doi%3D10.1016%2Fj.bmcl.2011.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargent, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaibi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawthorne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1021/ml4000673</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000673" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=441-445&author=E.+Christiansenauthor=S.+V.+F.+Hansenauthor=C.+Urbanauthor=B.+D.+Hudsonauthor=E.+T.+Wargentauthor=M.+Grundmannauthor=L.+Jenkinsauthor=M.+Zaibiauthor=C.+J.+Stockerauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=G.+Milliganauthor=M.+A.+Cawthorneauthor=T.+Ulven&title=Discovery+of+TUG-770%3A+a+highly+potent+free+fatty+acid+receptor+1+%28FFA1%2FGPR40%29+agonist+for+treatment+of+type+2+diabetes&doi=10.1021%2Fml4000673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Christiansen, Elisabeth; Hansen, Steffen V. F.; Urban, Christian; Hudson, Brian D.; Wargent, Edward T.; Grundmann, Manuel; Jenkins, Laura; Zaibi, Mohamed; Stocker, Claire J.; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Milligan, Graeme; Cawthorne, Michael A.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-445</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes.  We here report the discovery of a highly potent FFA1 agonist (I) with favorable physicochem. and pharmacokinetic properties.  The compd. efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoli6_yVTMDErVg90H21EOLACvtfcHk0li5WN-1HhgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsLw%253D&md5=0c01356f7776e02cc1ce3ff6fce560c0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml4000673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000673%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DHansen%26aufirst%3DS.%2BV.%2BF.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DWargent%26aufirst%3DE.%2BT.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DJenkins%26aufirst%3DL.%26aulast%3DZaibi%26aufirst%3DM.%26aulast%3DStocker%26aufirst%3DC.%2BJ.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TUG-770%253A%2520a%2520highly%2520potent%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA1%252FGPR40%2529%2520agonist%2520for%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D441%26epage%3D445%26doi%3D10.1021%2Fml4000673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krug, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Railkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ederveen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krefetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNoia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatosian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothare, P.</span></span> <span> </span><span class="NLM_article-title">Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1111/cts.12479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1111%2Fcts.12479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28727908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWjt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=404-411&author=A.+Krugauthor=P.+Vaddadyauthor=R.+Railkarauthor=B.+Musserauthor=J.+Coteauthor=A.+Ederveenauthor=D.+Krefetzauthor=E.+DeNoiaauthor=A.+Freeauthor=L.+Morrowauthor=M.+Chakravarthyauthor=E.+Kauhauthor=D.+Tatosianauthor=P.+Kothare&title=Leveraging+a+clinical+phase+Ib+proof-of-concept+study+for+the+GPR40+agonist+MK-8666+in+patients+with+type+2+diabetes+for+model-informed+phase+II+dose+selection&doi=10.1111%2Fcts.12479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection</span></div><div class="casAuthors">Krug, A. W.; Vaddady, P.; Railkar, R. A.; Musser, B. J.; Cote, J.; Ederveen, A. G. H.; Krefetz, D. G.; De Noia, E.; Free, A. L.; Morrow, L.; Chakravarthy, M. V.; Kauh, E.; Tatosian, D. A.; Kothare, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-411</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPR40 mediates free fatty acid-induced insulin secretion in beta cells.  We investigated the safety, pharmacokinetics, and glucose response of MK-8666, a partial GPR40 agonist, after once-daily multiple dosing in type 2 diabetes patients.  This double-blind, multisite, parallel-group study randomized 63 patients (placebo, n = 18; 50 mg, n = 9; 150 mg, n = 18; 500 mg, n = 18) for 14-day treatment.  The results showed no serious adverse effects or treatment-related hypoglycemia.  One patient (150-mg group) showed mild-to-moderate transaminitis at the end of dosing.  Median MK-8666 Tmax was 2.0-2.5 h and mean apparent terminal half-life was 22-32 h.  On Day 15, MK-8666 reduced fasting plasma glucose by 54.1 mg/dL (500 mg), 36.0 mg/dL (150 mg), and 30.8 mg/dL (50 mg) more than placebo, consistent with translational pharmacokinetic/pharmacodynamic model predictions.  Maximal efficacy for longer-term assessment is projected at 500 mg based on exposure-response anal.  In conclusion, MK-8666 was generally well tolerated with robust glucose-lowering efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaGJpYIHFoNbVg90H21EOLACvtfcHk0li5WN-1HhgZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWjt73P&md5=3aab859622dda7019868e9cbbd54dafd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fcts.12479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12479%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DA.%26aulast%3DVaddady%26aufirst%3DP.%26aulast%3DRailkar%26aufirst%3DR.%26aulast%3DMusser%26aufirst%3DB.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DEderveen%26aufirst%3DA.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DDeNoia%26aufirst%3DE.%26aulast%3DFree%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DL.%26aulast%3DChakravarthy%26aufirst%3DM.%26aulast%3DKauh%26aufirst%3DE.%26aulast%3DTatosian%26aufirst%3DD.%26aulast%3DKothare%26aufirst%3DP.%26atitle%3DLeveraging%2520a%2520clinical%2520phase%2520Ib%2520proof-of-concept%2520study%2520for%2520the%2520GPR40%2520agonist%2520MK-8666%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520for%2520model-informed%2520phase%2520II%2520dose%2520selection%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D404%26epage%3D411%26doi%3D10.1111%2Fcts.12479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seok, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-M.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPR40-dependent manner</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2017.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.4062%2Fbiomolther.2017.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1aisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=599-607&author=M.+Kimauthor=G.+J.+Guauthor=Y.-S.+Kohauthor=S.-H.+Leeauthor=Y.+R.+Naauthor=S.+H.+Seokauthor=K.-M.+Lim&title=Fasiglifam+%28TAK-875%29%2C+a+G+protein-coupled+receptor+40+%28GPR40%29+agonist%2C+may+induce+hepatotoxicity+through+reactive+oxygen+species+generation+in+a+GPR40-dependent+manner&doi=10.4062%2Fbiomolther.2017.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPR40-dependent manner</span></div><div class="casAuthors">Kim, MinJeong; Gu, Gyo Jeong; Koh, Yun-Sook; Lee, Su-Hyun; Na, Yi Rang; Seok, Seung Hyeok; Lim, Kyung-Min</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-607</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875) a G-protein coupled receptor 40 (GPR40) agonist, significantly improves hyperglycemia without hypoglycemia and wt. gain, the major side effects of conventional anti-diabetics.  Unfortunately, during multi-center Phase 3 clin. trials, unexpected liver toxicity resulted in premature termination of its development.  Here, we investigated whether TAK-875 directly inflicts toxicity on hepatocytes and explored its underlying mechanism of toxicity.  TAK-875 decreased viability of 2D and 3D cultures of HepG2, a human hepatocarcinoma cell line, in concn.- (>50μM) and time-dependent manners, both of which corresponded with ROS generation.  An antioxidant, N-acetylcysteine, attenuated TAK-875-mediated hepatotoxicity, which confirmed the role of ROS generation.  Of note, knockdown of GPR40 using siRNA abolished the hepatotoxicity of TAK-875 and attenuated ROS generation.  In contrast, TAK-875 induced no cytotoxicity in fibroblasts up to 500μM.  Supporting the hepatotoxic potential of TAK-875, exposure to TAK-875 resulted in increased mortality of zebrafish larvae at 25μM.  Histopathol. examn. of zebrafish exposed to TAK-875 revealed severe hepatotoxicity as manifested by degenerated hypertrophic hepatocytes with cytoplasmic vacuolation and acentric nuclei, confirming that TAK-875 may induce direct hepatotoxicity and that ROS generation may be involved in a GPR40-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZNXB5XjNld7Vg90H21EOLACvtfcHk0ljmahzNafMU5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1aisb%252FI&md5=d248b901a83bf75032d2023ec924787e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2017.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2017.225%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DG.%2BJ.%26aulast%3DKoh%26aufirst%3DY.-S.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DNa%26aufirst%3DY.%2BR.%26aulast%3DSeok%26aufirst%3DS.%2BH.%26aulast%3DLim%26aufirst%3DK.-M.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%252C%2520a%2520G%2520protein-coupled%2520receptor%252040%2520%2528GPR40%2529%2520agonist%252C%2520may%2520induce%2520hepatotoxicity%2520through%2520reactive%2520oxygen%2520species%2520generation%2520in%2520a%2520GPR40-dependent%2520manner%26jtitle%3DBiomol.%2520Ther.%26date%3D2018%26volume%3D26%26spage%3D599%26epage%3D607%26doi%3D10.4062%2Fbiomolther.2017.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.064121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fdmd.115.064121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=26276582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjtlygs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1751-1759&author=X.+Liauthor=K.+Zhongauthor=Z.+Guoauthor=D.+Zhongauthor=X.+Chen&title=Fasiglifam+%28TAK-875%29+Inhibits+Hepatobiliary+Transporters%3A+A+Possible+Factor+Contributing+to+Fasiglifam-Induced+Liver+Injury&doi=10.1124%2Fdmd.115.064121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury</span></div><div class="casAuthors">Li, Xiuli; Zhong, Kan; Guo, Zitao; Zhong, Dafang; Chen, Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875), a selective G-protein-coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus; however, its development was terminated in phase III clin. trials because of liver safety concerns.  Our preliminary study indicated that i.v. administration of 100 mg/kg of TAK-875 increased the serum total bile acid concn. by 3 to 4 times and total bilirubin levels by 1.5 to 2.6 times in rats.  In the present study, we examd. the inhibitory effects of TAK-875 on hepatobiliary transporters to explore the mechanisms underlying its hepatotoxicity.  TAK-875 decreased the biliary excretion index and the in vitro biliary clearance of d8-taurocholic acid in sandwich-cultured rat hepatocytes, suggesting that TAK-875 impaired biliary excretion of bile acids, possibly by inhibiting bile salt export pump (Bsep).  TAK-875 inhibited the efflux transporter multidrug resistance-assocd. protein 2 (Mrp2) in rat hepatocytes using 5 (and 6)-carboxy-2',7'-dichlorofluorescein as a substrate.  Inhibition of MRP2 was further confirmed by reduced transport of vinblastine in Madin-Darby canine kidney cells overexpressing MRP2 with IC50 values of 2.41 μM.  TAK-875 also inhibited the major bile acid uptake transporter Na+/taurocholate cotransporting polypeptide (Ntcp), which transports d8-taurocholic acid into rat hepatocytes, with an IC50 value of 10.9 μM.  TAK-875 significantly inhibited atorvastatin uptake in org. anion transporter protein (OATP) 1B1 and OATP1B3 cells with IC50 values of 2.28 and 3.98 μM, resp.  These results indicate that TAK-875 inhibited the efflux transporter MRP2/Mrp2 and uptake transporters Ntcp and OATP/Oatp, which may affect bile acid and bilirubin homeostasis, resulting in hyperbilirubinemia and cholestatic hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVcU03So6DrVg90H21EOLACvtfcHk0ljmahzNafMU5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjtlygs7k%253D&md5=8e3af83a77d21750d8eabd398d33f4a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.064121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.064121%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%2520Inhibits%2520Hepatobiliary%2520Transporters%253A%2520A%2520Possible%2520Factor%2520Contributing%2520to%2520Fasiglifam-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1751%26epage%3D1759%26doi%3D10.1124%2Fdmd.115.064121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1021/ml300133f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300133f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=726-730&author=S.+P.+Brownauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=X.+Jiaoauthor=L.+Zhuauthor=V.+Pattaropongauthor=Y.+Sunauthor=J.+Liuauthor=J.+Luoauthor=J.+Zhangauthor=S.+Wongauthor=R.+Zhuangauthor=Q.+Guoauthor=F.+Liauthor=J.+C.+Medinaauthor=G.+Swaminathauthor=D.+C.-H.+Linauthor=J.+B.+Houze&title=Discovery+of+AM-1638%3A+a+potent+and+orally+bioavailable+GPR40%2FFFA1+full+agonist&doi=10.1021%2Fml300133f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span></div><div class="casAuthors">Brown, Sean P.; Dransfield, Paul J.; Vimolratana, Marc; Jiao, XianYun; Zhu, Liusheng; Pattaropong, Vatee; Sun, Ying; Liu, Jinqian; Luo, Jian; Zhang, Jane; Wong, Simon; Zhuang, Run; Guo, Qi; Li, Frank; Medina, Julio C.; Swaminath, Gayathri; Lin, Daniel C.-H.; Houze, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-730</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels.  A potent, orally bioavailable small mol. GPR40 agonist is hypothesized to be an effective antidiabetic posing little or no risk of hypoglycemia.  The authors recently reported the discovery of AMG 837 (I), a potent partial agonist of GPR40.  Herein, they present the optimization from the GPR40 partial agonist I to the structurally and pharmacol. distinct GPR40 full agonist AM-1638 (II).  Moreover, they demonstrate the improved in vivo efficacy that GPR40 full agonist II exhibits in BDF/DIO mice as compared to partial agonist I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooInVzD6ZYdrVg90H21EOLACvtfcHk0ljywyZb2LLnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI&md5=d2abd60e8e86d96b0d0683b0401b62c8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml300133f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300133f%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520AM-1638%253A%2520a%2520potent%2520and%2520orally%2520bioavailable%2520GPR40%252FFFA1%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D726%26epage%3D730%26doi%3D10.1021%2Fml300133f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pachanski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatosian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, M. E.</span></span> <span> </span><span class="NLM_article-title">GPR40 partial agonists and AgoPAMs: differentiating effects on glucose and hormonal secretions in the rodent</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0186033</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0186033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1371%2Fjournal.pone.0186033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=29053717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFChs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+J.+Pachanskiauthor=M.+E.+Kirklandauthor=D.+T.+Kosinskiauthor=J.+Maneauthor=B.+Cheewatrakoolpongauthor=J.+Xueauthor=D.+Szetoauthor=G.+Forrestauthor=C.+Millerauthor=M.+Bunzelauthor=C.+W.+Plummerauthor=H.+R.+Chobanianauthor=M.+W.+Millerauthor=S.+Souzaauthor=B.+S.+Thomas-Fowlkesauthor=A.+M.+Ogawaauthor=A.+B.+Weinglassauthor=J.+Di+Salvoauthor=X.+Liauthor=Y.+Fengauthor=D.+A.+Tatosianauthor=A.+D.+Howardauthor=S.+L.+Collettiauthor=M.+E.+Trujillo&title=GPR40+partial+agonists+and+AgoPAMs%3A+differentiating+effects+on+glucose+and+hormonal+secretions+in+the+rodent&doi=10.1371%2Fjournal.pone.0186033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent</span></div><div class="casAuthors">Pachanski, Michele J.; Kirkland, Melissa E.; Kosinski, Daniel T.; Mane, Joel; Cheewatrakoolpong, Boonlert; Xue, Jiyan; Szeto, Daphne; Forrest, Gail; Miller, Corin; Bunzel, Michelle; Plummer, Christopher W.; Chobanian, Harry R.; Miller, Michael W.; Souza, Sarah; Thomas-Fowlkes, Brande S.; Ogawa, Aimie M.; Weinglass, Adam B.; Di Salvo, Jerry; Li, Xiaoyan; Feng, Yue; Tatosian, Daniel A.; Howard, Andrew D.; Colletti, Steven L.; Trujillo, Maria E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0186033/1-e0186033/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion.  However, not all GPR40 agonists are the same.  Partial agonists lower glucose through direct effects on the pancreas, whereas GPR40 AgoPAMs may incorporate addnl. therapeutic effects through increases in insulinotrophic incretins secreted by the gut.  Here we describe how GPR40 AgoPAMs stimulate both insulin and incretin secretion in vivo over time in diabetic GK rats.  We also describe effects of AgoPAMs in vivo to lower glucose and body wt. beyond what is seen with partial GPR40 agonists in both the acute and chronic setting.  Further comparisons of the glucose lowering profile of AgoPAMs suggest these compds. may possess greater glucose control even in the presence of elevated glucagon secretion, an unexpected feature obsd. with both acute and chronic treatment with AgoPAMs.  Together these studies highlight the complexity of GPR40 pharmacol. and the potential addnl. benefits AgoPAMs may possess above partial agonists for the diabetic patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-6HAFfThxWbVg90H21EOLACvtfcHk0ljywyZb2LLnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFChs7fK&md5=cbf18dc3a3cb3b810f9075d0c44455c6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0186033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0186033%26sid%3Dliteratum%253Aachs%26aulast%3DPachanski%26aufirst%3DM.%2BJ.%26aulast%3DKirkland%26aufirst%3DM.%2BE.%26aulast%3DKosinski%26aufirst%3DD.%2BT.%26aulast%3DMane%26aufirst%3DJ.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DBunzel%26aufirst%3DM.%26aulast%3DPlummer%26aufirst%3DC.%2BW.%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DSouza%26aufirst%3DS.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DOgawa%26aufirst%3DA.%2BM.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTatosian%26aufirst%3DD.%2BA.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26atitle%3DGPR40%2520partial%2520agonists%2520and%2520AgoPAMs%253A%2520differentiating%2520effects%2520on%2520glucose%2520and%2520hormonal%2520secretions%2520in%2520the%2520rodent%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0186033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestmar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husted, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelstoft, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lückmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.molmet.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25685685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=3-14&author=M.+Haugeauthor=M.+A.+Vestmarauthor=A.+S.+Hustedauthor=J.+P.+Ekbergauthor=M.+J.+Wrightauthor=J.+Di+Salvoauthor=A.+B.+Weinglassauthor=M.+S.+Engelstoftauthor=A.+N.+Madsenauthor=M.+L%C3%BCckmannauthor=M.+W.+Millerauthor=M.+E.+Trujilloauthor=T.+M.+Frimurerauthor=B.+Holstauthor=A.+D.+Howardauthor=T.+W.+Schwartz&title=GPR40+%28FFAR1%29+-+Combined+Gs+and+Gq+signaling+in+vitro+is+associated+with+robust+incretin+secretagogue+action+ex+vivo+and+in+vivo&doi=10.1016%2Fj.molmet.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span></div><div class="casAuthors">Hauge, Maria; Vestmar, Marie A.; Husted, Anna S.; Ekberg, Jeppe P.; Wright, Michael J.; Di Salvo, Jerry; Weinglass, Adam B.; Engelstoft, Maja S.; Madsen, Andreas N.; Luckmann, Michael; Miller, Michael W.; Trujillo, Maria E.; Frimurer, Thomas M.; Holst, Birgitte; Howard, Andrew D.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">GPR40 (FFAR1), a clin. proven anti-diabetes target, is a Gq-coupled receptor for long chain fatty acids (LCFA) stimulating insulin secretion directly and mediating a major part of the dietary triglyceride-induced secretion of the incretins GLP-1 and GIP.  In phase-II studies the GPR40 agonist TAK-875 decreased blood glucose but surprisingly without stimulating incretins.  Here we find that GPR40 can signal through not only Gq and IP3 but also Gs and cAMP when stimulated with certain agonists such as AM-1638 and AM-5262 in contrast to the endogenous LCFA ligands and agonists such as TAK-875 and AM-837, which only signal through Gq.  In competition binding against [3H]AM-1638 and [3H]L358 the Gq + Gs and the Gq-only agonists either competed for or showed pos. cooperativity by increasing the binding of the two different radio-ligands, in opposite ways.  Nevertheless, both the Gq-only and the Gq + Gs agonists all docked surprisingly well into the binding site for TAK-875 in the X-ray structure of GPR40.  In murine intestinal primary cell-cultures the endogenous LCFAs and the Gq-only agonists stimulated GLP-1 secretion with rather poor efficacy as compared with the high efficacy Gq + Gs GPR40 agonists and a prototype GPR119 agonist.  Similarly, in fasting both male and female mice the Gq + Gs agonists showed significantly higher efficacy than the Gq-only agonists in respect of increasing plasma GLP-1 and plasma GIP in a GPR40-dependent manner.  It is concluded that stimulation of GPR40 by endogenous LCFAs or by Gq-only synthetic agonists result in a rather limited incretin response, whereas Gq + Gs GPR40 agonists stimulate incretin secretion robustly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZyjcjTNd0QbVg90H21EOLACvtfcHk0ljywyZb2LLnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN&md5=895136bef8c9542711e6daf5fa57219c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DVestmar%26aufirst%3DM.%2BA.%26aulast%3DHusted%26aufirst%3DA.%2BS.%26aulast%3DEkberg%26aufirst%3DJ.%2BP.%26aulast%3DWright%26aufirst%3DM.%2BJ.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DEngelstoft%26aufirst%3DM.%2BS.%26aulast%3DMadsen%26aufirst%3DA.%2BN.%26aulast%3DL%25C3%25BCckmann%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DGPR40%2520%2528FFAR1%2529%2520-%2520Combined%2520Gs%2520and%2520Gq%2520signaling%2520in%2520vitro%2520is%2520associated%2520with%2520robust%2520incretin%2520secretagogue%2520action%2520ex%2520vivo%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2015%26volume%3D4%26spage%3D3%26epage%3D14%26doi%3D10.1016%2Fj.molmet.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershfinkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. D.</span></span> <span> </span><span class="NLM_article-title">Role of GPR40 in fatty acid action on the β cell line INS-1E</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2005.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bbrc.2005.07.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=16081037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2005&pages=97-104&author=H.+Shapiroauthor=S.+Shacharauthor=I.+Seklerauthor=M.+Hershfinkelauthor=M.+D.+Walker&title=Role+of+GPR40+in+fatty+acid+action+on+the+%CE%B2+cell+line+INS-1E&doi=10.1016%2Fj.bbrc.2005.07.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Role of GPR40 in fatty acid action on the β cell line INS-1E</span></div><div class="casAuthors">Shapiro, Hagit; Shachar, Sigal; Sekler, Israel; Hershfinkel, Michal; Walker, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GPR40 is a G protein-coupled receptor expressed preferentially in β cells, that has been implicated in mediating free fatty acid-stimulated insulin release.  GPR40 RNAi impaired the ability of palmitic acid (PA) to increase both insulin secretion and intracellular calcium ([Ca2+]i).  The PA-dependent [Ca2+]i increase was attenuated by inhibitors of Gαq, PLC, and SERCA.  Thus GPR40 activates the Gαq pathway, leading to release of Ca2+ from the ER.  Yet the GPR40-dependent [Ca2+]i rise was dependent on extracellular Ca2+ and elevated glucose, and was blocked by inhibition of L-type calcium channels (LTCC) or opening of the KATP channel; this suggests that GPR40 promotes Ca2+ influx through up-regulation of LTCC pre-activated by glucose and membrane depolarization.  Taken together, the data indicate that GPR40 mediates the increase in [Ca2+]i and insulin secretion through the Gαq-PLC pathway, resulting in release of Ca2+ from the ER and leading to up-regulation of Ca2+ influx via LTCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzW3S0OHY3rVg90H21EOLACvtfcHk0lhW7G-Itmr2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wqu7Y%253D&md5=f8b3167bb222eea1718689e2254777f1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2005.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2005.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DH.%26aulast%3DShachar%26aufirst%3DS.%26aulast%3DSekler%26aufirst%3DI.%26aulast%3DHershfinkel%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%2BD.%26atitle%3DRole%2520of%2520GPR40%2520in%2520fatty%2520acid%2520action%2520on%2520the%2520%25CE%25B2%2520cell%2520line%2520INS-1E%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2005%26volume%3D335%26spage%3D97%26epage%3D104%26doi%3D10.1016%2Fj.bbrc.2005.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöfl, C.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.mce.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=17101212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KgurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2007&pages=173-180&author=S.+Schnellauthor=M.+Schaeferauthor=C.+Sch%C3%B6fl&title=Free+fatty+acids+increase+cytosolic+free+calcium+and+stimulate+insulin+secretion+from+%CE%B2-cells+through+activation+of+GPR40&doi=10.1016%2Fj.mce.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40</span></div><div class="casAuthors">Schnell, Susanne; Schaefer, Michael; Schoefl, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Free fatty acids (FFA) cause a rise in cytosolic free Ca2+ ([Ca2+]i) and stimulate insulin release from pancreatic β-cells.  The G-protein coupled receptor GPR40 can be activated by medium- and long-chain FFA.  We investigated a potential role for GPR40 in the generation of the FFA-induced Ca2+ signal and insulin secretion. [Ca2+]i was measured in primary mouse β-cells and in INS-1 cells, and insulin secretion was assessed from INS-1 cells.  GPR40 expression was detd. by RT-PCR and downregulation of GPR40 expression by siRNA transfection was carried out in INS-1 cells.  A no. of satd., mono- and polyunsatd. medium- and long-chain FFA caused a rise in [Ca2+]i both in primary mouse β-cells and in INS-1 cells.  By contrast, the short-chain satd. caproic acid was ineffective at concns. up to 300 μM.  In INS-1 cells, the FFA-induced Ca2+ signal required mobilization of internal Ca2+ and Ca2+ influx through voltage-sensitive Ca2+ channels.  RT-PCR anal. revealed that GPR40 is expressed in INS-1 cells.  Downregulation of GPR40 by specific siRNA treatment lead to a significant inhibition of the FFA-induced [Ca2+]i response and insulin secretion, indicating that the FFA-stimulated Ca2+ signal and insulin secretion involve activation of GPR40 in pancreatic β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhyq6-hglH7rVg90H21EOLACvtfcHk0lhW7G-Itmr2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KgurzN&md5=eac888256316cd848c5cbde3ee1b78dc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSch%25C3%25B6fl%26aufirst%3DC.%26atitle%3DFree%2520fatty%2520acids%2520increase%2520cytosolic%2520free%2520calcium%2520and%2520stimulate%2520insulin%2520secretion%2520from%2520%25CE%25B2-cells%2520through%2520activation%2520of%2520GPR40%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2007%26volume%3D263%26spage%3D173%26epage%3D180%26doi%3D10.1016%2Fj.mce.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferdaoussi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrouki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poitout, V.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1007/s00125-012-2650-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1007%2Fs00125-012-2650-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22820510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWlsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2682-2692&author=M.+Ferdaoussiauthor=V.+Bergeronauthor=B.+Zarroukiauthor=J.+Kolicauthor=J.+Cantleyauthor=J.+Fielitzauthor=E.+N.+Olsonauthor=M.+Prentkiauthor=T.+Bidenauthor=P.+E.+MacDonaldauthor=V.+Poitout&title=G+protein-coupled+receptor+%28GPR%2940-dependent+potentiation+of+insulin+secretion+in+mouse+islets+is+mediated+by+protein+kinase+D1&doi=10.1007%2Fs00125-012-2650-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1</span></div><div class="casAuthors">Ferdaoussi, M.; Bergeron, V.; Zarrouki, B.; Kolic, J.; Cantley, J.; Fielitz, J.; Olson, E. N.; Prentki, M.; Biden, T.; MacDonald, P. E.; Poitout, V.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Activation of the G protein-coupled receptor (GPR)40 by long-chain fatty acids potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells, and GPR40 agonists are in clin. development for type 2 diabetes therapy.  GPR40 couples to the G protein subunit Gαq/11 but the signalling cascade activated downstream is unknown.  This study aimed to det. the mechanisms of GPR40-dependent potentiation of GSIS by fatty acids.  Methods: Insulin secretion in response to glucose, oleate or diacylglycerol (DAG) was assessed in dynamic perifusions and static incubations in islets from wild-type (WT) and Gpr40-/- mice.  Depolymn. of filamentous actin (F-actin) was visualized by phalloidin staining and epifluorescence.  Pharmacol. and mol. approaches were used to ascertain the roles of protein kinase D (PKD) and protein kinase C delta in GPR40-mediated potentiation of GSIS.  Results: Oleate potentiates the second phase of GSIS, and this effect is largely dependent upon GPR40.  Accordingly, oleate induces rapid F-actin remodelling in WT but not in Gpr40-/- islets.  Exogenous DAG potentiates GSIS in both WT and Gpr40-/- islets.  Oleate induces PKD phosphorylation at residues Ser-744/748 and Ser-916 in WT but not Gpr40-/- islets.  Importantly, oleate-induced F-actin depolymn. and potentiation of GSIS are lost upon pharmacol. inhibition of PKD1 or deletion of Prkd1.  Conclusions/interpretation: We conclude that the signalling cascade downstream of GPR40 activation by fatty acids involves activation of PKD1, F-actin depolymn. and potentiation of second-phase insulin secretion.  These results provide important information on the mechanisms of action of GPR40, a novel drug target for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRcajgd_2C7Vg90H21EOLACvtfcHk0lhW7G-Itmr2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWlsrvJ&md5=4deea241063f9f8619e71d00f2d12da0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00125-012-2650-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-012-2650-x%26sid%3Dliteratum%253Aachs%26aulast%3DFerdaoussi%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DV.%26aulast%3DZarrouki%26aufirst%3DB.%26aulast%3DKolic%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DJ.%26aulast%3DFielitz%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26aulast%3DPrentki%26aufirst%3DM.%26aulast%3DBiden%26aufirst%3DT.%26aulast%3DMacDonald%26aufirst%3DP.%2BE.%26aulast%3DPoitout%26aufirst%3DV.%26atitle%3DG%2520protein-coupled%2520receptor%2520%2528GPR%252940-dependent%2520potentiation%2520of%2520insulin%2520secretion%2520in%2520mouse%2520islets%2520is%2520mediated%2520by%2520protein%2520kinase%2520D1%26jtitle%3DDiabetologia%26date%3D2012%26volume%3D55%26spage%3D2682%26epage%3D2692%26doi%3D10.1007%2Fs00125-012-2650-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishigaki, N.</span></span> <span> </span><span class="NLM_article-title">GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0222653</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0222653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1371%2Fjournal.pone.0222653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=31525244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVWqtbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=H.+Uenoauthor=R.+Itoauthor=S.-i.+Abeauthor=H.+Oginoauthor=M.+Maruyamaauthor=H.+Miyashitaauthor=Y.+Miyamotoauthor=Y.+Moritohauthor=Y.+Tsujihataauthor=K.+Takeuchiauthor=N.+Nishigaki&title=GPR40+full+agonism+exerts+feeding+suppression+and+weight+loss+through+afferent+vagal+nerve&doi=10.1371%2Fjournal.pone.0222653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve</span></div><div class="casAuthors">Ueno, Hikaru; Ito, Ryo; Abe, Shin-ichi; Ogino, Hitomi; Maruyama, Minoru; Miyashita, Hirohisa; Miyamoto, Yasufumi; Moritoh, Yusuke; Tsujihata, Yoshiyuki; Takeuchi, Koji; Nishigaki, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0222653</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">GPR40/FFAR1 is a Gq protein-coupled receptor expressed in pancreatic β cells and enteroendocrine cells, and mediates insulin and incretin secretion to regulate feeding behavior.  Several GPR40 full agonists have been reported to reduce food intake in rodents by regulating gut hormone secretion in addn. to their potent glucose-lowering effects; however, detailed mechanisms of feeding suppression are still unknown.  In the present study, we characterized T-3601386, a novel compd. with potent full agonistic activity for GPR40, by using in vitro Ca2+ mobilization assay in Chinese hamster ovary (CHO) cells expressing FFAR1 and in vivo hormone secretion assay.  We also evaluated feeding suppression and wt. loss after the administration of T-3601386 and investigated the involvement of the vagal nerve in these effects.  T-3601386, but not a partial agonist fasiglifam, increased intracellular Ca2+ levels in CHO cells with low FFAR1 expression, and single dosing of T-3601386 in diet-induced obese (DIO) rats elevated plasma incretin levels, suggesting full agonistic properties of T-3601386 against GPR40.  Multiple doses of T-3601386, but not fasiglifam, in DIO rats showed dose-dependent wt. loss accompanied by feeding suppression and durable glucagon-like peptide-1 elevation, all of which were completely abolished in Ffar1-/- mice.  Immunohistochem. anal. in the nuclei of the solitary tract demonstrated that T-3601386 increased the no. of c-Fos pos. cells, which also disappeared in Ffar1-/- mice.  Surgical vagotomy and drug-induced deafferentation counteracted the feeding suppression and wt. loss induced by the administration of T-3601386.  These results suggest that T-3601386 exerts incretin release and wt. loss in a GPR40-dependent manner, and that afferent vagal nerves are important for the feeding suppression induced by GPR40 full agonism.  Our novel findings raise the possibility that GPR40 full agonist can induce periphery-derived wt. redn., which may provide benefits such as less adverse effects in central nervous system compared to centrally-acting anti-obesity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkFigiXcJe7Vg90H21EOLACvtfcHk0lj4ctaak66wiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVWqtbjN&md5=e2d89c5027961945e006dc479498daad</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0222653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0222653%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DAbe%26aufirst%3DS.-i.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DMiyashita%26aufirst%3DH.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DMoritoh%26aufirst%3DY.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DNishigaki%26aufirst%3DN.%26atitle%3DGPR40%2520full%2520agonism%2520exerts%2520feeding%2520suppression%2520and%2520weight%2520loss%2520through%2520afferent%2520vagal%2520nerve%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0222653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span> <span> </span><span class="NLM_article-title">SAR Studies of Indole-5-propanoic acid derivatives to develop novel GPR40 agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1336</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00460</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00460" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1336-1340&author=D.-O.+Yoonauthor=X.+Zhaoauthor=D.+Sonauthor=J.+T.+Hanauthor=J.+Yunauthor=D.+Shinauthor=H.-J.+Park&title=SAR+Studies+of+Indole-5-propanoic+acid+derivatives+to+develop+novel+GPR40+agonists&doi=10.1021%2Facsmedchemlett.7b00460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists</span></div><div class="casAuthors">Yoon, Dong-Oh; Zhao, Xiaodi; Son, Dohyun; Han, Jung Tae; Yun, Jaesook; Shin, Dongyun; Park, Hyun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1336-1340</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein coupled receptor 40 (GPR40) has been considered to be an attractive drug target for the treatment of type 2 diabetes because of its role in free fatty acids-mediated enhancement of glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells.  A series of indole-5-propanoic acid compds. were synthesized, and their GPR40 agonistic activities were evaluated by nuclear factor of activated T-cells reporter assay and GSIS assay in the MIN-6 insulinoma cells.  Three compds., 8h (3-(2-(2-chlorophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 58.6 nM), 8i (3-(2-(3-chlorophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 37.8 nM), and 8o (3-(2-(2-bromophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 9.4 nM), were identified as potent GPR40 agonists with good GSIS effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Phq-aJx2FbVg90H21EOLACvtfcHk0lj4ctaak66wiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FO&md5=1dc0c1cae53c5f19e964bf2c1b33c52f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00460%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DD.-O.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSon%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DJ.%2BT.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.-J.%26atitle%3DSAR%2520Studies%2520of%2520Indole-5-propanoic%2520acid%2520derivatives%2520to%2520develop%2520novel%2520GPR40%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1336%26epage%3D1340%26doi%3D10.1021%2Facsmedchemlett.7b00460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span> <span> </span><span class="NLM_article-title">Tools for GPCR drug discovery</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Faps.2011.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22266728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=372-384&author=R.+Zhangauthor=X.+Xie&title=Tools+for+GPCR+drug+discovery&doi=10.1038%2Faps.2011.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tools for GPCR drug discovery</span></div><div class="casAuthors">Zhang, Ru; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) mediate many important physiol. functions and are considered as one of the most successful therapeutic targets for a broad spectrum of diseases.  The design and implementation of high-throughput GPCR assays that allow the cost-effective screening of large compd. libraries to identify novel drug candidates are crit. in early drug discovery.  Early functional GPCR assays depend primarily on the measurement of G-protein-mediated 2nd messenger generation.  Taking advantage of the continuously deepening understanding of GPCR signal transduction, many G-protein-independent pathways are utilized to detect the activity of GPCRs, and may provide addnl. information on functional selectivity of candidate compds.  With the combination of automated imaging systems and label-free detection systems, such assays are now suitable for high-throughput screening (HTS).  In this review, we summarize the most widely used GPCR assays and recent advances in HTS technologies for GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pC8anrKpWLVg90H21EOLACvtfcHk0lj4ctaak66wiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D&md5=04ca4fed048dbca837d81c02566e6e25</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.173%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DTools%2520for%2520GPCR%2520drug%2520discovery%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D372%26epage%3D384%26doi%3D10.1038%2Faps.2011.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhurruth-Alcor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Røst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiorgis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heal, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design programprotobuild</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1039/c0ob00146e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1039%2FC0OB00146E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21157612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=1169-1188&author=Y.+Bhurruth-Alcorauthor=T.+R%C3%B8stauthor=M.+R.+Jorgensenauthor=C.+Kontogiorgisauthor=J.+Skorveauthor=R.+G.+Cooperauthor=J.+M.+Sheridanauthor=W.+D.+O.+Hamiltonauthor=J.+R.+Healauthor=R.+K.+Bergeauthor=A.+D.+Miller&title=Synthesis+of+novel+PPAR%CE%B1%2F%CE%B3+dual+agonists+as+potential+drugs+for+the+treatment+of+the+metabolic+syndrome+and+diabetes+type+II+designed+using+a+new+de+novo+design+programprotobuild&doi=10.1039%2Fc0ob00146e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program protobuild</span></div><div class="casAuthors">Bhurruth-Alcor, Yushma; Rost, Therese; Jorgensen, Michael R.; Kontogiorgis, Christos; Skorve, Jon; Cooper, Robert G.; Sheridan, Joseph M.; Hamilton, William D. O.; Heal, Jonathan R.; Berge, Rolf K.; Miller, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1169-1188</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Peroxisome proliferator activated receptors (PPARs) have been shown to have crit. roles in fatty acid oxidn., triglyceride synthesis, and lipid metab. - making them an important target in drug discovery.  Here we describe the in silico design, synthesis and in vitro characterization of a novel series of 2,5-disubstituted indoles as PPARα/γ dual agonists.  PPAR activation assays are performed with known agonists diazabenzene (WY14.643), aminopyridine (BRL49653) and bisaryl (L165.041), as pos. controls.  All the indole compds. synthesized are found to be active PPARα and PPARγ agonists, with particular efficacy from those with 2-naphthylmethyl substitution.  This is a useful demonstration of a new de novo design methodol. implemented by the protobuild program and its ability to rapidly produce novel modulators for a well characterized drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPSAs5UK2KrLVg90H21EOLACvtfcHk0lhKI_F0IptY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCjtrw%253D&md5=dd413b54526eadebcb182db17cc1f8f3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC0OB00146E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0OB00146E%26sid%3Dliteratum%253Aachs%26aulast%3DBhurruth-Alcor%26aufirst%3DY.%26aulast%3DR%25C3%25B8st%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DM.%2BR.%26aulast%3DKontogiorgis%26aufirst%3DC.%26aulast%3DSkorve%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DR.%2BG.%26aulast%3DSheridan%26aufirst%3DJ.%2BM.%26aulast%3DHamilton%26aufirst%3DW.%2BD.%2BO.%26aulast%3DHeal%26aufirst%3DJ.%2BR.%26aulast%3DBerge%26aufirst%3DR.%2BK.%26aulast%3DMiller%26aufirst%3DA.%2BD.%26atitle%3DSynthesis%2520of%2520novel%2520PPAR%25CE%25B1%252F%25CE%25B3%2520dual%2520agonists%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520the%2520metabolic%2520syndrome%2520and%2520diabetes%2520type%2520II%2520designed%2520using%2520a%2520new%2520de%2520novo%2520design%2520programprotobuild%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D1169%26epage%3D1188%26doi%3D10.1039%2Fc0ob00146e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Curto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span> <span> </span><span class="NLM_article-title">Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1111/bph.12879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1111%2Fbph.12879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25131623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3254-3265&author=G.+Milliganauthor=E.+Alvarez-Curtoauthor=K.+R.+Wattersonauthor=T.+Ulvenauthor=B.+D.+Hudson&title=Characterizing+pharmacological+ligands+to+study+the+long-chain+fatty+acid+receptors+GPR40%2FFFA1+and+GPR120%2FFFA4&doi=10.1111%2Fbph.12879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4</span></div><div class="casAuthors">Milligan, G.; Alvarez-Curto, E.; Watterson, K. R.; Ulven, T.; Hudson, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3254-3265</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The free fatty acid receptors (FFA) 1 (previously designated GPR40) and FFA4 (previously GPR120) are two GPCRs activated by satd. and unsatd. longer-chain free fatty acids.  With expression patterns and functions anticipated to directly or indirectly promote insulin secretion, provide homeostatic control of blood glucose and improve tissue insulin sensitivity, both receptors are being studied as potential therapeutic targets for the control of type 2 diabetes.  Furthermore, genetic and systems biol. studies in both humans and mouse models link FFA4 receptors to diabetes and obesity.  Although activated by the same group of free fatty acids, FFA1 and FFA4 receptors are not closely related and, while the basis of recognition of fatty acids by FFA1 receptors is similar to that of the short-chain fatty acid receptors FFA2 and FFA3, the amino acid residues involved in endogenous ligand recognition by FFA4 receptors are more akin to those of the sphingosine 1 phosphate receptor S1P1.  Screening and subsequent medicinal chem. programs have developed a no. of FFA1 receptor selective agonists that are effective in promoting insulin secretion in a glucose concn.-dependent manner, and in lowering blood glucose levels.  However, the recent termination of Phase III clin. trials employing TAK-875/fasiglifam has caused a setback and raises important questions over the exact nature and mechanistic causes of the problems.  Progress in the identification and development of highly FFA4 receptor-selective pharmacol. tools has been less rapid and several issues remain to be clarified to fully validate this receptor as a therapeutic target.  Despite this, the ongoing development of a range of novel ligands offers great opportunities to further unravel the contributions of these receptors.  Linked Articles : This article is part of a themed section on 5th BPS Focused Meeting on Cell Signalling.  To view the other articles in this section visit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH6wIjF6Rg3bVg90H21EOLACvtfcHk0lhKI_F0IptY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt73E&md5=361d7b4aefdf7f496d66d8082d9c38bb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fbph.12879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12879%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DAlvarez-Curto%26aufirst%3DE.%26aulast%3DWatterson%26aufirst%3DK.%2BR.%26aulast%3DUlven%26aufirst%3DT.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26atitle%3DCharacterizing%2520pharmacological%2520ligands%2520to%2520study%2520the%2520long-chain%2520fatty%2520acid%2520receptors%2520GPR40%252FFFA1%2520and%2520GPR120%252FFFA4%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3254%26epage%3D3265%26doi%3D10.1111%2Fbph.12879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakaj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span> <span> </span><span class="NLM_article-title">GPR40-Mediated Gα12 Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1124/mol.117.111369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fmol.117.111369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=29572336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=581-591&author=M.-L.+Rivesauthor=B.+Radyauthor=N.+Swansonauthor=S.+Zhaoauthor=J.+Qiauthor=E.+Arnoultauthor=I.+Bakajauthor=A.+Manciniauthor=B.+Bretonauthor=S.+P.+Leeauthor=M.+R.+Playerauthor=A.+Pocai&title=GPR40-Mediated+G%CE%B112+Activation+by+Allosteric+Full+Agonists+Highly+Efficacious+at+Potentiating+Glucose-Stimulated+Insulin+Secretion+in+Human+Islets&doi=10.1124%2Fmol.117.111369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40-mediated Gα12 activation by allosteric full agonists highly efficacious at potentiating glucose-stimulated insulin secretion in human islets</span></div><div class="casAuthors">Rives, Marie-Laure; Rady, Brian; Swanson, Nadia; Zhao, Shuyuan; Qi, Jenson; Arnoult, Eric; Bakaj, Ivona; Mancini, Arturo; Breton, Billy; Lee, S. Paul; Player, Mark R.; Pocai, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-591</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GPR40 is a clin. validated mol. target for the treatment of diabetes.  Many GPR40 agonists have been identified to date, with the partial agonist fasiglifam (TAK-875) reaching phase III clin. trials before its development was terminated due to off-target liver toxicity.  Since then, attention has shifted toward the development of full agonists that exhibit superior efficacy in preclin. models.  Full agonists bind to a distinct binding site, suggesting conformational plasticity and a potential for biased agonism.  Indeed, it has been suggested that alternative pharmacol. may be required for meaningful efficacy.  In this study, we described the discovery and characterization of Compd. A, a newly identified GPR40 allosteric full agonist highly efficacious in human islets at potentiating glucose-stimulated insulin secretion.  We compared Compd. A-induced GPR40 activity to that induced by both fasiglifam and AM-1638, another allosteric full agonist previously reported to be highly efficacious in preclin. models, at a panel of G proteins.  Compd. A was a full agonist at both the Gaq and Gai2 pathways, and in contrast to fasiglifam Compd. A also induced Gα12 coupling.  Compd. A and AM-1638 displayed similar activity at all pathways tested.  The Gα12/Gα13-mediated signaling pathway has been linked to protein kinase D activation as well as actin remodeling, well known to contribute to the release of insulin vesicles.  Our data suggest that the pharmacol. of GPR40 is complex and that Gα12/Gα13-mediated signaling, which may contribute to GPR40 agonists therapeutic efficacy, is a specific property of GPR40 allosteric full agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq4ElVfBqrC7Vg90H21EOLACvtfcHk0lhKI_F0IptY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnu7rI&md5=cf26bf07ab86583e86e5727bcb499e32</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fmol.117.111369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.117.111369%26sid%3Dliteratum%253Aachs%26aulast%3DRives%26aufirst%3DM.-L.%26aulast%3DRady%26aufirst%3DB.%26aulast%3DSwanson%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DBakaj%26aufirst%3DI.%26aulast%3DMancini%26aufirst%3DA.%26aulast%3DBreton%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%2BP.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPocai%26aufirst%3DA.%26atitle%3DGPR40-Mediated%2520G%25CE%25B112%2520Activation%2520by%2520Allosteric%2520Full%2520Agonists%2520Highly%2520Efficacious%2520at%2520Potentiating%2520Glucose-Stimulated%2520Insulin%2520Secretion%2520in%2520Human%2520Islets%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D93%26spage%3D581%26epage%3D591%26doi%3D10.1124%2Fmol.117.111369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slice, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozengurt, E.</span></span> <span> </span><span class="NLM_article-title">Activation of Protein Kinase D by Signaling through Rho and the α Subunit of the Heterotrimeric G Protein G13</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">38619</span>– <span class="NLM_lpage">38627</span>, <span class="refDoi"> DOI: 10.1074/jbc.m105530200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1074%2Fjbc.M105530200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=11507098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=38619-38627&author=J.+Yuanauthor=L.+W.+Sliceauthor=E.+Rozengurt&title=Activation+of+Protein+Kinase+D+by+Signaling+through+Rho+and+the+%CE%B1+Subunit+of+the+Heterotrimeric+G+Protein+G13&doi=10.1074%2Fjbc.m105530200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of protein kinase D by signaling through Rho and the α subunit of the heterotrimeric G protein G13</span></div><div class="casAuthors">Yuan, Jingzhen; Slice, Lee W.; Rozengurt, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">38619-38627</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein kinase D (PKD/PKCμ) immunopptd. from COS-7 cells transiently transfected with either a constitutively active mutant of Rho (RhoQ63L) or the Rho-specific guanine nucleotide exchange factor pOnco-Lbc exhibited a marked increase in basal activity.  Addn. of aluminum fluoride to cells co-transfected with PKD and wild type Gα13 also induced PKD activation.  Co-transfection of Clostridium botulinum C3 toxin blocked activation of PKD by RhoQ63L, Lbc, or aluminum fluoride-stimulated Gα13.  Treatment with the protein kinase C inhibitors GF I or Ro 31-8220 prevented the increase in PKD activity induced by RhoQ63L, Lbc, or aluminum fluoride-stimulated Gα13.  PKD activation in response to Gα13 signaling was also completely prevented by mutation of Ser-744 and Ser-748 to Ala in the kinase activation loop of PKD.  Co-expression of C. botulinum C3 toxin and a C-terminal fragment of Gαq that acts in a dominant-neg. fashion blocked PKD activation in response to agonist stimulation of bombesin receptor.  Expression of the C-terminal region of Gα13 also attenuated PKD activation in response to bombesin receptor stimulation.  Our results show that Gα13 contributes to PKD activation through a Rho- and protein kinase C-dependent signaling pathway and indicate that PKD activation is mediated by both Gαq and Gα13 in response to bombesin receptor stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6mIMylgxe_bVg90H21EOLACvtfcHk0ljK5DHF_85Rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVentrY%253D&md5=2b608a529c34c9ccf9c56b1054600d8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M105530200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M105530200%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DSlice%26aufirst%3DL.%2BW.%26aulast%3DRozengurt%26aufirst%3DE.%26atitle%3DActivation%2520of%2520Protein%2520Kinase%2520D%2520by%2520Signaling%2520through%2520Rho%2520and%2520the%2520%25CE%25B1%2520Subunit%2520of%2520the%2520Heterotrimeric%2520G%2520Protein%2520G13%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D38619%26epage%3D38627%26doi%3D10.1074%2Fjbc.m105530200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siehler, S.</span></span> <span> </span><span class="NLM_article-title">G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.12.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1517%2F17460441.2.12.1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23488903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1591-1604&author=S.+Siehler&title=G12%2F13-dependent+signaling+of+G-protein-coupled+receptors%3A+disease+context+and+impact+on+drug+discovery&doi=10.1517%2F17460441.2.12.1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery</span></div><div class="casAuthors">Siehler, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1591-1604</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) transmit extracellular signals across the plasma membrane via intracellular activation of heterotrimeric G proteins.  The signal transduction pathways of Gs, Gi and Gq protein families are widely studied, whereas signaling properties of G12 proteins are only emerging.  Many GPCRs were found to couple to G12/13 proteins in addn. to coupling to one or more other types of G proteins.  G12/13 proteins couple GPCRs to activation of the small monomeric GTPase RhoA.  Activation of RhoA modulates various downstream effector systems relevant to diseases such as hypertension, atherosclerosis, asthma and cancer.  GPCR screening assays exist for Gs-, Gi- and Gq-linked pathways, whereas a drug-screening assay for the G12-Rho pathway was developed only recently.  The review gives an overview of the present understanding of the G12/13-related biol. of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqidJhepHOJV7Vg90H21EOLACvtfcHk0ljK5DHF_85Rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSnsg%253D%253D&md5=79a1e26e9937575143ef694472bc966f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.12.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.12.1591%26sid%3Dliteratum%253Aachs%26aulast%3DSiehler%26aufirst%3DS.%26atitle%3DG12%252F13-dependent%2520signaling%2520of%2520G-protein-coupled%2520receptors%253A%2520disease%2520context%2520and%2520impact%2520on%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D1591%26epage%3D1604%26doi%3D10.1517%2F17460441.2.12.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">Fatty acids and β-cell toxicity</span>. <i>Curr. Opin. Clin. Nutr. Metab. Care</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1097/mco.0b013e328321e423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1097%2FMCO.0b013e328321e423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=19202382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=117-122&author=N.+G.+Morgan&title=Fatty+acids+and+%CE%B2-cell+toxicity&doi=10.1097%2Fmco.0b013e328321e423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty acids and β-cell toxicity</span></div><div class="casAuthors">Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Clinical Nutrition and Metabolic Care</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-122</span>CODEN:
                <span class="NLM_cas:coden">COCMF3</span>;
        ISSN:<span class="NLM_cas:issn">1363-1950</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The rising incidence of type 2 diabetes is due, in part, to the detrimental effects of certain fatty acids on pancreatic β-cell function and viability.  The present review examines recent advances in the understanding of the mol. mechanisms by which fatty acids influence the life and death of β cells.  Recent findings: There are important differences in the cytotoxic potential of fatty acids, with long-chain satd. mols. being the most potent.  By contrast, monounsaturates and polyunsaturates are relatively well tolerated and, in some cases, are actively cytoprotective.  The mechanisms underlying the toxicity of the sats. may reflect a decrease in protein processing, which drives the accumulation of unfolded proteins in the endoplasmic reticulum.  This triggers an apoptotic response by virtue of enhanced endoplasmic reticulum stress and induction of CHOP-10 synthesis.  Alterations in the regulatory control of other proapoptotic genes via changes in microRNA synthesis may also contribute.  The cytoprotection deriving from incubation with long-chain mono-unsaturates is probably receptor mediated and involves antagonistic actions on the effector arm of the endoplasmic reticulum stress pathway.  Summary: The findings have implications for the development of new therapeutic agents designed to minimize β-cell dysfunction and the loss of β-cell viability in type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66l-nAsJnALVg90H21EOLACvtfcHk0ljK5DHF_85Rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKksLk%253D&md5=752871887c7bd0221d10452efbca015c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FMCO.0b013e328321e423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCO.0b013e328321e423%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DFatty%2520acids%2520and%2520%25CE%25B2-cell%2520toxicity%26jtitle%3DCurr.%2520Opin.%2520Clin.%2520Nutr.%2520Metab.%2520Care%26date%3D2009%26volume%3D12%26spage%3D117%26epage%3D122%26doi%3D10.1097%2Fmco.0b013e328321e423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm2012968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2012968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1538-1552&author=N.+Negoroauthor=S.+Sasakiauthor=M.+Itoauthor=S.+Kitamuraauthor=Y.+Tsujihataauthor=R.+Itoauthor=M.+Suzukiauthor=K.+Takeuchiauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=T.+Odaniauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=T.+Yasumaauthor=Y.+Momose&title=Identification+of+fused-ring+alkanoic+acids+with+improved+pharmacokinetic+profiles+that+act+as+G+protein-coupled+receptor+40%2Ffree+fatty+acid+receptor+1+agonists&doi=10.1021%2Fjm2012968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonists</span></div><div class="casAuthors">Negoro, Nobuyuki; Sasaki, Shinobu; Ito, Masahiro; Kitamura, Shuji; Tsujihata, Yoshiyuki; Ito, Ryo; Suzuki, Masami; Takeuchi, Koji; Suzuki, Nobuhiro; Miyazaki, Junichi; Santou, Takashi; Odani, Tomoyuki; Kanzaki, Naoyuki; Funami, Miyuki; Tanaka, Toshimasa; Yasuma, Tsuneo; Momose, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1538-1552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency.  We previously identified 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid as a potent and orally available GPR40/FFA1 agonist; however, it exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidn. at the phenylpropanoic acid moiety.  To identify long-acting compds., we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure.  Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced.  Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of the dihydrobenzofuran (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid (I), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvX-exJHNoe7Vg90H21EOLACvtfcHk0lhAFGfODC9fbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFGrtA%253D%253D&md5=0841278f5c72041d6ed5ac3b90230d29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm2012968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2012968%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520fused-ring%2520alkanoic%2520acids%2520with%2520improved%2520pharmacokinetic%2520profiles%2520that%2520act%2520as%2520G%2520protein-coupled%2520receptor%252040%252Ffree%2520fatty%2520acid%2520receptor%25201%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1538%26epage%3D1552%26doi%3D10.1021%2Fjm2012968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span> <span> </span><span class="NLM_article-title">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1124/mol.112.079640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fmol.112.079640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22859723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=843-859&author=D.+C.-H.+Linauthor=Q.+Guoauthor=J.+Luoauthor=J.+Zhangauthor=K.+Nguyenauthor=M.+Chenauthor=T.+Tranauthor=P.+J.+Dransfieldauthor=S.+P.+Brownauthor=J.+Houzeauthor=M.+Vimolratanaauthor=X.+Y.+Jiaoauthor=Y.+Wangauthor=N.+J.+M.+Birdsallauthor=G.+Swaminath&title=Identification+and+pharmacological+characterization+of+multiple+allosteric+binding+sites+on+the+free+fatty+acid+1+receptor&doi=10.1124%2Fmol.112.079640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span></div><div class="casAuthors">Lin, Daniel C.-H.; Guo, Qi; Luo, Jian; Zhang, Jane; Nguyen, Kathy; Chen, Michael; Tran, Thanh; Dransfield, Paul J.; Brown, Sean P.; Houze, Jonathan; Vimolratana, Marc; Jiao, Xian Yun; Wang, Yingcai; Birdsall, Nigel J. M.; Swaminath, Gayathri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-859</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of FFA1 (GPR40), a member of G protein-coupling receptor family A, is mediated by medium- and long-chain fatty acids and leads to amplification of glucose-stimulated insulin secretion, suggesting a potential role for free fatty acid 1 (FFA1) as a target for type 2 diabetes.  It was assumed previously that there is a single binding site for fatty acids and synthetic FFA1 agonists.  However, using members of two chem. series of partial and full agonists that have been identified, radioligand binding interaction studies revealed that the full agonists do not bind to the same site as the partial agonists but exhibit pos. heterotropic cooperativity.  Anal. of functional data reveals pos. functional cooperativity between the full agonists and partial agonists in various functional assays (in vitro and ex vivo) and also in vivo.  Furthermore, the endogenous fatty acid docosahexaenoic acid (DHA) shows neg. or neutral cooperativity with members of both series of agonists in binding assays but displays pos. cooperativity in functional assays.  Another synthetic agonist is allosteric with members of both agonist series, but apparently competitive with DHA.  Therefore, there appear to be three allosterically linked binding sites on FFA1 with agonists specific for each of these sites.  Activation of free fatty acid 1 receptor (FFAR1) by each of these agonists is differentially affected by mutations of two arginine residues, previously found to be important for FFAR1 binding and activation.  These ligands with their high potencies and strong pos. functional cooperativity with endogenous fatty acids, demonstrated in vitro and in vivo, have the potential to deliver therapeutic benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-mJkDwpnmbVg90H21EOLACvtfcHk0lhAFGfODC9fbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE&md5=2437a31476d8c7d7b4fb06972e1f43d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.079640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.079640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DSwaminath%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520pharmacological%2520characterization%2520of%2520multiple%2520allosteric%2520binding%2520sites%2520on%2520the%2520free%2520fatty%2520acid%25201%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D843%26epage%3D859%26doi%3D10.1124%2Fmol.112.079640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirozane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruswitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivetac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1038/nature13494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnature13494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25043059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=124-127&author=A.+Srivastavaauthor=J.+Yanoauthor=Y.+Hirozaneauthor=G.+Kefalaauthor=F.+Gruswitzauthor=G.+Snellauthor=W.+Laneauthor=A.+Ivetacauthor=K.+Aertgeertsauthor=J.+Nguyenauthor=A.+Jenningsauthor=K.+Okada&title=High-resolution+structure+of+the+human+GPR40+receptor+bound+to+allosteric+agonist+TAK-875&doi=10.1038%2Fnature13494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875</span></div><div class="casAuthors">Srivastava, Ankita; Yano, Jason; Hirozane, Yoshihiko; Kefala, Georgia; Gruswitz, Franz; Snell, Gyorgy; Lane, Weston; Ivetac, Anthony; Aertgeerts, Kathleen; Nguyen, Jasmine; Jennings, Andy; Okada, Kengo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">124-127</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human GPR40 receptor (hGPR40), also known as free fatty-acid receptor 1 (FFAR1), is a G-protein-coupled receptor that binds long-chain free fatty acids to enhance glucose-dependent insulin secretion.  Novel treatments for type-2 diabetes mellitus are therefore possible by targeting hGPR40 with partial or full agonists.  TAK-875, or fasiglifam, is an orally available, potent and selective partial agonist of hGPR40 receptor, which reached phase III clin. trials for the potential treatment of type-2 diabetes mellitus.  Data from clin. studies indicate that TAK-875, which is an ago-allosteric modulator of hGPR40 (ref. 3), demonstrates improved glycemic control and low hypoglycemic risk in diabetic patients.  Here the authors report the crystal structure of hGPR40 receptor bound to TAK-875 at 2.3 Å resoln.  The co-complex structure reveals a unique binding mode of TAK-875 and suggests that entry to the non-canonical binding pocket most probably occurs via the lipid bilayer.  The at. details of the extensive charge network in the ligand binding pocket reveal addnl. interactions not identified in previous studies and contribute to a clear understanding of TAK-875 binding to the receptor.  The hGPR40-TAK-875 structure also provides insights into the plausible binding of multiple ligands to the receptor, which has been obsd. in radioligand binding and Ca2+ influx assay studies.  Comparison of the transmembrane helix architecture with other G-protein-coupled receptors suggests that the crystd. TAK-875-bound hGPR40 complex is in an inactive-like state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO9EJ42g7iaLVg90H21EOLACvtfcHk0lhAFGfODC9fbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvK&md5=06e38fa105ab0783715a541bc2008311</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature13494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13494%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DHirozane%26aufirst%3DY.%26aulast%3DKefala%26aufirst%3DG.%26aulast%3DGruswitz%26aufirst%3DF.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DW.%26aulast%3DIvetac%26aufirst%3DA.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DHigh-resolution%2520structure%2520of%2520the%2520human%2520GPR40%2520receptor%2520bound%2520to%2520allosteric%2520agonist%2520TAK-875%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D124%26epage%3D127%26doi%3D10.1038%2Fnature13494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span> <i>Schrödinger
Release 2019-4</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Schr%C3%B6dinger%0ARelease+2019-4%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSchr%25C3%25B6dinger%250ARelease%25202019-4%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnsmb.3417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28581512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Onu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=570-577&author=J.+Luauthor=N.+Byrneauthor=J.+Wangauthor=G.+Bricogneauthor=F.+K.+Brownauthor=H.+R.+Chobanianauthor=S.+L.+Collettiauthor=J.+Di+Salvoauthor=B.+Thomas-Fowlkesauthor=Y.+Guoauthor=D.+L.+Hallauthor=J.+Hadixauthor=N.+B.+Hastingsauthor=J.+D.+Hermesauthor=T.+Hoauthor=A.+D.+Howardauthor=H.+Josienauthor=M.+Kornienkoauthor=K.+J.+Lumbauthor=M.+W.+Millerauthor=S.+B.+Patelauthor=B.+Pioauthor=C.+W.+Plummerauthor=B.+S.+Sherborneauthor=P.+Shethauthor=S.+Souzaauthor=S.+Tummalaauthor=C.+Vonrheinauthor=M.+Webbauthor=S.+J.+Allenauthor=J.+M.+Johnstonauthor=A.+B.+Weinglassauthor=S.+Sharmaauthor=S.+M.+Soisson&title=Structural+basis+for+the+cooperative+allosteric+activation+of+the+free+fatty+acid+receptor+GPR40&doi=10.1038%2Fnsmb.3417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40</span></div><div class="casAuthors">Lu, Jun; Byrne, Noel; Wang, John; Bricogne, Gerard; Brown, Frank K.; Chobanian, Harry R.; Colletti, Steven L.; Di Salvo, Jerry; Thomas-Fowlkes, Brande; Guo, Yan; Hall, Dawn L.; Hadix, Jennifer; Hastings, Nicholas B.; Hermes, Jeffrey D.; Ho, Thu; Howard, Andrew D.; Josien, Hubert; Kornienko, Maria; Lumb, Kevin J.; Miller, Michael W.; Patel, Sangita B.; Pio, Barbara; Plummer, Christopher W.; Sherborne, Bradley S.; Sheth, Payal; Souza, Sarah; Tummala, Srivanya; Vonrhein, Clemens; Webb, Maria; Allen, Samantha J.; Johnston, Jennifer M.; Weinglass, Adam B.; Sharma, Sujata; Soisson, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">570-577</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clin. studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus.  Full allosteric agonists (AgoPAMs) of GPR40 bind to a site distinct from partial agonists and can provide addnl. efficacy.  We report the 3.2-Å crystal structure of human GPR40 (hGPR40) in complex with both the partial agonist MK-8666 and an AgoPAM, which exposes a novel lipid-facing AgoPAM-binding pocket outside the transmembrane helical bundle.  Comparison with an addnl. 2.2-Å structure of the hGPR40-MK-8666 binary complex reveals an induced-fit conformational coupling between the partial agonist and AgoPAM binding sites, involving rearrangements of the transmembrane helixes 4 and 5 (TM4 and TM5) and transition of the intracellular loop 2 (ICL2) into a short helix.  These conformational changes likely prime GPR40 to a more active-like state and explain the binding cooperativity between these ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIlYQcPgGaErVg90H21EOLACvtfcHk0liSws8qs4LXlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Onu7c%253D&md5=9f54c7b79ef28da029cce91dc7c02274</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3417%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBricogne%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DF.%2BK.%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHadix%26aufirst%3DJ.%26aulast%3DHastings%26aufirst%3DN.%2BB.%26aulast%3DHermes%26aufirst%3DJ.%2BD.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DPio%26aufirst%3DB.%26aulast%3DPlummer%26aufirst%3DC.%2BW.%26aulast%3DSherborne%26aufirst%3DB.%2BS.%26aulast%3DSheth%26aufirst%3DP.%26aulast%3DSouza%26aufirst%3DS.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DWebb%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DS.%2BJ.%26aulast%3DJohnston%26aufirst%3DJ.%2BM.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26atitle%3DStructural%2520basis%2520for%2520the%2520cooperative%2520allosteric%2520activation%2520of%2520the%2520free%2520fatty%2520acid%2520receptor%2520GPR40%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D570%26epage%3D577%26doi%3D10.1038%2Fnsmb.3417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renato L  Carvalho</span>, <span class="hlFld-ContribAuthor ">Amanda S  de Miranda</span>, <span class="hlFld-ContribAuthor ">Mateus P  Nunes</span>, <span class="hlFld-ContribAuthor ">Roberto S  Gomes</span>, <span class="hlFld-ContribAuthor ">Guilherme A M  Jardim</span>, <span class="hlFld-ContribAuthor ">Eufrânio N da Silva  Júnior</span>. </span><span class="cited-content_cbyCitation_article-title">On the application of 3d metals for C–H activation toward bioactive compounds: The key step for the synthesis of silver bullets. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>17 </em>, 1849-1938. <a href="https://doi.org/10.3762/bjoc.17.126" title="DOI URL">https://doi.org/10.3762/bjoc.17.126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.17.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.17.126%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOn%252Bthe%252Bapplication%252Bof%252B3d%252Bmetals%252Bfor%252BC%2525E2%252580%252593H%252Bactivation%252Btoward%252Bbioactive%252Bcompounds%25253A%252BThe%252Bkey%252Bstep%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bsilver%252Bbullets%26aulast%3DCarvalho%26aufirst%3DRenato%2BL%26date%3D2021%26date%3D2021%26volume%3D17%26spage%3D1849%26epage%3D1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative GPR40 Agonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ar-Br or I, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, DMF, 90 °C, and 30–69%; (b) AuCl<sub>3</sub>, EtOH, 60 °C, and 50–82%; and (c) 1 N NaOH, MeOH, 60 °C, and 52–75%.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. GPR40 transcription activity of <b>4k</b> and <b>4o</b>. Effect of <b>4k</b> and <b>4o</b>, in comparison with DHA and TAK875, in CHO cells transfected with 30 ng/well of GPR40 expression plasmid (A) and 0.5 ng/well of GPR40 expression plasmid (B). (C) GPR40 transactivation by <b>4k</b>, <b>4o</b>, and TAK875. Transcriptional activity was determined in CHO cells transiently co-transfected with GPR40 plasmid and luciferase reporter SRE-Luc (G<sub>q</sub>), CRE-Luc (G<sub>s</sub>), or SRF-Luc (G<sub>12/13</sub>). After 3 h of transfection, cells were treated with compounds (10 μM) for an additional 24 h. <sup>###</sup><i>p</i> ≤ 0.01; ***<i>p</i> ≤ 0.005 vs DMSO alone. (D) Concentration-dependent CRE-Luc reporter assay and (E) detection of cAMP accumulation in the presence of <b>4k</b>, <b>4o</b>, and TAK875.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A,B) Evaluation of GSIS by <b>4k</b> and <b>4o</b> in MIN6 cells, in comparison with TAK875. The data are presented as mean ± standard error (<i>n</i> = 3). <sup>###</sup><i>p</i> ≤ 0.01; *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs 17 mM glucose alone by Student’s <i>t</i>-test. (C) <b>4k</b> and <b>4o</b> promote GLP-1 secretion in STC-1 cells. The data are presented as mean ± standard error (<i>n</i> = 3). *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs DMSO. GLP-1, glucagon-like peptide 1; DMSO, dimethyl sulfoxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>4k</b> and <b>4o</b> do not exacerbate FFA-induced apoptotic signaling in MIN6 cells. (A) Caspase 3/7 activity in MIN6 cells after 72 h of exposure to 62.5 to 1000 μM BSA–PA conjugate or 0.5 to 100 μM of drugs. (B) Co-treatment of <b>4k</b> or <b>4o</b> with BSA–PA conjugate. The data are presented as mean ± standard error (<i>n</i> = 3). *<i>p</i> ≤ 0.05, **<i>p</i> ≤ 0.01, and ***<i>p</i> ≤ 0.005 vs DMSO. BSA–PA, bovine serum albumin–palmitic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>4k</b> and <b>4o</b> show positive cooperativity with the partial agonist TAK875 and endogenous ligand DHA<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> in functional assays. The effects of increasing concentrations of TAK875 (A,B) or DHA (C,D) on the dose–response curves of <b>4k</b> (A,C) and <b>4o</b> (B,D) are illustrated in the reporter assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>4k</b>, <b>4o</b>, and <b>6k</b> at the AP8-binding site of GPR40 (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY">5TZY</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>). (A) Superimposition of <b>4k</b> and <b>4o</b> over the X-ray pose of AP8 (depicted as a blue stick) in the inner-leaflet pocket of GPR40. <b>4k</b> and <b>4o</b> are rendered as yellow and magenta sticks, respectively. The binding site is represented as a gray molecular surface. (B) A close-up view of key interactions involved in stabilizing <b>4k</b> in the binding pocket. Hydrogen bonds are depicted as yellow dotted lines. (C) 2D view of interactions between <b>4k</b> and GPR40. (D) Binding mode of <b>4k</b> and <b>6k</b>. <b>6k</b> is depicted as a green stick. Surrounding key amino acid residues are shown as gray sticks and are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) potassium <i>tert</i>-butoxide (1.5 equiv), iodomethane (2.0 equiv), THF, and r.t. and (b) NaOH, MeOH, and 40 °C.</p></p></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/medium/jm1c00031_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Anti-diabetic efficacy of <b>4k</b> and <b>4o</b> in rodent Models. <i>In vivo</i> glucose-lowering effect of <b>4k</b> and <b>4o</b> in C57BL/6J (A,B) or db/db mice (C,D), and GLP-1 secretion effect of <b>4o</b> in C57BL/6J mice (E). Time-dependent changes in plasma glucose levels (A,C) after oral administration of full agonists <b>4k</b> and <b>4o</b> or partial agonist TAK875. (B,D) Incremental AUC<sub>0–120</sub> min of plasma glucose levels. Compounds were administered orally 1 h before oral administtation of glucose, and plasma glucose levels were measured at −60, 0, 15, 30, 60, and 120 min. Values are presented as mean ± SD (<i>n</i> = 8). (E) The <i>in vivo</i> effect of <b>4o</b> on the level of plasma-active GLP-1 in C57BL/6J mice. Following the administration of 30 mpk TAK875 or <b>4o</b>, together with the 10 mpk DPP4 inhibitor (KR-62436) at <i>t</i> = 0 min, the levels of serum-active GLP-1 were measured at 30 min. Only the 10 mpk DPP4 inhibitor was treated with the control group. Values are presented as mean ± SD (<i>n</i> = 5). **<i>p</i> ≤ 0.01 compared with the control by Students’ <i>t</i>-test. Assays were performed by NECMD (National Efficacy Evaluation Center for Metabolic Disease Therapeutics, <a href="http://necmd.co.kr" class="extLink">http://necmd.co.kr</a>), South Korea.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00031/20210331/images/large/jm1c00031_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00031&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danaei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finucane, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzadfar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khang, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzati, M.</span></span> <span> </span><span class="NLM_article-title">National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(11)60679-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2FS0140-6736%2811%2960679-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21705069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlyltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=31-40&author=G.+Danaeiauthor=M.+M.+Finucaneauthor=Y.+Luauthor=G.+M.+Singhauthor=M.+J.+Cowanauthor=C.+J.+Paciorekauthor=J.+K.+Linauthor=F.+Farzadfarauthor=Y.-H.+Khangauthor=G.+A.+Stevensauthor=M.+Raoauthor=M.+K.+Aliauthor=L.+M.+Rileyauthor=C.+A.+Robinsonauthor=M.+Ezzati&title=National%2C+regional%2C+and+global+trends+in+fasting+plasma+glucose+and+diabetes+prevalence+since+1980%3A+systematic+analysis+of+health+examination+surveys+and+epidemiological+studies+with+370+country-years+and+2%C2%B77+million+participants&doi=10.1016%2Fs0140-6736%2811%2960679-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants</span></div><div class="casAuthors">Danaei, Goodarz; Finucane, Mariel M.; Lu, Yuan; Singh, Gitanjali M.; Cowan, Melanie J.; Paciorek, Christopher J.; Lin, John K.; Farzadfar, Farshad; Khang, Young-Ho; Stevens, Gretchen A.; Rao, Mayuree; Ali, Mohammed K.; Riley, Leanne M.; Robinson, Carolyn A.; Ezzati, Majid; Danaei, Goodarz; Finucane, Mariel M.; Lu, Yuan; Singh, Gitanjali M.; Cowan, Melanie J.; Paciorek, Christopher J.; Lin, John K.; Farzadfar, Farshad; Khang, Young-Ho; Stevens, Gretchen A.; Rao, Mayuree; Ali, Mohammad K.; Riley, Leanne M.; Robinson, Carolyn A.; Ezzati, Majid; Abdeen, Ziad; Aekplakorn, Wichai; Afifi, Mustafa M.; Agabiti-Rosei, Enrico; Salinas, Carlos A. Aguilar; Alnsour, Mohannad; Ambady, Ramachandran; Barbagallo, Carlo M.; Barcelo, Alberto; Barros, Henrique; Bautista, Leonelo E.; Benetos, Athanase; Bjerregaad, Peter; Bo, Simona; Bovert, Pascal; Burszytn, Michael; Cabrera de Leon, Antonio; Castellano, Maurizio; Castetbon, Katia; Chaouki, Noureddine; Chen, Chien-Jen; Chua, Lily; Cifkova, Renata; Corsi, Anna Maria; Delgado, Elias; Doi, Yasufumi; Esteghamati, Alireza; Fall, Caroline H. D.; Fan, Jian-Gao; Ferreccio, Catterina; Fezeu, Leopold; Fuller, Eva L.; Giampaoli, Simona; Gomez, Luis F.; Carvajal, Ramiro Guerrero; Herman, Willaim H.; Herrera, Victor M.; Ho, Suzanne; Hussain, Akhtar; Ikeda, Nayu; Jafar, Tazeen H.; Jonas, Jost B.; Kadiki, Othman A.; Karalis, Ioannis; Katz, Joanne; Khalilzadeh, Omid; Kiechl, Stefan; Kurjata, Pawel; Lee, Jeannette; Lee, Jeannette; Lim, Stephen; Lim, T. O.; Lin, Cheng-Chieh; Lin, Xu; Lin, Hsien-Ho; Liu, Xiaoqing; Lorbeer, Roberto; Ma, Stefan; Maggi, Stefania; Magliano, Dianna J.; McFarlane-Anderson, Norma; Miettola, Juhani; Miranda, J. Jaime; Mohamed, Mostafa K.; Mohan, V.; Mokdad, Ali; Morales, Dante D.; Nabipour, Iraj; Nakagami, Tomoko; Nangia, Vinay; Neuhauser, Hannelore; Noale, Marianna; Onat, Altan; Orostegui, Myriam; panagiotakos, Demosthenes B.; Passos, Valeria M. A.; Perez, Cynthia; Pichardo, Rafael; Phua, Hwee Pin; Plans, Pedro; Qiao, Qing; Ramos, Luiz R.; Rampal, Sanjay; Rampal, Lekhraj; Redon, Josep; Revilla, Luis; Rosero-Bixby, Luis; Sanisoglu, Selim Y.; Scazufca, Marcia; Schaan, Beatriz D.; Sekuri, Cevad; Shera, Abdul S.; Shi, Zumin; Silva, Egle; Simons, Leon A.; Soederberg, Stefan; Solfrizzi, Vincenzo; Soysal, Ahmet; Stein, Aryeh D.; Stessman, Jochanan; Vanderpump, Mark P.; Viet, Lucie; Vollenweider, Peter; Wang, Ningli; Wang, Ya X.; Waspadji, Sarwono; Willeit, Johann; Woodward, Mark; Xu, Laing; Yang, Xiaoguang; Yoon, Jin-Sang; Yu, Zhijie; Zhang, Jian; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9785</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Data for trends in glycemia and diabetes prevalence are needed to understand the effects of diet and lifestyle within populations, assess the performance of interventions, and plan health services.  No consistent and comparable global anal. of trends has been done.  We estd. trends and their uncertainties in mean fasting plasma glucose (FPG) and diabetes prevalence for adults aged 25 years and older in 199 countries and territories.  We obtained data from health examn. surveys and epidemiol. studies (370 country-years and 2.7 million participants).  We converted systematically between different glycemic metrics.  For each sex, we used a Bayesian hierarchical model to est. mean FPG and its uncertainty by age, country, and year, accounting for whether a study was nationally, subnationally, or community representative.  In 2008, global age-standardized mean FPG was 5.50 mmol/L (95% uncertainty interval 5.37-5.63) for men and 5.42 mmol/L (5.29-5.54) for women, having risen by 0.07 mmol/L and 0.09 mmol/L per decade, resp.  Age-standardized adult diabetes prevalence was 9.8% (8.6-11.2) in men and 9.2% (8.0-10.5) in women in 2008, up from 8.3% (6.5-10.4) and 7.5% (5.8-9.6) in 1980.  The no. of people with diabetes increased from 153 (127-182) million in 1980, to 347 (314-382) million in 2008.  We recorded almost no change in mean FPG in east and southeast Asia and central and eastern Europe.  Oceania had the largest rise, and the highest mean FPG (6.09 mmol/L, 5.73-6.49 for men; 6.08 mmol/L, 5.72-6.46 for women) and diabetes prevalence (15.5%, 11.6-20.1 for men; and 15.9%, 12.1-20.5 for women) in 2008.  Mean FPG and diabetes prevalence in 2008 were also high in south Asia, Latin America and the Caribbean, and central Asia, north Africa, and the Middle East.  Mean FPG in 2008 was lowest in sub-Saharan Africa, east and southeast Asia, and high-income Asia-Pacific.  In high-income subregions, western Europe had the smallest rise, 0.07 mmol/L per decade for men and 0.03 mmol/L per decade for women; North America had the largest rise, 0.18 mmol/L per decade for men and 0.14 mmol/L per decade for women.  Glycemia and diabetes are rising globally, driven both by population growth and ageing and by increasing age-specific prevalences.  Effective preventive interventions are needed, and health systems should prep. to detect and manage diabetes and its sequelae.  Funding: Bill & Melinda Gates Foundation and WHO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Jw1i50e7MbVg90H21EOLACvtfcHk0lhQZu6NppAJug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlyltbo%253D&md5=ba23963b4ccdf9d19804194ac9dad09f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960679-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960679-X%26sid%3Dliteratum%253Aachs%26aulast%3DDanaei%26aufirst%3DG.%26aulast%3DFinucane%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DG.%2BM.%26aulast%3DCowan%26aufirst%3DM.%2BJ.%26aulast%3DPaciorek%26aufirst%3DC.%2BJ.%26aulast%3DLin%26aufirst%3DJ.%2BK.%26aulast%3DFarzadfar%26aufirst%3DF.%26aulast%3DKhang%26aufirst%3DY.-H.%26aulast%3DStevens%26aufirst%3DG.%2BA.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DM.%2BK.%26aulast%3DRiley%26aufirst%3DL.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BA.%26aulast%3DEzzati%26aufirst%3DM.%26atitle%3DNational%252C%2520regional%252C%2520and%2520global%2520trends%2520in%2520fasting%2520plasma%2520glucose%2520and%2520diabetes%2520prevalence%2520since%25201980%253A%2520systematic%2520analysis%2520of%2520health%2520examination%2520surveys%2520and%2520epidemiological%2520studies%2520with%2520370%2520country-years%2520and%25202%25C2%25B77%2520million%2520participants%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D31%26epage%3D40%26doi%3D10.1016%2Fs0140-6736%2811%2960679-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span> <span> </span><span class="NLM_article-title">Free Fatty Acid Receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1002/med.21441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1002%2Fmed.21441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28328012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=381-425&author=Z.+Liauthor=X.+Xuauthor=W.+Huangauthor=H.+Qian&title=Free+Fatty+Acid+Receptor+1+%28FFAR1%29+as+an+emerging+therapeutic+target+for+type+2+diabetes+mellitus%3A+recent+progress+and+prevailing+challenges&doi=10.1002%2Fmed.21441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges</span></div><div class="casAuthors">Li, Zheng; Xu, Xue; Huang, Wenlong; Qian, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">381-425</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFAR1/GPR40) amplifies glucose-dependent insulin secretion; therefore, it has attracted widespread attention as a promising antidiabetic target.  Current clin. proof of concept also indicates that FFAR1 agonists achieve the initially therapeutic endpoint for the treatment of type 2 diabetes mellitus (T2DM) without the hypoglycemic risk.  Thus, many pharmaceutical companies and academic institutes are competing to develop FFAR1 agonists.  However, several candidates have been discontinued in clin. trials, often without reporting the underlying reasons.  Herein, we review the challenges and corresponding strategies chosen by different medicinal chem. teams to improve the physicochem. properties, potency, pharmacokinetics, and safety profiles of FFAR1 agonists, with a brief introduction to the biol. and pharmacol. of related targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0HQt6yW9YZbVg90H21EOLACvtfcHk0lhTyIfdrFklYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ntrY%253D&md5=5cf3e724e97cb0ae2e6741ee5d85663a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fmed.21441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21441%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DH.%26atitle%3DFree%2520Fatty%2520Acid%2520Receptor%25201%2520%2528FFAR1%2529%2520as%2520an%2520emerging%2520therapeutic%2520target%2520for%2520type%25202%2520diabetes%2520mellitus%253A%2520recent%2520progress%2520and%2520prevailing%2520challenges%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D381%26epage%3D425%26doi%3D10.1002%2Fmed.21441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olokoba, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obateru, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olokoba, L. B.</span></span> <span> </span><span class="NLM_article-title">Type 2 diabetes mellitus: a review of current trends</span>. <i>Oman Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.5001/omj.2012.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.5001%2Fomj.2012.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23071876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=269-273&author=A.+B.+Olokobaauthor=O.+A.+Obateruauthor=L.+B.+Olokoba&title=Type+2+diabetes+mellitus%3A+a+review+of+current+trends&doi=10.5001%2Fomj.2012.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 diabetes mellitus: a review of current trends</span></div><div class="casAuthors">Olokoba, Abdulfatai B.; Obateru, Olusegun A.; Olokoba, Lateefat B.</div><div class="citationInfo"><span class="NLM_cas:title">Oman Medical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">OMJMAF</span>;
        ISSN:<span class="NLM_cas:issn">1999-768X</span>.
    
            (<span class="NLM_cas:orgname">Oman Medical Specialty Board</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (DM) is a chronic metabolic disorder in which prevalence has been increasing steadily all over the world.  As a result of this trend, it is fast becoming an epidemic in some countries of the world with the no. of people affected expected to double in the next decade due to increase in ageing population, thereby adding to the already existing burden for healthcare providers, esp. in poorly developed countries.  This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications.  Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment.  Only articles in English were included.  Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Assocn. (ADA) criteria which include both clin. and lab. parameters.  No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers like metformin, a biguanide that reduces insulin resistance, is still the recommended first line medication esp. for obese patients.  Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin.  Recent research into the pathophysiol. of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11β-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine.  Inhaled insulin was licensed for use in 2006 but has been withdrawn from the market because of low patronage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FqowDHbsTLVg90H21EOLACvtfcHk0lhTyIfdrFklYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsLzE&md5=3696f50d1424f787219201349414c833</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.5001%2Fomj.2012.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5001%252Fomj.2012.68%26sid%3Dliteratum%253Aachs%26aulast%3DOlokoba%26aufirst%3DA.%2BB.%26aulast%3DObateru%26aufirst%3DO.%2BA.%26aulast%3DOlokoba%26aufirst%3DL.%2BB.%26atitle%3DType%25202%2520diabetes%2520mellitus%253A%2520a%2520review%2520of%2520current%2520trends%26jtitle%3DOman%2520Med.%2520J.%26date%3D2012%26volume%3D27%26spage%3D269%26epage%3D273%26doi%3D10.5001%2Fomj.2012.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burant, C. F.</span></span> <span> </span><span class="NLM_article-title">Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">S175</span>– <span class="NLM_lpage">S179</span>, <span class="refDoi"> DOI: 10.2337/dcs13-2037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.2337%2FdcS13-2037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23882043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ksrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=S175-S179&author=C.+F.+Burant&title=Activation+of+GPR40+as+a+therapeutic+target+for+the+treatment+of+type+2+diabetes&doi=10.2337%2Fdcs13-2037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes</span></div><div class="casAuthors">Burant, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S175-S179</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review.  The stimulation of insulin secretion by glucose can be modulated by multiple nutritive, hormonal, and pharmacol. inputs.  Fatty acids potentiate insulin secretion through the generation of intracellular signaling mols. and through the activation of cell surface receptors.  The G-protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (we will use GPR40 in this review), has emerged as an important component in the fatty acid augmentation of insulin secretion.  By signaling predominantly through Gαq/11, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion.  Synthetic small-mol. agonists of GPR40 enhance insulin secretion in a glucose-dependent manner in vitro and in vivo with a mechanism similar to that found with fatty acids.  GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.  Recent phase I and phase II clin. trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis.  These data suggest that targeting the GPR40 receptor can be a viable therapeutic option for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Q7a81IRLMLVg90H21EOLACvtfcHk0lhTyIfdrFklYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ksrrJ&md5=c93db4fe37969f285dcde2896b8facef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2337%2FdcS13-2037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252FdcS13-2037%26sid%3Dliteratum%253Aachs%26aulast%3DBurant%26aufirst%3DC.%2BF.%26atitle%3DActivation%2520of%2520GPR40%2520as%2520a%2520therapeutic%2520target%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3DS175%26epage%3DS179%26doi%3D10.2337%2Fdcs13-2037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Defossa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2991</span>– <span class="NLM_lpage">3000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bmcl.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=24881568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslKnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2991-3000&author=E.+Defossaauthor=M.+Wagner&title=Recent+developments+in+the+discovery+of+FFA1+receptor+agonists+as+novel+oral+treatment+for+type+2+diabetes+mellitus&doi=10.1016%2Fj.bmcl.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus</span></div><div class="casAuthors">Defossa, Elisabeth; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2991-3000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Despite the availability of established medication for treatment of type 2 diabetes mellitus (T2DM) there still remains a significant unmet need for new effective, oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile.  In this regard the FFA1 receptor has emerged as an attractive target in recent years.  Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells.  The current review highlights on the latest developments and clin. data from evolving research on the potential of FFA1 agonists as effective treatment for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozko1kPZFdu7Vg90H21EOLACvtfcHk0lhTyIfdrFklYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslKnsL8%253D&md5=d7b5d1e01b15d3434bcd8efa3173c4c2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DDefossa%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DM.%26atitle%3DRecent%2520developments%2520in%2520the%2520discovery%2520of%2520FFA1%2520receptor%2520agonists%2520as%2520novel%2520oral%2520treatment%2520for%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2991%26epage%3D3000%26doi%3D10.1016%2Fj.bmcl.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukusumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+fatty+acids+regulate+insulin+secretion+from+pancreatic+%CE%B2+cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic β cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0lgLqbqOXlmGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520fatty%2520acids%2520regulate%2520insulin%2520secretion%2520from%2520pancreatic%2520%25CE%25B2%2520cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briscoe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilert, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshourbagy, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinage, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekeres, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignar, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, A. I.</span></span> <span> </span><span class="NLM_article-title">The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">11303</span>– <span class="NLM_lpage">11311</span>, <span class="refDoi"> DOI: 10.1074/jbc.m211495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1074%2Fjbc.M211495200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=12496284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1KgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=11303-11311&author=C.+P.+Briscoeauthor=M.+Tadayyonauthor=J.+L.+Andrewsauthor=W.+G.+Bensonauthor=J.+K.+Chambersauthor=M.+M.+Eilertauthor=C.+Ellisauthor=N.+A.+Elshourbagyauthor=A.+S.+Goetzauthor=D.+T.+Minnickauthor=P.+R.+Murdockauthor=H.+R.+Saulsauthor=U.+Shabonauthor=L.+D.+Spinageauthor=J.+C.+Strumauthor=P.+G.+Szekeresauthor=K.+B.+Tanauthor=J.+M.+Wayauthor=D.+M.+Ignarauthor=S.+Wilsonauthor=A.+I.+Muir&title=The+orphan+G+protein-coupled+receptor+GPR40+is+activated+by+medium+and+long+chain+fatty+acids&doi=10.1074%2Fjbc.m211495200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids</span></div><div class="casAuthors">Briscoe, Celia P.; Tadayyon, Mohammad; Andrews, John L.; Benson, William G.; Chambers, Jon K.; Eilert, Michelle M.; Ellis, Catherine; Elshourbagy, Nabil A.; Goetz, Aaron S.; Minnick, Dana T.; Murdock, Paul R.; Sauls, Howard R., Jr.; Shabon, Usman; Spinage, Lisa D.; Strum, Jay C.; Szekeres, Philip G.; Tan, Kong B.; Way, James M.; Ignar, Diane M.; Wilson, Shelagh; Muir, Alison I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">11303-11311</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GPR40 is a member of a subfamily of homologous G protein-coupled receptors that include GPR41 and GPR43 and that have no current function or ligand ascribed.  Ligand fishing expts. in HEK293 cells expressing human GPR40 revealed that a range of satd. and unsatd. carboxylic acids with carbon chain lengths greater than six were able to induce an elevation of [Ca2+]i, measured using a fluorometric imaging plate reader. 5,8,11-Eicosatriynoic acid was the most potent fatty acid tested, with a pEC50 of 5.7.  G protein coupling of GPR40 was examd. in Chinese hamster ovary cells expressing the Gαq/i-responsive Gal4-Elk1 reporter system.  Expression of human GPR40 led to a constitutive induction of luciferase activity, which was further increased by exposure of the cells to eicosatriynoic acid.  Neither the constitutive nor ligand-mediated luciferase induction was inhibited by pertussis toxin treatment, suggesting that GPR40 was coupled to Gαq/11.  Expression anal. by quant. reverse transcription-PCR showed that GPR40 was specifically expressed in brain and pancreas, with expression in rodent pancreas being localized to insulin-producing β-cells.  These data suggest that some of the physiol. effects of fatty acids in pancreatic islets and brain may be mediated through a cell-surface receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXzfE9PNW7-LVg90H21EOLACvtfcHk0lgLqbqOXlmGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1KgsbY%253D&md5=a8c2105e13f07a7487315d7515fdcf56</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211495200%26sid%3Dliteratum%253Aachs%26aulast%3DBriscoe%26aufirst%3DC.%2BP.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%2BL.%26aulast%3DBenson%26aufirst%3DW.%2BG.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DEilert%26aufirst%3DM.%2BM.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMinnick%26aufirst%3DD.%2BT.%26aulast%3DMurdock%26aufirst%3DP.%2BR.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DShabon%26aufirst%3DU.%26aulast%3DSpinage%26aufirst%3DL.%2BD.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DSzekeres%26aufirst%3DP.%2BG.%26aulast%3DTan%26aufirst%3DK.%2BB.%26aulast%3DWay%26aufirst%3DJ.%2BM.%26aulast%3DIgnar%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26atitle%3DThe%2520orphan%2520G%2520protein-coupled%2520receptor%2520GPR40%2520is%2520activated%2520by%2520medium%2520and%2520long%2520chain%2520fatty%2520acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D11303%26epage%3D11311%26doi%3D10.1074%2Fjbc.m211495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendoloski, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3762</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1021/jp980230o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp980230o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=3762-3772&author=A.+K.+Ghoseauthor=V.+N.+Viswanadhanauthor=J.+J.+Wendoloski&title=Prediction+of+hydrophobic+%28lipophilic%29+properties+of+small+organic+molecules+using+fragmental+methods%3A+an+analysis+of+ALOGP+and+CLOGP+methods&doi=10.1021%2Fjp980230o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods</span></div><div class="casAuthors">Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3762-3772</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. hydrophobicity (lipophilicity), usually quantified as log P (the logarithm of 1-octanol/water partition coeff.), is an important mol. characteristic in drug discovery.  ALOGP and CLOGP are two of the most widely used methods for the estn. of log P.  This work describes an extensive reparametrization of the at. log P values and a detailed comparison of the performance of ALOGP and CLOGP methods on the Pomona Medchem database.  Only the "star list" compds. having precisely measured log P values were used in this anal.  While the overall results with both methods are similar, anal. shows that the CLOGP method is better for very small mols. in the range of 1-20 atoms.  The two methods are almost comparable in the range of 21-45 atoms, while the ALOGP method has better accuracy for mols. with more than 45 atoms.  Although the rms deviation and the correlation coeff. for CLOGP predictions were marginally better than those for corresponding ALOGP predictions, the latter showed a very stable performance for all classes of org. compds. analyzed.  Importantly, the ALOGP method can be used to compute ests. for all mols. in the database, whereas the CLOGP method fails to offer ests. for a substantial part of the database.  Finally, unlike CLOGP and other methods of predicting lipophilicity, the ALOGP method has multiple uses, such as the estn. of local hydrophobicity, the visualization of mol. hydrophobicity maps, and the evaluation of hydrophobic interactions in protein-ligand complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXdn8wsqV3frVg90H21EOLACvtfcHk0liSWlcSedhPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12rsrY%253D&md5=ef58841437913e164dc2d6e73eb5c87d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjp980230o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp980230o%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DWendoloski%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520hydrophobic%2520%2528lipophilic%2529%2520properties%2520of%2520small%2520organic%2520molecules%2520using%2520fragmental%2520methods%253A%2520an%2520analysis%2520of%2520ALOGP%2520and%2520CLOGP%2520methods%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1998%26volume%3D102%26spage%3D3762%26epage%3D3772%26doi%3D10.1021%2Fjp980230o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yada, T.</span></span> <span> </span><span class="NLM_article-title">Oleic acid interacts with GPR40 to induce Ca<sup>2+</sup> signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release</span>. <i>Am. J. Physiol.: Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">E670</span>– <span class="NLM_lpage">E677</span>, <span class="refDoi"> DOI: 10.1152/ajpendo.00035.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1152%2Fajpendo.00035.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=15914509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFens7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2005&pages=E670-E677&author=K.+Fujiwaraauthor=F.+Maekawaauthor=T.+Yada&title=Oleic+acid+interacts+with+GPR40+to+induce+Ca2%2B+signaling+in+rat+islet+beta-cells%3A+mediation+by+PLC+and+L-type+Ca2%2B+channel+and+link+to+insulin+release&doi=10.1152%2Fajpendo.00035.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet β-cells: Mediation by PLC and L-type Ca2+ channel and link to insulin release</span></div><div class="casAuthors">Fujiwara, Ken; Maekawa, Fumihiko; Yada, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">4, Pt. 1</span>),
    <span class="NLM_cas:pages">E670-E677</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">It has long been thought that long-chain free fatty acids (FFAs) stimulate insulin secretion via mechanisms involving their metab. in pancreatic β-cells.  Recently, it was reported that FFAs function as endogenous ligands for GPR40, a G protein-coupled receptor, to amplify glucose-stimulated insulin secretion in an insulinoma cell line and rat islets.  However, signal transduction mechanisms for GPR40 in β-cells are little known.  The present study was aimed at elucidating GPR40-linked Ca2+ signaling mechanisms in rat pancreatic β-cells.  The authors employed oleic acid (OA), an FFA that has a high affinity for the rat GPR40, and examd. its effect on cytosolic Ca2+ concn. ([Ca2+]i) in single β-cells by fura 2 fluorescence imaging.  OA at 1-10 μM concn.-dependently increased [Ca2+]i in the presence of 5.6, 8.3, and 11.2 mM, but not 2.8 mM, glucose.  OA-induced [Ca2+]i increases at 11.2 mM glucose were inhibited in β-cells transfected with small interfering RNA targeted to rat GPR40 mRNA.  OA-induced [Ca2+]i increases were also inhibited by phospholipase C (PLC) inhibitors, U73122 and neomycin, Ca2+-free conditions, and an L-type Ca2+ channel blocker, nitrendipine.  Furthermore, OA increased insulin release from isolated islets at 8.3 mM glucose, and it was markedly attenuated by PLC and L-type Ca2+ channel inhibitors.  These results demonstrate that OA interacts with GPR40 to increase [Ca2+]i via PLC- and L-type Ca2+ channel-mediated pathway in rat islet β-cells, which may be link to insulin release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp05YzJpu8oXrVg90H21EOLACvtfcHk0liSWlcSedhPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFens7fF&md5=735907743264c8a62a74a35ab7a9d9af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1152%2Fajpendo.00035.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpendo.00035.2005%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DF.%26aulast%3DYada%26aufirst%3DT.%26atitle%3DOleic%2520acid%2520interacts%2520with%2520GPR40%2520to%2520induce%2520Ca2%252B%2520signaling%2520in%2520rat%2520islet%2520beta-cells%253A%2520mediation%2520by%2520PLC%2520and%2520L-type%2520Ca2%252B%2520channel%2520and%2520link%2520to%2520insulin%2520release%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Endocrinol.%2520Metab.%26date%3D2005%26volume%3D289%26spage%3DE670%26epage%3DE677%26doi%3D10.1152%2Fajpendo.00035.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span> <span> </span><span class="NLM_article-title">TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.183772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fjpet.111.183772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21752941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=228-237&author=Y.+Tsujihataauthor=R.+Itoauthor=M.+Suzukiauthor=A.+Haradaauthor=N.+Negoroauthor=T.+Yasumaauthor=Y.+Momoseauthor=K.+Takeuchi&title=TAK-875%2C+an+orally+available+G+protein-coupled+receptor+40%2Ffree+fatty+acid+receptor+1+agonist%2C+enhances+glucose-dependent+insulin+secretion+and+improves+both+postprandial+and+fasting+hyperglycemia+in+type+2+diabetic+rats&doi=10.1124%2Fjpet.111.183772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats</span></div><div class="casAuthors">Tsujihata, Yoshiyuki; Ito, Ryo; Suzuki, Masami; Harada, Ayako; Negoro, Nobuyuki; Yasuma, Tsuneo; Momose, Yu; Takeuchi, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-237</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA1) is highly expressed in pancreatic β cells and mediates free fatty acid-induced insulin secretion.  This study examd. the pharmacol. effects and potential for avoidance of lipotoxicity of [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate) (TAK-875), a novel, orally available, selective GPR40 agonist.  Insulinoma cell lines and primary rat islets were used to assess the effects of TAK-875 in vitro.  The in vivo effects of TAK-875 on postprandial hyperglycemia, fasting hyperglycemia, and normoglycemia were examd. in type 2 diabetic and normal rats.  In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concn., consistent with activation of the Gqα signaling pathway.  The insulinotropic action of TAK-875 (10 μM) in INS-1 833/15 and primary rat islets was glucose-dependent.  Prolonged exposure of cytokine-sensitive INS-1 832/13 to TAK-875 for 72 h at pharmacol. active concns. did not alter glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas prolonged exposure to palmitic or oleic acid impaired β cell function and survival.  In an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats, TAK-875 (1-10 mg/kg p.o.) showed a clear improvement in glucose tolerance and augmented insulin secretion.  In addn., TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg.  TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlHyHXk_pVjbVg90H21EOLACvtfcHk0liSWlcSedhPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFehtbbL&md5=2c7f2d472a9608d41b60f05c3fffd509</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.183772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.183772%26sid%3Dliteratum%253Aachs%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26atitle%3DTAK-875%252C%2520an%2520orally%2520available%2520G%2520protein-coupled%2520receptor%252040%252Ffree%2520fatty%2520acid%2520receptor%25201%2520agonist%252C%2520enhances%2520glucose-dependent%2520insulin%2520secretion%2520and%2520improves%2520both%2520postprandial%2520and%2520fasting%2520hyperglycemia%2520in%2520type%25202%2520diabetic%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D228%26epage%3D237%26doi%3D10.1124%2Fjpet.111.183772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfleiderer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristiansen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1021/ml100106c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100106c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=345-349&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=N.+Mertenauthor=M.+Pfleidererauthor=K.+K.+Karlsenauthor=S.+S.+Rasmussenauthor=M.+Steensgaardauthor=A.+Hamacherauthor=J.+Schmidtauthor=C.+Drewkeauthor=R.+K.+Petersenauthor=K.+Kristiansenauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Structure%E2%80%93Activity+Study+of+Dihydrocinnamic+Acids+and+Discovery+of+the+Potent+FFA1+%28GPR40%29+Agonist+TUG-469&doi=10.1021%2Fml100106c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span></div><div class="casAuthors">Christiansen, Elisabeth; Due-Hansen, Maria E.; Urban, Christian; Merten, Nicole; Pfleiderer, Michael; Karlsen, Kasper K.; Rasmussen, Sanne S.; Steensgaard, Mette; Hamacher, Alexandra; Schmidt, Johannes; Drewke, Christel; Petersen, Rasmus Koefoed; Kristiansen, Karsten; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic β-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes.  Several FFA1 agonists contg. the para-substituted dihydrocinnamic acid moiety are known.  We here present a structure-activity relationship study of this compd. family suggesting that the central methyleneoxy linker is preferable for the smaller compds., whereas the central methyleneamine linker gives higher potency to the larger compds.  The study resulted in the discovery of the potent and selective full FFA1 agonist TUG-469 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Ue5bdjcoY7Vg90H21EOLACvtfcHk0ljODbB374o2Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D&md5=e3a7642f2fd42b1bc932fa9470cfb75c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml100106c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100106c%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DPfleiderer%26aufirst%3DM.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DRasmussen%26aufirst%3DS.%2BS.%26aulast%3DSteensgaard%26aufirst%3DM.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DR.%2BK.%26aulast%3DKristiansen%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DStructure%25E2%2580%2593Activity%2520Study%2520of%2520Dihydrocinnamic%2520Acids%2520and%2520Discovery%2520of%2520the%2520Potent%2520FFA1%2520%2528GPR40%2529%2520Agonist%2520TUG-469%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D345%26epage%3D349%26doi%3D10.1021%2Fml100106c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span> <span> </span><span class="NLM_article-title">AMG 837: a potent, orally bioavailable GPR40 agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1267</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bmcl.2011.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22217876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1267-1270&author=J.+B.+Houzeauthor=L.+Zhuauthor=Y.+Sunauthor=M.+Akermanauthor=W.+Qiuauthor=A.+J.+Zhangauthor=R.+Sharmaauthor=M.+Schmittauthor=Y.+Wangauthor=J.+Liuauthor=J.+Liuauthor=J.+C.+Medinaauthor=J.+D.+Reaganauthor=J.+Luoauthor=G.+Tonnauthor=J.+Zhangauthor=J.+Y.-L.+Luauthor=M.+Chenauthor=E.+Lopezauthor=K.+Nguyenauthor=L.+Yangauthor=L.+Tangauthor=H.+Tianauthor=S.+J.+Shuttleworthauthor=D.+C.-H.+Lin&title=AMG+837%3A+a+potent%2C+orally+bioavailable+GPR40+agonist&doi=10.1016%2Fj.bmcl.2011.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 837: A potent, orally bioavailable GPR40 agonist</span></div><div class="casAuthors">Houze, Jonathan B.; Zhu, Liusheng; Sun, Ying; Akerman, Michelle; Qiu, Wei; Zhang, Alex J.; Sharma, Rajiv; Schmitt, Michael; Wang, Yingcai; Liu, Jiwen; Liu, Jinqian; Medina, Julio C.; Reagan, Jeff D.; Luo, Jian; Tonn, George; Zhang, Jane; Lu, Jenny Ying-Lin; Chen, Michael; Lopez, Edwin; Nguyen, Kathy; Yang, Li; Tang, Liang; Tian, Hui; Shuttleworth, Steven J.; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1267-1270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents.  Optimization of a series of β-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJp4-u_YDyLVg90H21EOLACvtfcHk0ljODbB374o2Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D&md5=7e7d38679794abb7244d5a64d6f5ecd7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAkerman%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.-L.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26atitle%3DAMG%2520837%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520GPR40%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1267%26epage%3D1270%26doi%3D10.1016%2Fj.bmcl.2011.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargent, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaibi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawthorne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1021/ml4000673</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000673" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=441-445&author=E.+Christiansenauthor=S.+V.+F.+Hansenauthor=C.+Urbanauthor=B.+D.+Hudsonauthor=E.+T.+Wargentauthor=M.+Grundmannauthor=L.+Jenkinsauthor=M.+Zaibiauthor=C.+J.+Stockerauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=G.+Milliganauthor=M.+A.+Cawthorneauthor=T.+Ulven&title=Discovery+of+TUG-770%3A+a+highly+potent+free+fatty+acid+receptor+1+%28FFA1%2FGPR40%29+agonist+for+treatment+of+type+2+diabetes&doi=10.1021%2Fml4000673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Christiansen, Elisabeth; Hansen, Steffen V. F.; Urban, Christian; Hudson, Brian D.; Wargent, Edward T.; Grundmann, Manuel; Jenkins, Laura; Zaibi, Mohamed; Stocker, Claire J.; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Milligan, Graeme; Cawthorne, Michael A.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-445</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes.  We here report the discovery of a highly potent FFA1 agonist (I) with favorable physicochem. and pharmacokinetic properties.  The compd. efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoli6_yVTMDErVg90H21EOLACvtfcHk0lj7iSmNuhnX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsLw%253D&md5=0c01356f7776e02cc1ce3ff6fce560c0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml4000673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000673%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DHansen%26aufirst%3DS.%2BV.%2BF.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DWargent%26aufirst%3DE.%2BT.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DJenkins%26aufirst%3DL.%26aulast%3DZaibi%26aufirst%3DM.%26aulast%3DStocker%26aufirst%3DC.%2BJ.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TUG-770%253A%2520a%2520highly%2520potent%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA1%252FGPR40%2529%2520agonist%2520for%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D441%26epage%3D445%26doi%3D10.1021%2Fml4000673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krug, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Railkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ederveen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krefetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNoia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatosian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothare, P.</span></span> <span> </span><span class="NLM_article-title">Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1111/cts.12479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1111%2Fcts.12479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28727908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWjt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=404-411&author=A.+Krugauthor=P.+Vaddadyauthor=R.+Railkarauthor=B.+Musserauthor=J.+Coteauthor=A.+Ederveenauthor=D.+Krefetzauthor=E.+DeNoiaauthor=A.+Freeauthor=L.+Morrowauthor=M.+Chakravarthyauthor=E.+Kauhauthor=D.+Tatosianauthor=P.+Kothare&title=Leveraging+a+clinical+phase+Ib+proof-of-concept+study+for+the+GPR40+agonist+MK-8666+in+patients+with+type+2+diabetes+for+model-informed+phase+II+dose+selection&doi=10.1111%2Fcts.12479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection</span></div><div class="casAuthors">Krug, A. W.; Vaddady, P.; Railkar, R. A.; Musser, B. J.; Cote, J.; Ederveen, A. G. H.; Krefetz, D. G.; De Noia, E.; Free, A. L.; Morrow, L.; Chakravarthy, M. V.; Kauh, E.; Tatosian, D. A.; Kothare, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-411</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPR40 mediates free fatty acid-induced insulin secretion in beta cells.  We investigated the safety, pharmacokinetics, and glucose response of MK-8666, a partial GPR40 agonist, after once-daily multiple dosing in type 2 diabetes patients.  This double-blind, multisite, parallel-group study randomized 63 patients (placebo, n = 18; 50 mg, n = 9; 150 mg, n = 18; 500 mg, n = 18) for 14-day treatment.  The results showed no serious adverse effects or treatment-related hypoglycemia.  One patient (150-mg group) showed mild-to-moderate transaminitis at the end of dosing.  Median MK-8666 Tmax was 2.0-2.5 h and mean apparent terminal half-life was 22-32 h.  On Day 15, MK-8666 reduced fasting plasma glucose by 54.1 mg/dL (500 mg), 36.0 mg/dL (150 mg), and 30.8 mg/dL (50 mg) more than placebo, consistent with translational pharmacokinetic/pharmacodynamic model predictions.  Maximal efficacy for longer-term assessment is projected at 500 mg based on exposure-response anal.  In conclusion, MK-8666 was generally well tolerated with robust glucose-lowering efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaGJpYIHFoNbVg90H21EOLACvtfcHk0lj7iSmNuhnX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWjt73P&md5=3aab859622dda7019868e9cbbd54dafd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fcts.12479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12479%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DA.%26aulast%3DVaddady%26aufirst%3DP.%26aulast%3DRailkar%26aufirst%3DR.%26aulast%3DMusser%26aufirst%3DB.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DEderveen%26aufirst%3DA.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DDeNoia%26aufirst%3DE.%26aulast%3DFree%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DL.%26aulast%3DChakravarthy%26aufirst%3DM.%26aulast%3DKauh%26aufirst%3DE.%26aulast%3DTatosian%26aufirst%3DD.%26aulast%3DKothare%26aufirst%3DP.%26atitle%3DLeveraging%2520a%2520clinical%2520phase%2520Ib%2520proof-of-concept%2520study%2520for%2520the%2520GPR40%2520agonist%2520MK-8666%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520for%2520model-informed%2520phase%2520II%2520dose%2520selection%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D404%26epage%3D411%26doi%3D10.1111%2Fcts.12479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seok, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-M.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPR40-dependent manner</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2017.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.4062%2Fbiomolther.2017.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1aisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=599-607&author=M.+Kimauthor=G.+J.+Guauthor=Y.-S.+Kohauthor=S.-H.+Leeauthor=Y.+R.+Naauthor=S.+H.+Seokauthor=K.-M.+Lim&title=Fasiglifam+%28TAK-875%29%2C+a+G+protein-coupled+receptor+40+%28GPR40%29+agonist%2C+may+induce+hepatotoxicity+through+reactive+oxygen+species+generation+in+a+GPR40-dependent+manner&doi=10.4062%2Fbiomolther.2017.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPR40-dependent manner</span></div><div class="casAuthors">Kim, MinJeong; Gu, Gyo Jeong; Koh, Yun-Sook; Lee, Su-Hyun; Na, Yi Rang; Seok, Seung Hyeok; Lim, Kyung-Min</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-607</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875) a G-protein coupled receptor 40 (GPR40) agonist, significantly improves hyperglycemia without hypoglycemia and wt. gain, the major side effects of conventional anti-diabetics.  Unfortunately, during multi-center Phase 3 clin. trials, unexpected liver toxicity resulted in premature termination of its development.  Here, we investigated whether TAK-875 directly inflicts toxicity on hepatocytes and explored its underlying mechanism of toxicity.  TAK-875 decreased viability of 2D and 3D cultures of HepG2, a human hepatocarcinoma cell line, in concn.- (>50μM) and time-dependent manners, both of which corresponded with ROS generation.  An antioxidant, N-acetylcysteine, attenuated TAK-875-mediated hepatotoxicity, which confirmed the role of ROS generation.  Of note, knockdown of GPR40 using siRNA abolished the hepatotoxicity of TAK-875 and attenuated ROS generation.  In contrast, TAK-875 induced no cytotoxicity in fibroblasts up to 500μM.  Supporting the hepatotoxic potential of TAK-875, exposure to TAK-875 resulted in increased mortality of zebrafish larvae at 25μM.  Histopathol. examn. of zebrafish exposed to TAK-875 revealed severe hepatotoxicity as manifested by degenerated hypertrophic hepatocytes with cytoplasmic vacuolation and acentric nuclei, confirming that TAK-875 may induce direct hepatotoxicity and that ROS generation may be involved in a GPR40-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZNXB5XjNld7Vg90H21EOLACvtfcHk0lhGpYHbKjRQ9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1aisb%252FI&md5=d248b901a83bf75032d2023ec924787e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2017.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2017.225%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DG.%2BJ.%26aulast%3DKoh%26aufirst%3DY.-S.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DNa%26aufirst%3DY.%2BR.%26aulast%3DSeok%26aufirst%3DS.%2BH.%26aulast%3DLim%26aufirst%3DK.-M.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%252C%2520a%2520G%2520protein-coupled%2520receptor%252040%2520%2528GPR40%2529%2520agonist%252C%2520may%2520induce%2520hepatotoxicity%2520through%2520reactive%2520oxygen%2520species%2520generation%2520in%2520a%2520GPR40-dependent%2520manner%26jtitle%3DBiomol.%2520Ther.%26date%3D2018%26volume%3D26%26spage%3D599%26epage%3D607%26doi%3D10.4062%2Fbiomolther.2017.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.064121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fdmd.115.064121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=26276582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjtlygs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1751-1759&author=X.+Liauthor=K.+Zhongauthor=Z.+Guoauthor=D.+Zhongauthor=X.+Chen&title=Fasiglifam+%28TAK-875%29+Inhibits+Hepatobiliary+Transporters%3A+A+Possible+Factor+Contributing+to+Fasiglifam-Induced+Liver+Injury&doi=10.1124%2Fdmd.115.064121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury</span></div><div class="casAuthors">Li, Xiuli; Zhong, Kan; Guo, Zitao; Zhong, Dafang; Chen, Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875), a selective G-protein-coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus; however, its development was terminated in phase III clin. trials because of liver safety concerns.  Our preliminary study indicated that i.v. administration of 100 mg/kg of TAK-875 increased the serum total bile acid concn. by 3 to 4 times and total bilirubin levels by 1.5 to 2.6 times in rats.  In the present study, we examd. the inhibitory effects of TAK-875 on hepatobiliary transporters to explore the mechanisms underlying its hepatotoxicity.  TAK-875 decreased the biliary excretion index and the in vitro biliary clearance of d8-taurocholic acid in sandwich-cultured rat hepatocytes, suggesting that TAK-875 impaired biliary excretion of bile acids, possibly by inhibiting bile salt export pump (Bsep).  TAK-875 inhibited the efflux transporter multidrug resistance-assocd. protein 2 (Mrp2) in rat hepatocytes using 5 (and 6)-carboxy-2',7'-dichlorofluorescein as a substrate.  Inhibition of MRP2 was further confirmed by reduced transport of vinblastine in Madin-Darby canine kidney cells overexpressing MRP2 with IC50 values of 2.41 μM.  TAK-875 also inhibited the major bile acid uptake transporter Na+/taurocholate cotransporting polypeptide (Ntcp), which transports d8-taurocholic acid into rat hepatocytes, with an IC50 value of 10.9 μM.  TAK-875 significantly inhibited atorvastatin uptake in org. anion transporter protein (OATP) 1B1 and OATP1B3 cells with IC50 values of 2.28 and 3.98 μM, resp.  These results indicate that TAK-875 inhibited the efflux transporter MRP2/Mrp2 and uptake transporters Ntcp and OATP/Oatp, which may affect bile acid and bilirubin homeostasis, resulting in hyperbilirubinemia and cholestatic hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVcU03So6DrVg90H21EOLACvtfcHk0ljSMe6E7Ca4Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjtlygs7k%253D&md5=8e3af83a77d21750d8eabd398d33f4a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.064121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.064121%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%2520Inhibits%2520Hepatobiliary%2520Transporters%253A%2520A%2520Possible%2520Factor%2520Contributing%2520to%2520Fasiglifam-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1751%26epage%3D1759%26doi%3D10.1124%2Fdmd.115.064121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1021/ml300133f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300133f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=726-730&author=S.+P.+Brownauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=X.+Jiaoauthor=L.+Zhuauthor=V.+Pattaropongauthor=Y.+Sunauthor=J.+Liuauthor=J.+Luoauthor=J.+Zhangauthor=S.+Wongauthor=R.+Zhuangauthor=Q.+Guoauthor=F.+Liauthor=J.+C.+Medinaauthor=G.+Swaminathauthor=D.+C.-H.+Linauthor=J.+B.+Houze&title=Discovery+of+AM-1638%3A+a+potent+and+orally+bioavailable+GPR40%2FFFA1+full+agonist&doi=10.1021%2Fml300133f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span></div><div class="casAuthors">Brown, Sean P.; Dransfield, Paul J.; Vimolratana, Marc; Jiao, XianYun; Zhu, Liusheng; Pattaropong, Vatee; Sun, Ying; Liu, Jinqian; Luo, Jian; Zhang, Jane; Wong, Simon; Zhuang, Run; Guo, Qi; Li, Frank; Medina, Julio C.; Swaminath, Gayathri; Lin, Daniel C.-H.; Houze, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-730</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels.  A potent, orally bioavailable small mol. GPR40 agonist is hypothesized to be an effective antidiabetic posing little or no risk of hypoglycemia.  The authors recently reported the discovery of AMG 837 (I), a potent partial agonist of GPR40.  Herein, they present the optimization from the GPR40 partial agonist I to the structurally and pharmacol. distinct GPR40 full agonist AM-1638 (II).  Moreover, they demonstrate the improved in vivo efficacy that GPR40 full agonist II exhibits in BDF/DIO mice as compared to partial agonist I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooInVzD6ZYdrVg90H21EOLACvtfcHk0ljSMe6E7Ca4Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI&md5=d2abd60e8e86d96b0d0683b0401b62c8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml300133f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300133f%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520AM-1638%253A%2520a%2520potent%2520and%2520orally%2520bioavailable%2520GPR40%252FFFA1%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D726%26epage%3D730%26doi%3D10.1021%2Fml300133f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pachanski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatosian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, M. E.</span></span> <span> </span><span class="NLM_article-title">GPR40 partial agonists and AgoPAMs: differentiating effects on glucose and hormonal secretions in the rodent</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0186033</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0186033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1371%2Fjournal.pone.0186033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=29053717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFChs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+J.+Pachanskiauthor=M.+E.+Kirklandauthor=D.+T.+Kosinskiauthor=J.+Maneauthor=B.+Cheewatrakoolpongauthor=J.+Xueauthor=D.+Szetoauthor=G.+Forrestauthor=C.+Millerauthor=M.+Bunzelauthor=C.+W.+Plummerauthor=H.+R.+Chobanianauthor=M.+W.+Millerauthor=S.+Souzaauthor=B.+S.+Thomas-Fowlkesauthor=A.+M.+Ogawaauthor=A.+B.+Weinglassauthor=J.+Di+Salvoauthor=X.+Liauthor=Y.+Fengauthor=D.+A.+Tatosianauthor=A.+D.+Howardauthor=S.+L.+Collettiauthor=M.+E.+Trujillo&title=GPR40+partial+agonists+and+AgoPAMs%3A+differentiating+effects+on+glucose+and+hormonal+secretions+in+the+rodent&doi=10.1371%2Fjournal.pone.0186033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent</span></div><div class="casAuthors">Pachanski, Michele J.; Kirkland, Melissa E.; Kosinski, Daniel T.; Mane, Joel; Cheewatrakoolpong, Boonlert; Xue, Jiyan; Szeto, Daphne; Forrest, Gail; Miller, Corin; Bunzel, Michelle; Plummer, Christopher W.; Chobanian, Harry R.; Miller, Michael W.; Souza, Sarah; Thomas-Fowlkes, Brande S.; Ogawa, Aimie M.; Weinglass, Adam B.; Di Salvo, Jerry; Li, Xiaoyan; Feng, Yue; Tatosian, Daniel A.; Howard, Andrew D.; Colletti, Steven L.; Trujillo, Maria E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0186033/1-e0186033/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion.  However, not all GPR40 agonists are the same.  Partial agonists lower glucose through direct effects on the pancreas, whereas GPR40 AgoPAMs may incorporate addnl. therapeutic effects through increases in insulinotrophic incretins secreted by the gut.  Here we describe how GPR40 AgoPAMs stimulate both insulin and incretin secretion in vivo over time in diabetic GK rats.  We also describe effects of AgoPAMs in vivo to lower glucose and body wt. beyond what is seen with partial GPR40 agonists in both the acute and chronic setting.  Further comparisons of the glucose lowering profile of AgoPAMs suggest these compds. may possess greater glucose control even in the presence of elevated glucagon secretion, an unexpected feature obsd. with both acute and chronic treatment with AgoPAMs.  Together these studies highlight the complexity of GPR40 pharmacol. and the potential addnl. benefits AgoPAMs may possess above partial agonists for the diabetic patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-6HAFfThxWbVg90H21EOLACvtfcHk0lj8NLUtaxUx2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFChs7fK&md5=cbf18dc3a3cb3b810f9075d0c44455c6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0186033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0186033%26sid%3Dliteratum%253Aachs%26aulast%3DPachanski%26aufirst%3DM.%2BJ.%26aulast%3DKirkland%26aufirst%3DM.%2BE.%26aulast%3DKosinski%26aufirst%3DD.%2BT.%26aulast%3DMane%26aufirst%3DJ.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DBunzel%26aufirst%3DM.%26aulast%3DPlummer%26aufirst%3DC.%2BW.%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DSouza%26aufirst%3DS.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DOgawa%26aufirst%3DA.%2BM.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTatosian%26aufirst%3DD.%2BA.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26atitle%3DGPR40%2520partial%2520agonists%2520and%2520AgoPAMs%253A%2520differentiating%2520effects%2520on%2520glucose%2520and%2520hormonal%2520secretions%2520in%2520the%2520rodent%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0186033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestmar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husted, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelstoft, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lückmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.molmet.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25685685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=3-14&author=M.+Haugeauthor=M.+A.+Vestmarauthor=A.+S.+Hustedauthor=J.+P.+Ekbergauthor=M.+J.+Wrightauthor=J.+Di+Salvoauthor=A.+B.+Weinglassauthor=M.+S.+Engelstoftauthor=A.+N.+Madsenauthor=M.+L%C3%BCckmannauthor=M.+W.+Millerauthor=M.+E.+Trujilloauthor=T.+M.+Frimurerauthor=B.+Holstauthor=A.+D.+Howardauthor=T.+W.+Schwartz&title=GPR40+%28FFAR1%29+-+Combined+Gs+and+Gq+signaling+in+vitro+is+associated+with+robust+incretin+secretagogue+action+ex+vivo+and+in+vivo&doi=10.1016%2Fj.molmet.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span></div><div class="casAuthors">Hauge, Maria; Vestmar, Marie A.; Husted, Anna S.; Ekberg, Jeppe P.; Wright, Michael J.; Di Salvo, Jerry; Weinglass, Adam B.; Engelstoft, Maja S.; Madsen, Andreas N.; Luckmann, Michael; Miller, Michael W.; Trujillo, Maria E.; Frimurer, Thomas M.; Holst, Birgitte; Howard, Andrew D.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">GPR40 (FFAR1), a clin. proven anti-diabetes target, is a Gq-coupled receptor for long chain fatty acids (LCFA) stimulating insulin secretion directly and mediating a major part of the dietary triglyceride-induced secretion of the incretins GLP-1 and GIP.  In phase-II studies the GPR40 agonist TAK-875 decreased blood glucose but surprisingly without stimulating incretins.  Here we find that GPR40 can signal through not only Gq and IP3 but also Gs and cAMP when stimulated with certain agonists such as AM-1638 and AM-5262 in contrast to the endogenous LCFA ligands and agonists such as TAK-875 and AM-837, which only signal through Gq.  In competition binding against [3H]AM-1638 and [3H]L358 the Gq + Gs and the Gq-only agonists either competed for or showed pos. cooperativity by increasing the binding of the two different radio-ligands, in opposite ways.  Nevertheless, both the Gq-only and the Gq + Gs agonists all docked surprisingly well into the binding site for TAK-875 in the X-ray structure of GPR40.  In murine intestinal primary cell-cultures the endogenous LCFAs and the Gq-only agonists stimulated GLP-1 secretion with rather poor efficacy as compared with the high efficacy Gq + Gs GPR40 agonists and a prototype GPR119 agonist.  Similarly, in fasting both male and female mice the Gq + Gs agonists showed significantly higher efficacy than the Gq-only agonists in respect of increasing plasma GLP-1 and plasma GIP in a GPR40-dependent manner.  It is concluded that stimulation of GPR40 by endogenous LCFAs or by Gq-only synthetic agonists result in a rather limited incretin response, whereas Gq + Gs GPR40 agonists stimulate incretin secretion robustly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZyjcjTNd0QbVg90H21EOLACvtfcHk0lhYo0V8ge54_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN&md5=895136bef8c9542711e6daf5fa57219c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DVestmar%26aufirst%3DM.%2BA.%26aulast%3DHusted%26aufirst%3DA.%2BS.%26aulast%3DEkberg%26aufirst%3DJ.%2BP.%26aulast%3DWright%26aufirst%3DM.%2BJ.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DEngelstoft%26aufirst%3DM.%2BS.%26aulast%3DMadsen%26aufirst%3DA.%2BN.%26aulast%3DL%25C3%25BCckmann%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DGPR40%2520%2528FFAR1%2529%2520-%2520Combined%2520Gs%2520and%2520Gq%2520signaling%2520in%2520vitro%2520is%2520associated%2520with%2520robust%2520incretin%2520secretagogue%2520action%2520ex%2520vivo%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2015%26volume%3D4%26spage%3D3%26epage%3D14%26doi%3D10.1016%2Fj.molmet.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershfinkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. D.</span></span> <span> </span><span class="NLM_article-title">Role of GPR40 in fatty acid action on the β cell line INS-1E</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2005.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.bbrc.2005.07.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=16081037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2005&pages=97-104&author=H.+Shapiroauthor=S.+Shacharauthor=I.+Seklerauthor=M.+Hershfinkelauthor=M.+D.+Walker&title=Role+of+GPR40+in+fatty+acid+action+on+the+%CE%B2+cell+line+INS-1E&doi=10.1016%2Fj.bbrc.2005.07.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Role of GPR40 in fatty acid action on the β cell line INS-1E</span></div><div class="casAuthors">Shapiro, Hagit; Shachar, Sigal; Sekler, Israel; Hershfinkel, Michal; Walker, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GPR40 is a G protein-coupled receptor expressed preferentially in β cells, that has been implicated in mediating free fatty acid-stimulated insulin release.  GPR40 RNAi impaired the ability of palmitic acid (PA) to increase both insulin secretion and intracellular calcium ([Ca2+]i).  The PA-dependent [Ca2+]i increase was attenuated by inhibitors of Gαq, PLC, and SERCA.  Thus GPR40 activates the Gαq pathway, leading to release of Ca2+ from the ER.  Yet the GPR40-dependent [Ca2+]i rise was dependent on extracellular Ca2+ and elevated glucose, and was blocked by inhibition of L-type calcium channels (LTCC) or opening of the KATP channel; this suggests that GPR40 promotes Ca2+ influx through up-regulation of LTCC pre-activated by glucose and membrane depolarization.  Taken together, the data indicate that GPR40 mediates the increase in [Ca2+]i and insulin secretion through the Gαq-PLC pathway, resulting in release of Ca2+ from the ER and leading to up-regulation of Ca2+ influx via LTCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzW3S0OHY3rVg90H21EOLACvtfcHk0lhYo0V8ge54_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wqu7Y%253D&md5=f8b3167bb222eea1718689e2254777f1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2005.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2005.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DH.%26aulast%3DShachar%26aufirst%3DS.%26aulast%3DSekler%26aufirst%3DI.%26aulast%3DHershfinkel%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%2BD.%26atitle%3DRole%2520of%2520GPR40%2520in%2520fatty%2520acid%2520action%2520on%2520the%2520%25CE%25B2%2520cell%2520line%2520INS-1E%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2005%26volume%3D335%26spage%3D97%26epage%3D104%26doi%3D10.1016%2Fj.bbrc.2005.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöfl, C.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1016%2Fj.mce.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=17101212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KgurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2007&pages=173-180&author=S.+Schnellauthor=M.+Schaeferauthor=C.+Sch%C3%B6fl&title=Free+fatty+acids+increase+cytosolic+free+calcium+and+stimulate+insulin+secretion+from+%CE%B2-cells+through+activation+of+GPR40&doi=10.1016%2Fj.mce.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40</span></div><div class="casAuthors">Schnell, Susanne; Schaefer, Michael; Schoefl, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Free fatty acids (FFA) cause a rise in cytosolic free Ca2+ ([Ca2+]i) and stimulate insulin release from pancreatic β-cells.  The G-protein coupled receptor GPR40 can be activated by medium- and long-chain FFA.  We investigated a potential role for GPR40 in the generation of the FFA-induced Ca2+ signal and insulin secretion. [Ca2+]i was measured in primary mouse β-cells and in INS-1 cells, and insulin secretion was assessed from INS-1 cells.  GPR40 expression was detd. by RT-PCR and downregulation of GPR40 expression by siRNA transfection was carried out in INS-1 cells.  A no. of satd., mono- and polyunsatd. medium- and long-chain FFA caused a rise in [Ca2+]i both in primary mouse β-cells and in INS-1 cells.  By contrast, the short-chain satd. caproic acid was ineffective at concns. up to 300 μM.  In INS-1 cells, the FFA-induced Ca2+ signal required mobilization of internal Ca2+ and Ca2+ influx through voltage-sensitive Ca2+ channels.  RT-PCR anal. revealed that GPR40 is expressed in INS-1 cells.  Downregulation of GPR40 by specific siRNA treatment lead to a significant inhibition of the FFA-induced [Ca2+]i response and insulin secretion, indicating that the FFA-stimulated Ca2+ signal and insulin secretion involve activation of GPR40 in pancreatic β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhyq6-hglH7rVg90H21EOLACvtfcHk0liz5Osu8CLwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KgurzN&md5=eac888256316cd848c5cbde3ee1b78dc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DS.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSch%25C3%25B6fl%26aufirst%3DC.%26atitle%3DFree%2520fatty%2520acids%2520increase%2520cytosolic%2520free%2520calcium%2520and%2520stimulate%2520insulin%2520secretion%2520from%2520%25CE%25B2-cells%2520through%2520activation%2520of%2520GPR40%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2007%26volume%3D263%26spage%3D173%26epage%3D180%26doi%3D10.1016%2Fj.mce.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferdaoussi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrouki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poitout, V.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1007/s00125-012-2650-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1007%2Fs00125-012-2650-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22820510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWlsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2682-2692&author=M.+Ferdaoussiauthor=V.+Bergeronauthor=B.+Zarroukiauthor=J.+Kolicauthor=J.+Cantleyauthor=J.+Fielitzauthor=E.+N.+Olsonauthor=M.+Prentkiauthor=T.+Bidenauthor=P.+E.+MacDonaldauthor=V.+Poitout&title=G+protein-coupled+receptor+%28GPR%2940-dependent+potentiation+of+insulin+secretion+in+mouse+islets+is+mediated+by+protein+kinase+D1&doi=10.1007%2Fs00125-012-2650-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1</span></div><div class="casAuthors">Ferdaoussi, M.; Bergeron, V.; Zarrouki, B.; Kolic, J.; Cantley, J.; Fielitz, J.; Olson, E. N.; Prentki, M.; Biden, T.; MacDonald, P. E.; Poitout, V.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Activation of the G protein-coupled receptor (GPR)40 by long-chain fatty acids potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells, and GPR40 agonists are in clin. development for type 2 diabetes therapy.  GPR40 couples to the G protein subunit Gαq/11 but the signalling cascade activated downstream is unknown.  This study aimed to det. the mechanisms of GPR40-dependent potentiation of GSIS by fatty acids.  Methods: Insulin secretion in response to glucose, oleate or diacylglycerol (DAG) was assessed in dynamic perifusions and static incubations in islets from wild-type (WT) and Gpr40-/- mice.  Depolymn. of filamentous actin (F-actin) was visualized by phalloidin staining and epifluorescence.  Pharmacol. and mol. approaches were used to ascertain the roles of protein kinase D (PKD) and protein kinase C delta in GPR40-mediated potentiation of GSIS.  Results: Oleate potentiates the second phase of GSIS, and this effect is largely dependent upon GPR40.  Accordingly, oleate induces rapid F-actin remodelling in WT but not in Gpr40-/- islets.  Exogenous DAG potentiates GSIS in both WT and Gpr40-/- islets.  Oleate induces PKD phosphorylation at residues Ser-744/748 and Ser-916 in WT but not Gpr40-/- islets.  Importantly, oleate-induced F-actin depolymn. and potentiation of GSIS are lost upon pharmacol. inhibition of PKD1 or deletion of Prkd1.  Conclusions/interpretation: We conclude that the signalling cascade downstream of GPR40 activation by fatty acids involves activation of PKD1, F-actin depolymn. and potentiation of second-phase insulin secretion.  These results provide important information on the mechanisms of action of GPR40, a novel drug target for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRcajgd_2C7Vg90H21EOLACvtfcHk0liz5Osu8CLwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWlsrvJ&md5=4deea241063f9f8619e71d00f2d12da0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00125-012-2650-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-012-2650-x%26sid%3Dliteratum%253Aachs%26aulast%3DFerdaoussi%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DV.%26aulast%3DZarrouki%26aufirst%3DB.%26aulast%3DKolic%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DJ.%26aulast%3DFielitz%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26aulast%3DPrentki%26aufirst%3DM.%26aulast%3DBiden%26aufirst%3DT.%26aulast%3DMacDonald%26aufirst%3DP.%2BE.%26aulast%3DPoitout%26aufirst%3DV.%26atitle%3DG%2520protein-coupled%2520receptor%2520%2528GPR%252940-dependent%2520potentiation%2520of%2520insulin%2520secretion%2520in%2520mouse%2520islets%2520is%2520mediated%2520by%2520protein%2520kinase%2520D1%26jtitle%3DDiabetologia%26date%3D2012%26volume%3D55%26spage%3D2682%26epage%3D2692%26doi%3D10.1007%2Fs00125-012-2650-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishigaki, N.</span></span> <span> </span><span class="NLM_article-title">GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0222653</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0222653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1371%2Fjournal.pone.0222653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=31525244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVWqtbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=H.+Uenoauthor=R.+Itoauthor=S.-i.+Abeauthor=H.+Oginoauthor=M.+Maruyamaauthor=H.+Miyashitaauthor=Y.+Miyamotoauthor=Y.+Moritohauthor=Y.+Tsujihataauthor=K.+Takeuchiauthor=N.+Nishigaki&title=GPR40+full+agonism+exerts+feeding+suppression+and+weight+loss+through+afferent+vagal+nerve&doi=10.1371%2Fjournal.pone.0222653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve</span></div><div class="casAuthors">Ueno, Hikaru; Ito, Ryo; Abe, Shin-ichi; Ogino, Hitomi; Maruyama, Minoru; Miyashita, Hirohisa; Miyamoto, Yasufumi; Moritoh, Yusuke; Tsujihata, Yoshiyuki; Takeuchi, Koji; Nishigaki, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0222653</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">GPR40/FFAR1 is a Gq protein-coupled receptor expressed in pancreatic β cells and enteroendocrine cells, and mediates insulin and incretin secretion to regulate feeding behavior.  Several GPR40 full agonists have been reported to reduce food intake in rodents by regulating gut hormone secretion in addn. to their potent glucose-lowering effects; however, detailed mechanisms of feeding suppression are still unknown.  In the present study, we characterized T-3601386, a novel compd. with potent full agonistic activity for GPR40, by using in vitro Ca2+ mobilization assay in Chinese hamster ovary (CHO) cells expressing FFAR1 and in vivo hormone secretion assay.  We also evaluated feeding suppression and wt. loss after the administration of T-3601386 and investigated the involvement of the vagal nerve in these effects.  T-3601386, but not a partial agonist fasiglifam, increased intracellular Ca2+ levels in CHO cells with low FFAR1 expression, and single dosing of T-3601386 in diet-induced obese (DIO) rats elevated plasma incretin levels, suggesting full agonistic properties of T-3601386 against GPR40.  Multiple doses of T-3601386, but not fasiglifam, in DIO rats showed dose-dependent wt. loss accompanied by feeding suppression and durable glucagon-like peptide-1 elevation, all of which were completely abolished in Ffar1-/- mice.  Immunohistochem. anal. in the nuclei of the solitary tract demonstrated that T-3601386 increased the no. of c-Fos pos. cells, which also disappeared in Ffar1-/- mice.  Surgical vagotomy and drug-induced deafferentation counteracted the feeding suppression and wt. loss induced by the administration of T-3601386.  These results suggest that T-3601386 exerts incretin release and wt. loss in a GPR40-dependent manner, and that afferent vagal nerves are important for the feeding suppression induced by GPR40 full agonism.  Our novel findings raise the possibility that GPR40 full agonist can induce periphery-derived wt. redn., which may provide benefits such as less adverse effects in central nervous system compared to centrally-acting anti-obesity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkFigiXcJe7Vg90H21EOLACvtfcHk0lhbOBAFQowjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVWqtbjN&md5=e2d89c5027961945e006dc479498daad</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0222653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0222653%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DAbe%26aufirst%3DS.-i.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DMiyashita%26aufirst%3DH.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DMoritoh%26aufirst%3DY.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DNishigaki%26aufirst%3DN.%26atitle%3DGPR40%2520full%2520agonism%2520exerts%2520feeding%2520suppression%2520and%2520weight%2520loss%2520through%2520afferent%2520vagal%2520nerve%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0222653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span> <span> </span><span class="NLM_article-title">SAR Studies of Indole-5-propanoic acid derivatives to develop novel GPR40 agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1336</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00460</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00460" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1336-1340&author=D.-O.+Yoonauthor=X.+Zhaoauthor=D.+Sonauthor=J.+T.+Hanauthor=J.+Yunauthor=D.+Shinauthor=H.-J.+Park&title=SAR+Studies+of+Indole-5-propanoic+acid+derivatives+to+develop+novel+GPR40+agonists&doi=10.1021%2Facsmedchemlett.7b00460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists</span></div><div class="casAuthors">Yoon, Dong-Oh; Zhao, Xiaodi; Son, Dohyun; Han, Jung Tae; Yun, Jaesook; Shin, Dongyun; Park, Hyun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1336-1340</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein coupled receptor 40 (GPR40) has been considered to be an attractive drug target for the treatment of type 2 diabetes because of its role in free fatty acids-mediated enhancement of glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells.  A series of indole-5-propanoic acid compds. were synthesized, and their GPR40 agonistic activities were evaluated by nuclear factor of activated T-cells reporter assay and GSIS assay in the MIN-6 insulinoma cells.  Three compds., 8h (3-(2-(2-chlorophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 58.6 nM), 8i (3-(2-(3-chlorophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 37.8 nM), and 8o (3-(2-(2-bromophenyl)-1H-indol-5-yl)propanoic acid) (EC50 = 9.4 nM), were identified as potent GPR40 agonists with good GSIS effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Phq-aJx2FbVg90H21EOLACvtfcHk0lhbOBAFQowjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCks7%252FO&md5=1dc0c1cae53c5f19e964bf2c1b33c52f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00460%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DD.-O.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSon%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DJ.%2BT.%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.-J.%26atitle%3DSAR%2520Studies%2520of%2520Indole-5-propanoic%2520acid%2520derivatives%2520to%2520develop%2520novel%2520GPR40%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1336%26epage%3D1340%26doi%3D10.1021%2Facsmedchemlett.7b00460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span> <span> </span><span class="NLM_article-title">Tools for GPCR drug discovery</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Faps.2011.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22266728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=372-384&author=R.+Zhangauthor=X.+Xie&title=Tools+for+GPCR+drug+discovery&doi=10.1038%2Faps.2011.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Tools for GPCR drug discovery</span></div><div class="casAuthors">Zhang, Ru; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) mediate many important physiol. functions and are considered as one of the most successful therapeutic targets for a broad spectrum of diseases.  The design and implementation of high-throughput GPCR assays that allow the cost-effective screening of large compd. libraries to identify novel drug candidates are crit. in early drug discovery.  Early functional GPCR assays depend primarily on the measurement of G-protein-mediated 2nd messenger generation.  Taking advantage of the continuously deepening understanding of GPCR signal transduction, many G-protein-independent pathways are utilized to detect the activity of GPCRs, and may provide addnl. information on functional selectivity of candidate compds.  With the combination of automated imaging systems and label-free detection systems, such assays are now suitable for high-throughput screening (HTS).  In this review, we summarize the most widely used GPCR assays and recent advances in HTS technologies for GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pC8anrKpWLVg90H21EOLACvtfcHk0liimjzxmSBdVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1elu7Y%253D&md5=04ca4fed048dbca837d81c02566e6e25</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.173%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DTools%2520for%2520GPCR%2520drug%2520discovery%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D372%26epage%3D384%26doi%3D10.1038%2Faps.2011.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhurruth-Alcor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Røst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiorgis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heal, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design programprotobuild</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1039/c0ob00146e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1039%2FC0OB00146E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=21157612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=1169-1188&author=Y.+Bhurruth-Alcorauthor=T.+R%C3%B8stauthor=M.+R.+Jorgensenauthor=C.+Kontogiorgisauthor=J.+Skorveauthor=R.+G.+Cooperauthor=J.+M.+Sheridanauthor=W.+D.+O.+Hamiltonauthor=J.+R.+Healauthor=R.+K.+Bergeauthor=A.+D.+Miller&title=Synthesis+of+novel+PPAR%CE%B1%2F%CE%B3+dual+agonists+as+potential+drugs+for+the+treatment+of+the+metabolic+syndrome+and+diabetes+type+II+designed+using+a+new+de+novo+design+programprotobuild&doi=10.1039%2Fc0ob00146e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program protobuild</span></div><div class="casAuthors">Bhurruth-Alcor, Yushma; Rost, Therese; Jorgensen, Michael R.; Kontogiorgis, Christos; Skorve, Jon; Cooper, Robert G.; Sheridan, Joseph M.; Hamilton, William D. O.; Heal, Jonathan R.; Berge, Rolf K.; Miller, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1169-1188</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Peroxisome proliferator activated receptors (PPARs) have been shown to have crit. roles in fatty acid oxidn., triglyceride synthesis, and lipid metab. - making them an important target in drug discovery.  Here we describe the in silico design, synthesis and in vitro characterization of a novel series of 2,5-disubstituted indoles as PPARα/γ dual agonists.  PPAR activation assays are performed with known agonists diazabenzene (WY14.643), aminopyridine (BRL49653) and bisaryl (L165.041), as pos. controls.  All the indole compds. synthesized are found to be active PPARα and PPARγ agonists, with particular efficacy from those with 2-naphthylmethyl substitution.  This is a useful demonstration of a new de novo design methodol. implemented by the protobuild program and its ability to rapidly produce novel modulators for a well characterized drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPSAs5UK2KrLVg90H21EOLACvtfcHk0liimjzxmSBdVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCjtrw%253D&md5=dd413b54526eadebcb182db17cc1f8f3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC0OB00146E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0OB00146E%26sid%3Dliteratum%253Aachs%26aulast%3DBhurruth-Alcor%26aufirst%3DY.%26aulast%3DR%25C3%25B8st%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DM.%2BR.%26aulast%3DKontogiorgis%26aufirst%3DC.%26aulast%3DSkorve%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DR.%2BG.%26aulast%3DSheridan%26aufirst%3DJ.%2BM.%26aulast%3DHamilton%26aufirst%3DW.%2BD.%2BO.%26aulast%3DHeal%26aufirst%3DJ.%2BR.%26aulast%3DBerge%26aufirst%3DR.%2BK.%26aulast%3DMiller%26aufirst%3DA.%2BD.%26atitle%3DSynthesis%2520of%2520novel%2520PPAR%25CE%25B1%252F%25CE%25B3%2520dual%2520agonists%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520the%2520metabolic%2520syndrome%2520and%2520diabetes%2520type%2520II%2520designed%2520using%2520a%2520new%2520de%2520novo%2520design%2520programprotobuild%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D1169%26epage%3D1188%26doi%3D10.1039%2Fc0ob00146e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Curto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span> <span> </span><span class="NLM_article-title">Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3254</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1111/bph.12879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1111%2Fbph.12879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25131623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3254-3265&author=G.+Milliganauthor=E.+Alvarez-Curtoauthor=K.+R.+Wattersonauthor=T.+Ulvenauthor=B.+D.+Hudson&title=Characterizing+pharmacological+ligands+to+study+the+long-chain+fatty+acid+receptors+GPR40%2FFFA1+and+GPR120%2FFFA4&doi=10.1111%2Fbph.12879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4</span></div><div class="casAuthors">Milligan, G.; Alvarez-Curto, E.; Watterson, K. R.; Ulven, T.; Hudson, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3254-3265</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The free fatty acid receptors (FFA) 1 (previously designated GPR40) and FFA4 (previously GPR120) are two GPCRs activated by satd. and unsatd. longer-chain free fatty acids.  With expression patterns and functions anticipated to directly or indirectly promote insulin secretion, provide homeostatic control of blood glucose and improve tissue insulin sensitivity, both receptors are being studied as potential therapeutic targets for the control of type 2 diabetes.  Furthermore, genetic and systems biol. studies in both humans and mouse models link FFA4 receptors to diabetes and obesity.  Although activated by the same group of free fatty acids, FFA1 and FFA4 receptors are not closely related and, while the basis of recognition of fatty acids by FFA1 receptors is similar to that of the short-chain fatty acid receptors FFA2 and FFA3, the amino acid residues involved in endogenous ligand recognition by FFA4 receptors are more akin to those of the sphingosine 1 phosphate receptor S1P1.  Screening and subsequent medicinal chem. programs have developed a no. of FFA1 receptor selective agonists that are effective in promoting insulin secretion in a glucose concn.-dependent manner, and in lowering blood glucose levels.  However, the recent termination of Phase III clin. trials employing TAK-875/fasiglifam has caused a setback and raises important questions over the exact nature and mechanistic causes of the problems.  Progress in the identification and development of highly FFA4 receptor-selective pharmacol. tools has been less rapid and several issues remain to be clarified to fully validate this receptor as a therapeutic target.  Despite this, the ongoing development of a range of novel ligands offers great opportunities to further unravel the contributions of these receptors.  Linked Articles : This article is part of a themed section on 5th BPS Focused Meeting on Cell Signalling.  To view the other articles in this section visit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH6wIjF6Rg3bVg90H21EOLACvtfcHk0ljw90e8KN0mPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqt73E&md5=361d7b4aefdf7f496d66d8082d9c38bb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fbph.12879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12879%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DAlvarez-Curto%26aufirst%3DE.%26aulast%3DWatterson%26aufirst%3DK.%2BR.%26aulast%3DUlven%26aufirst%3DT.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26atitle%3DCharacterizing%2520pharmacological%2520ligands%2520to%2520study%2520the%2520long-chain%2520fatty%2520acid%2520receptors%2520GPR40%252FFFA1%2520and%2520GPR120%252FFFA4%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3254%26epage%3D3265%26doi%3D10.1111%2Fbph.12879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakaj, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span> <span> </span><span class="NLM_article-title">GPR40-Mediated Gα12 Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1124/mol.117.111369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fmol.117.111369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=29572336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOnu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=581-591&author=M.-L.+Rivesauthor=B.+Radyauthor=N.+Swansonauthor=S.+Zhaoauthor=J.+Qiauthor=E.+Arnoultauthor=I.+Bakajauthor=A.+Manciniauthor=B.+Bretonauthor=S.+P.+Leeauthor=M.+R.+Playerauthor=A.+Pocai&title=GPR40-Mediated+G%CE%B112+Activation+by+Allosteric+Full+Agonists+Highly+Efficacious+at+Potentiating+Glucose-Stimulated+Insulin+Secretion+in+Human+Islets&doi=10.1124%2Fmol.117.111369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40-mediated Gα12 activation by allosteric full agonists highly efficacious at potentiating glucose-stimulated insulin secretion in human islets</span></div><div class="casAuthors">Rives, Marie-Laure; Rady, Brian; Swanson, Nadia; Zhao, Shuyuan; Qi, Jenson; Arnoult, Eric; Bakaj, Ivona; Mancini, Arturo; Breton, Billy; Lee, S. Paul; Player, Mark R.; Pocai, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-591</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GPR40 is a clin. validated mol. target for the treatment of diabetes.  Many GPR40 agonists have been identified to date, with the partial agonist fasiglifam (TAK-875) reaching phase III clin. trials before its development was terminated due to off-target liver toxicity.  Since then, attention has shifted toward the development of full agonists that exhibit superior efficacy in preclin. models.  Full agonists bind to a distinct binding site, suggesting conformational plasticity and a potential for biased agonism.  Indeed, it has been suggested that alternative pharmacol. may be required for meaningful efficacy.  In this study, we described the discovery and characterization of Compd. A, a newly identified GPR40 allosteric full agonist highly efficacious in human islets at potentiating glucose-stimulated insulin secretion.  We compared Compd. A-induced GPR40 activity to that induced by both fasiglifam and AM-1638, another allosteric full agonist previously reported to be highly efficacious in preclin. models, at a panel of G proteins.  Compd. A was a full agonist at both the Gaq and Gai2 pathways, and in contrast to fasiglifam Compd. A also induced Gα12 coupling.  Compd. A and AM-1638 displayed similar activity at all pathways tested.  The Gα12/Gα13-mediated signaling pathway has been linked to protein kinase D activation as well as actin remodeling, well known to contribute to the release of insulin vesicles.  Our data suggest that the pharmacol. of GPR40 is complex and that Gα12/Gα13-mediated signaling, which may contribute to GPR40 agonists therapeutic efficacy, is a specific property of GPR40 allosteric full agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq4ElVfBqrC7Vg90H21EOLACvtfcHk0ljw90e8KN0mPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOnu7rI&md5=cf26bf07ab86583e86e5727bcb499e32</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fmol.117.111369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.117.111369%26sid%3Dliteratum%253Aachs%26aulast%3DRives%26aufirst%3DM.-L.%26aulast%3DRady%26aufirst%3DB.%26aulast%3DSwanson%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DBakaj%26aufirst%3DI.%26aulast%3DMancini%26aufirst%3DA.%26aulast%3DBreton%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%2BP.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPocai%26aufirst%3DA.%26atitle%3DGPR40-Mediated%2520G%25CE%25B112%2520Activation%2520by%2520Allosteric%2520Full%2520Agonists%2520Highly%2520Efficacious%2520at%2520Potentiating%2520Glucose-Stimulated%2520Insulin%2520Secretion%2520in%2520Human%2520Islets%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D93%26spage%3D581%26epage%3D591%26doi%3D10.1124%2Fmol.117.111369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slice, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozengurt, E.</span></span> <span> </span><span class="NLM_article-title">Activation of Protein Kinase D by Signaling through Rho and the α Subunit of the Heterotrimeric G Protein G13</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">38619</span>– <span class="NLM_lpage">38627</span>, <span class="refDoi"> DOI: 10.1074/jbc.m105530200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1074%2Fjbc.M105530200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=11507098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=38619-38627&author=J.+Yuanauthor=L.+W.+Sliceauthor=E.+Rozengurt&title=Activation+of+Protein+Kinase+D+by+Signaling+through+Rho+and+the+%CE%B1+Subunit+of+the+Heterotrimeric+G+Protein+G13&doi=10.1074%2Fjbc.m105530200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of protein kinase D by signaling through Rho and the α subunit of the heterotrimeric G protein G13</span></div><div class="casAuthors">Yuan, Jingzhen; Slice, Lee W.; Rozengurt, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">38619-38627</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein kinase D (PKD/PKCμ) immunopptd. from COS-7 cells transiently transfected with either a constitutively active mutant of Rho (RhoQ63L) or the Rho-specific guanine nucleotide exchange factor pOnco-Lbc exhibited a marked increase in basal activity.  Addn. of aluminum fluoride to cells co-transfected with PKD and wild type Gα13 also induced PKD activation.  Co-transfection of Clostridium botulinum C3 toxin blocked activation of PKD by RhoQ63L, Lbc, or aluminum fluoride-stimulated Gα13.  Treatment with the protein kinase C inhibitors GF I or Ro 31-8220 prevented the increase in PKD activity induced by RhoQ63L, Lbc, or aluminum fluoride-stimulated Gα13.  PKD activation in response to Gα13 signaling was also completely prevented by mutation of Ser-744 and Ser-748 to Ala in the kinase activation loop of PKD.  Co-expression of C. botulinum C3 toxin and a C-terminal fragment of Gαq that acts in a dominant-neg. fashion blocked PKD activation in response to agonist stimulation of bombesin receptor.  Expression of the C-terminal region of Gα13 also attenuated PKD activation in response to bombesin receptor stimulation.  Our results show that Gα13 contributes to PKD activation through a Rho- and protein kinase C-dependent signaling pathway and indicate that PKD activation is mediated by both Gαq and Gα13 in response to bombesin receptor stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6mIMylgxe_bVg90H21EOLACvtfcHk0lhX8TUhsEFgmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVentrY%253D&md5=2b608a529c34c9ccf9c56b1054600d8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M105530200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M105530200%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DSlice%26aufirst%3DL.%2BW.%26aulast%3DRozengurt%26aufirst%3DE.%26atitle%3DActivation%2520of%2520Protein%2520Kinase%2520D%2520by%2520Signaling%2520through%2520Rho%2520and%2520the%2520%25CE%25B1%2520Subunit%2520of%2520the%2520Heterotrimeric%2520G%2520Protein%2520G13%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D38619%26epage%3D38627%26doi%3D10.1074%2Fjbc.m105530200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siehler, S.</span></span> <span> </span><span class="NLM_article-title">G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.12.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1517%2F17460441.2.12.1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=23488903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1591-1604&author=S.+Siehler&title=G12%2F13-dependent+signaling+of+G-protein-coupled+receptors%3A+disease+context+and+impact+on+drug+discovery&doi=10.1517%2F17460441.2.12.1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery</span></div><div class="casAuthors">Siehler, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1591-1604</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) transmit extracellular signals across the plasma membrane via intracellular activation of heterotrimeric G proteins.  The signal transduction pathways of Gs, Gi and Gq protein families are widely studied, whereas signaling properties of G12 proteins are only emerging.  Many GPCRs were found to couple to G12/13 proteins in addn. to coupling to one or more other types of G proteins.  G12/13 proteins couple GPCRs to activation of the small monomeric GTPase RhoA.  Activation of RhoA modulates various downstream effector systems relevant to diseases such as hypertension, atherosclerosis, asthma and cancer.  GPCR screening assays exist for Gs-, Gi- and Gq-linked pathways, whereas a drug-screening assay for the G12-Rho pathway was developed only recently.  The review gives an overview of the present understanding of the G12/13-related biol. of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqidJhepHOJV7Vg90H21EOLACvtfcHk0lhX8TUhsEFgmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSnsg%253D%253D&md5=79a1e26e9937575143ef694472bc966f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.12.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.12.1591%26sid%3Dliteratum%253Aachs%26aulast%3DSiehler%26aufirst%3DS.%26atitle%3DG12%252F13-dependent%2520signaling%2520of%2520G-protein-coupled%2520receptors%253A%2520disease%2520context%2520and%2520impact%2520on%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D1591%26epage%3D1604%26doi%3D10.1517%2F17460441.2.12.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span> <span> </span><span class="NLM_article-title">Fatty acids and β-cell toxicity</span>. <i>Curr. Opin. Clin. Nutr. Metab. Care</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1097/mco.0b013e328321e423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1097%2FMCO.0b013e328321e423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=19202382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=117-122&author=N.+G.+Morgan&title=Fatty+acids+and+%CE%B2-cell+toxicity&doi=10.1097%2Fmco.0b013e328321e423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty acids and β-cell toxicity</span></div><div class="casAuthors">Morgan, Noel G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Clinical Nutrition and Metabolic Care</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-122</span>CODEN:
                <span class="NLM_cas:coden">COCMF3</span>;
        ISSN:<span class="NLM_cas:issn">1363-1950</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The rising incidence of type 2 diabetes is due, in part, to the detrimental effects of certain fatty acids on pancreatic β-cell function and viability.  The present review examines recent advances in the understanding of the mol. mechanisms by which fatty acids influence the life and death of β cells.  Recent findings: There are important differences in the cytotoxic potential of fatty acids, with long-chain satd. mols. being the most potent.  By contrast, monounsaturates and polyunsaturates are relatively well tolerated and, in some cases, are actively cytoprotective.  The mechanisms underlying the toxicity of the sats. may reflect a decrease in protein processing, which drives the accumulation of unfolded proteins in the endoplasmic reticulum.  This triggers an apoptotic response by virtue of enhanced endoplasmic reticulum stress and induction of CHOP-10 synthesis.  Alterations in the regulatory control of other proapoptotic genes via changes in microRNA synthesis may also contribute.  The cytoprotection deriving from incubation with long-chain mono-unsaturates is probably receptor mediated and involves antagonistic actions on the effector arm of the endoplasmic reticulum stress pathway.  Summary: The findings have implications for the development of new therapeutic agents designed to minimize β-cell dysfunction and the loss of β-cell viability in type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66l-nAsJnALVg90H21EOLACvtfcHk0lhX8TUhsEFgmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKksLk%253D&md5=752871887c7bd0221d10452efbca015c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FMCO.0b013e328321e423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCO.0b013e328321e423%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26atitle%3DFatty%2520acids%2520and%2520%25CE%25B2-cell%2520toxicity%26jtitle%3DCurr.%2520Opin.%2520Clin.%2520Nutr.%2520Metab.%2520Care%26date%3D2009%26volume%3D12%26spage%3D117%26epage%3D122%26doi%3D10.1097%2Fmco.0b013e328321e423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm2012968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2012968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1538-1552&author=N.+Negoroauthor=S.+Sasakiauthor=M.+Itoauthor=S.+Kitamuraauthor=Y.+Tsujihataauthor=R.+Itoauthor=M.+Suzukiauthor=K.+Takeuchiauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=T.+Odaniauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=T.+Yasumaauthor=Y.+Momose&title=Identification+of+fused-ring+alkanoic+acids+with+improved+pharmacokinetic+profiles+that+act+as+G+protein-coupled+receptor+40%2Ffree+fatty+acid+receptor+1+agonists&doi=10.1021%2Fjm2012968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonists</span></div><div class="casAuthors">Negoro, Nobuyuki; Sasaki, Shinobu; Ito, Masahiro; Kitamura, Shuji; Tsujihata, Yoshiyuki; Ito, Ryo; Suzuki, Masami; Takeuchi, Koji; Suzuki, Nobuhiro; Miyazaki, Junichi; Santou, Takashi; Odani, Tomoyuki; Kanzaki, Naoyuki; Funami, Miyuki; Tanaka, Toshimasa; Yasuma, Tsuneo; Momose, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1538-1552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency.  We previously identified 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid as a potent and orally available GPR40/FFA1 agonist; however, it exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidn. at the phenylpropanoic acid moiety.  To identify long-acting compds., we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure.  Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced.  Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of the dihydrobenzofuran (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid (I), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvX-exJHNoe7Vg90H21EOLACvtfcHk0lhCw4uEliuKSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFGrtA%253D%253D&md5=0841278f5c72041d6ed5ac3b90230d29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm2012968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2012968%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520fused-ring%2520alkanoic%2520acids%2520with%2520improved%2520pharmacokinetic%2520profiles%2520that%2520act%2520as%2520G%2520protein-coupled%2520receptor%252040%252Ffree%2520fatty%2520acid%2520receptor%25201%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1538%26epage%3D1552%26doi%3D10.1021%2Fjm2012968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span> <span> </span><span class="NLM_article-title">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1124/mol.112.079640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1124%2Fmol.112.079640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=22859723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=843-859&author=D.+C.-H.+Linauthor=Q.+Guoauthor=J.+Luoauthor=J.+Zhangauthor=K.+Nguyenauthor=M.+Chenauthor=T.+Tranauthor=P.+J.+Dransfieldauthor=S.+P.+Brownauthor=J.+Houzeauthor=M.+Vimolratanaauthor=X.+Y.+Jiaoauthor=Y.+Wangauthor=N.+J.+M.+Birdsallauthor=G.+Swaminath&title=Identification+and+pharmacological+characterization+of+multiple+allosteric+binding+sites+on+the+free+fatty+acid+1+receptor&doi=10.1124%2Fmol.112.079640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span></div><div class="casAuthors">Lin, Daniel C.-H.; Guo, Qi; Luo, Jian; Zhang, Jane; Nguyen, Kathy; Chen, Michael; Tran, Thanh; Dransfield, Paul J.; Brown, Sean P.; Houze, Jonathan; Vimolratana, Marc; Jiao, Xian Yun; Wang, Yingcai; Birdsall, Nigel J. M.; Swaminath, Gayathri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-859</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of FFA1 (GPR40), a member of G protein-coupling receptor family A, is mediated by medium- and long-chain fatty acids and leads to amplification of glucose-stimulated insulin secretion, suggesting a potential role for free fatty acid 1 (FFA1) as a target for type 2 diabetes.  It was assumed previously that there is a single binding site for fatty acids and synthetic FFA1 agonists.  However, using members of two chem. series of partial and full agonists that have been identified, radioligand binding interaction studies revealed that the full agonists do not bind to the same site as the partial agonists but exhibit pos. heterotropic cooperativity.  Anal. of functional data reveals pos. functional cooperativity between the full agonists and partial agonists in various functional assays (in vitro and ex vivo) and also in vivo.  Furthermore, the endogenous fatty acid docosahexaenoic acid (DHA) shows neg. or neutral cooperativity with members of both series of agonists in binding assays but displays pos. cooperativity in functional assays.  Another synthetic agonist is allosteric with members of both agonist series, but apparently competitive with DHA.  Therefore, there appear to be three allosterically linked binding sites on FFA1 with agonists specific for each of these sites.  Activation of free fatty acid 1 receptor (FFAR1) by each of these agonists is differentially affected by mutations of two arginine residues, previously found to be important for FFAR1 binding and activation.  These ligands with their high potencies and strong pos. functional cooperativity with endogenous fatty acids, demonstrated in vitro and in vivo, have the potential to deliver therapeutic benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-mJkDwpnmbVg90H21EOLACvtfcHk0lhCw4uEliuKSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE&md5=2437a31476d8c7d7b4fb06972e1f43d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.079640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.079640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DSwaminath%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520pharmacological%2520characterization%2520of%2520multiple%2520allosteric%2520binding%2520sites%2520on%2520the%2520free%2520fatty%2520acid%25201%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D843%26epage%3D859%26doi%3D10.1124%2Fmol.112.079640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirozane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruswitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivetac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1038/nature13494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnature13494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=25043059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=124-127&author=A.+Srivastavaauthor=J.+Yanoauthor=Y.+Hirozaneauthor=G.+Kefalaauthor=F.+Gruswitzauthor=G.+Snellauthor=W.+Laneauthor=A.+Ivetacauthor=K.+Aertgeertsauthor=J.+Nguyenauthor=A.+Jenningsauthor=K.+Okada&title=High-resolution+structure+of+the+human+GPR40+receptor+bound+to+allosteric+agonist+TAK-875&doi=10.1038%2Fnature13494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875</span></div><div class="casAuthors">Srivastava, Ankita; Yano, Jason; Hirozane, Yoshihiko; Kefala, Georgia; Gruswitz, Franz; Snell, Gyorgy; Lane, Weston; Ivetac, Anthony; Aertgeerts, Kathleen; Nguyen, Jasmine; Jennings, Andy; Okada, Kengo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">124-127</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human GPR40 receptor (hGPR40), also known as free fatty-acid receptor 1 (FFAR1), is a G-protein-coupled receptor that binds long-chain free fatty acids to enhance glucose-dependent insulin secretion.  Novel treatments for type-2 diabetes mellitus are therefore possible by targeting hGPR40 with partial or full agonists.  TAK-875, or fasiglifam, is an orally available, potent and selective partial agonist of hGPR40 receptor, which reached phase III clin. trials for the potential treatment of type-2 diabetes mellitus.  Data from clin. studies indicate that TAK-875, which is an ago-allosteric modulator of hGPR40 (ref. 3), demonstrates improved glycemic control and low hypoglycemic risk in diabetic patients.  Here the authors report the crystal structure of hGPR40 receptor bound to TAK-875 at 2.3 Å resoln.  The co-complex structure reveals a unique binding mode of TAK-875 and suggests that entry to the non-canonical binding pocket most probably occurs via the lipid bilayer.  The at. details of the extensive charge network in the ligand binding pocket reveal addnl. interactions not identified in previous studies and contribute to a clear understanding of TAK-875 binding to the receptor.  The hGPR40-TAK-875 structure also provides insights into the plausible binding of multiple ligands to the receptor, which has been obsd. in radioligand binding and Ca2+ influx assay studies.  Comparison of the transmembrane helix architecture with other G-protein-coupled receptors suggests that the crystd. TAK-875-bound hGPR40 complex is in an inactive-like state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO9EJ42g7iaLVg90H21EOLACvtfcHk0lg9L82shBFqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvK&md5=06e38fa105ab0783715a541bc2008311</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature13494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13494%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DHirozane%26aufirst%3DY.%26aulast%3DKefala%26aufirst%3DG.%26aulast%3DGruswitz%26aufirst%3DF.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DW.%26aulast%3DIvetac%26aufirst%3DA.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DHigh-resolution%2520structure%2520of%2520the%2520human%2520GPR40%2520receptor%2520bound%2520to%2520allosteric%2520agonist%2520TAK-875%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D124%26epage%3D127%26doi%3D10.1038%2Fnature13494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span> <i>Schrödinger
Release 2019-4</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Schr%C3%B6dinger%0ARelease+2019-4%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSchr%25C3%25B6dinger%250ARelease%25202019-4%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinglass, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">570</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=10.1038%2Fnsmb.3417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=28581512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Onu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=570-577&author=J.+Luauthor=N.+Byrneauthor=J.+Wangauthor=G.+Bricogneauthor=F.+K.+Brownauthor=H.+R.+Chobanianauthor=S.+L.+Collettiauthor=J.+Di+Salvoauthor=B.+Thomas-Fowlkesauthor=Y.+Guoauthor=D.+L.+Hallauthor=J.+Hadixauthor=N.+B.+Hastingsauthor=J.+D.+Hermesauthor=T.+Hoauthor=A.+D.+Howardauthor=H.+Josienauthor=M.+Kornienkoauthor=K.+J.+Lumbauthor=M.+W.+Millerauthor=S.+B.+Patelauthor=B.+Pioauthor=C.+W.+Plummerauthor=B.+S.+Sherborneauthor=P.+Shethauthor=S.+Souzaauthor=S.+Tummalaauthor=C.+Vonrheinauthor=M.+Webbauthor=S.+J.+Allenauthor=J.+M.+Johnstonauthor=A.+B.+Weinglassauthor=S.+Sharmaauthor=S.+M.+Soisson&title=Structural+basis+for+the+cooperative+allosteric+activation+of+the+free+fatty+acid+receptor+GPR40&doi=10.1038%2Fnsmb.3417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40</span></div><div class="casAuthors">Lu, Jun; Byrne, Noel; Wang, John; Bricogne, Gerard; Brown, Frank K.; Chobanian, Harry R.; Colletti, Steven L.; Di Salvo, Jerry; Thomas-Fowlkes, Brande; Guo, Yan; Hall, Dawn L.; Hadix, Jennifer; Hastings, Nicholas B.; Hermes, Jeffrey D.; Ho, Thu; Howard, Andrew D.; Josien, Hubert; Kornienko, Maria; Lumb, Kevin J.; Miller, Michael W.; Patel, Sangita B.; Pio, Barbara; Plummer, Christopher W.; Sherborne, Bradley S.; Sheth, Payal; Souza, Sarah; Tummala, Srivanya; Vonrhein, Clemens; Webb, Maria; Allen, Samantha J.; Johnston, Jennifer M.; Weinglass, Adam B.; Sharma, Sujata; Soisson, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">570-577</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clin. studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus.  Full allosteric agonists (AgoPAMs) of GPR40 bind to a site distinct from partial agonists and can provide addnl. efficacy.  We report the 3.2-Å crystal structure of human GPR40 (hGPR40) in complex with both the partial agonist MK-8666 and an AgoPAM, which exposes a novel lipid-facing AgoPAM-binding pocket outside the transmembrane helical bundle.  Comparison with an addnl. 2.2-Å structure of the hGPR40-MK-8666 binary complex reveals an induced-fit conformational coupling between the partial agonist and AgoPAM binding sites, involving rearrangements of the transmembrane helixes 4 and 5 (TM4 and TM5) and transition of the intracellular loop 2 (ICL2) into a short helix.  These conformational changes likely prime GPR40 to a more active-like state and explain the binding cooperativity between these ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIlYQcPgGaErVg90H21EOLACvtfcHk0li6T3NiP6hj0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Onu7c%253D&md5=9f54c7b79ef28da029cce91dc7c02274</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3417%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBricogne%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DF.%2BK.%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHadix%26aufirst%3DJ.%26aulast%3DHastings%26aufirst%3DN.%2BB.%26aulast%3DHermes%26aufirst%3DJ.%2BD.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DPio%26aufirst%3DB.%26aulast%3DPlummer%26aufirst%3DC.%2BW.%26aulast%3DSherborne%26aufirst%3DB.%2BS.%26aulast%3DSheth%26aufirst%3DP.%26aulast%3DSouza%26aufirst%3DS.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DWebb%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DS.%2BJ.%26aulast%3DJohnston%26aufirst%3DJ.%2BM.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26atitle%3DStructural%2520basis%2520for%2520the%2520cooperative%2520allosteric%2520activation%2520of%2520the%2520free%2520fatty%2520acid%2520receptor%2520GPR40%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D570%26epage%3D577%26doi%3D10.1038%2Fnsmb.3417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TZY','PDB','5TZY'); return false;">PDB: 5TZY</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i52"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41066"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00031?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00031</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_001.csv">CSV</a>)</p></li><li><p class="inline">Compliance statement (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Atomic coordinates for docking models for the compounds (<b>4k</b><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_003.pdb">PDB</a>, <b>4o</b><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_004.pdb">PDB</a>, and <b>6k</b><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_005.pdb">PDB</a>) in Figure 5, will be released upon article publication</p></li><li><p class="inline">Solubility of <b>4k</b> and <b>4o</b>, site-directed mutation assay data and method, and HPLC and HRMS spectra for the compounds studied in this paper (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_001.csv">jm1c00031_si_001.csv (0.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_002.pdf">jm1c00031_si_002.pdf (322.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_003.pdb">jm1c00031_si_003.pdb (473.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_004.pdb">jm1c00031_si_004.pdb (471.68 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_005.pdb">jm1c00031_si_005.pdb (473.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00031/suppl_file/jm1c00031_si_006.pdf">jm1c00031_si_006.pdf (4.25 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00031&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00031" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00031" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b6527b523c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
